

CITATION REPORT

List of articles citing

Tumorigenesis and the angiogenic switch

DOI: 10.1038/nrc1093

Nature Reviews Cancer, 2003, 3, 401-10.

Source: <https://exaly.com/paper-pdf/35291543/citation-report.pdf>

Version: 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2271	Design and evaluation of a laboratory prototype system for 3D photoacoustic full breast tomography. 2013 , 4, 2555		
2270	Design and evaluation of a laboratory prototype system for 3D photoacoustic full breast tomography. 2013 , 4, 2555		
2269	Design and evaluation of a laboratory prototype system for 3D photoacoustic full breast tomography. 2013 , 4, 2555		
2268	Design and evaluation of a laboratory prototype system for 3D photoacoustic full breast tomography. 2013 , 4, 2555		
2267	Early contribution of pericytes to angiogenic sprouting and tube formation. 2003 , 6, 241-9		192
2266	Vascular remodeling by intussusceptive angiogenesis. 2003 , 314, 107-17		225
2265	Matrix reloaded to circulation hits the tumor target. 2003 , 3, 513-4		8
2264	Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone. 2003 , 98, 1377-85		94
2263	Multiscale Modeling and Mathematical Problems Related to Tumor Evolution and Medical Therapy. 2003 , 5, 111-136		76
2262	Impact of IGF-I/IGF-IR circuit on the angiogenetic properties of Ewing's sarcoma cells. 2003 , 35, 675-84		50
2261	Blood level of phosphoglycerate kinase does not correlate with presence or extent of tumor. 2004 , 19, 170-2		
2260	Gene transfer for therapeutic vascular growth in myocardial and peripheral ischemia. 2004 , 52, 117-64		24
2259	Involvement of membrane-type matrix metalloproteinases (MT-MMPs) in capillary tube formation by human endometrial microvascular endothelial cells: role of MT3-MMP. 2004 , 89, 5828-36		60
2258	Human endocrine gland-derived vascular endothelial growth factor: expression early in development and in Leydig cell tumors suggests roles in normal and pathological testis angiogenesis. 2004 , 89, 4078-88		51
2257	Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas. 2004 , 351, 250-9		292
2256	Angiogenesis and anti-angiogenic therapy in myelofibrosis with myeloid metaplasia. 2004 , 45, 2373-86		13
2255	Assessing tumor angiogenesis: increased circulating VE-cadherin RNA in patients with cancer indicates viability of circulating endothelial cells. 2004 , 64, 4373-7		80

2254	Transduction of soluble Flt-1 gene to peritoneal mesothelial cells can effectively suppress peritoneal metastasis of gastric cancer. 2004 , 64, 3624-8	52
2253	Sp1 is involved in Akt-mediated induction of VEGF expression through an HIF-1-independent mechanism. 2004 , 15, 4841-53	186
2252	Cannabinoids inhibit the vascular endothelial growth factor pathway in gliomas. 2004 , 64, 5617-23	180
2251	Inhibition of xenografted human melanoma growth and prevention of metastasis development by dual antiangiogenic/antitumor activities of pigment epithelium-derived factor. 2004 , 64, 5632-42	80
2250	Soluble tumor necrosis factor-like weak inducer of apoptosis overexpression in HEK293 cells promotes tumor growth and angiogenesis in athymic nude mice. 2004 , 64, 8968-72	75
2249	Snail and E47 repressors of E-cadherin induce distinct invasive and angiogenic properties in vivo. 2004 , 117, 2827-39	130
2248	Role of Ang1 and its interaction with VEGF-A in astrocytomas. 2004 , 63, 978-89	26
2247	Liposomal mediated transfer of ErbB2 antisense DNA: coming of age in the war against cancer. 2004 , 3, 205-6	3
2246	Do shorter wavelengths improve contrast in optical mammography?. 2004 , 49, 1203-15	23
2245	A novel orally bioavailable inhibitor of kinase insert domain-containing receptor induces antiangiogenic effects and prevents tumor growth in vivo. 2004 , 64, 751-6	24
2244	The immunohistochemical expression of calcitonin receptor-like receptor (CRLR) in human gliomas. 2004 , 57, 172-6	12
2243	Targeting protein kinases in cancer therapy: a success?. 2004 , 4, 1113-24	41
2242	The role of thymidine phosphorylase, an angiogenic enzyme, in tumor progression. 2004 , 95, 851-7	83
2241	Cyclooxygenase-2 expression and angiogenesis in squamous cell carcinoma of the skin and its precursors: a paired immunohistochemical study of 35 cases. 2004 , 151, 837-45	64
2240	The chemokine system -- a major regulator of angiogenesis in health and disease. 2004 , 112, 481-95	207
2239	Friends or foes - bipolar effects of the tumour stroma in cancer. <i>Nature Reviews Cancer</i> , 2004 , 4, 839-49	313 1446
2238	Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. 2004 , 3, 391-400	1872
2237	Expression of the thrombospondin 1 fragment 167-569 in C6 glioma cells stimulates tumorigenicity despite reduced neovascularization. 2004 , 23, 3642-9	18

2236	Antitumour efficacy of VEGFR2 tyrosine kinase inhibitor correlates with expression of VEGF and its receptor VEGFR2 in tumour models. 2004 , 91, 1391-8	37
2235	Novel endothelial cell markers in hepatocellular carcinoma. 2004 , 17, 1198-210	69
2234	Autocrine signaling in carcinoma: VEGF and the alpha6beta4 integrin. 2004 , 14, 115-22	60
2233	Somatostatin analogues: multiple roles in cellular proliferation, neoplasia, and angiogenesis. 2004 , 102, 61-85	138
2232	Molecular approach to breast cancer treatment. 2004 , 31, 6-13	59
2231	Roles of Angiogenesis and Vascular Remodeling in Brain Vascular Malformations. 2004 , 4, 217-225	7
2230	Molecular imaging applications in nanomedicine. 2004 , 6, 113-6	66
2229	Vascular endothelial growth factor in colorectal cancer. 2004 , 19, 510-7	44
2228	Pathological angiogenesis is reduced by targeting pericytes via the NG2 proteoglycan. 2004 , 7, 269-76	144
2227	Molecular targeting of angiogenesis for imaging and therapy. 2004 , 31, 1327-41	29
2226	The angiogenic status of B-CLL B cells: role of the VEGF receptors. 2004 , 28, 221-2	16
2225	Inhibitors of angiogenesis and cancer-related receptor tyrosine kinases. 2004 , 8, 432-41	39
2224	Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis. 2004 , 1697, 17-27	110
2223	Perillyl alcohol is an angiogenesis inhibitor. 2004 , 311, 568-75	67
2222	Angiogenesis in colorectal cancer: therapeutic implications and future directions. 2004 , 18, 1087-119, ix	5
2221	Halofuginone inhibits angiogenesis and growth in implanted metastatic rat brain tumor model--an MRI study. 2004 , 6, 480-9	43
2220	Translational regulation of XIAP expression and cell survival during hypoxia in human cholangiocarcinoma. 2004 , 127, 1787-97	28
2219	Vascular endothelial growth factor: basic science and clinical progress. 2004 , 25, 581-611	2749

2218	Antiangiogenic gene therapy of cancer: recent developments. 2004 , 2, 22	79
2217	JunD reduces tumor angiogenesis by protecting cells from oxidative stress. 2004 , 118, 781-94	478
2216	PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma. 2004 , 15, 275-86	259
2215	Anti-vascular tumor therapy: recent advances, pitfalls and clinical perspectives. 2004 , 7, 125-38	62
2214	Regulated angiogenesis and vascular regression in mice overexpressing vascular endothelial growth factor in airways. 2004 , 165, 1071-85	104
2213	CXC chemokines: the regulatory link between inflammation and angiogenesis. 2004 , 25, 201-9	327
2212	Orthotopic implantation of human hepatocellular carcinoma in mice: analysis of tumor progression and establishment of the BCLC-9 cell line. 2004 , 10, 2150-7	22
2211	Angiogenic switch in multiple myeloma. 2004 , 9, 377-81	20
2210	Tumor endothelial markers: new targets for cancer therapy. 2004 , 16, 44-9	108
2209	Angiogenic switch during 5T2MM murine myeloma tumorigenesis: role of CD45 heterogeneity. 2004 , 103, 3131-7	45
2208	Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression. 2004 , 104, 1159-65	123
2207	Cancer anti-angiogenic therapy. 2004 , 27, 599-605	62
2206	Role of Immunohistochemical Expression of p53 and Vascular Endothelial Growth Factor in Gastric Carcinoma. 2005 , 4, 109-115	
2205	Angiogenesis in lymphoproliferative disorders: a therapeutic target?. 2005 , 12, 279-83	5
2204	Structural basis for the functions of endogenous angiogenesis inhibitors. 2005 , 70, 399-410	19
2203	Addicted to death: invasive cancer and the immune response to unscheduled cell death. 2005 , 28, 1-9	126
2202	Stromal cells as new therapeutic targets in rheumatoid arthritis. 2005 , 2, 121-129	1
2201	Unresolved questions, changing definitions, and novel paradigms for defining endothelial progenitor cells. 2005 , 106, 1525-31	382

2200	Regulator of G-protein signaling-5 induction in pericytes coincides with active vessel remodeling during neovascularization. 2005 , 105, 1094-101	159
2199	CD97, an adhesion receptor on inflammatory cells, stimulates angiogenesis through binding integrin counterreceptors on endothelial cells. 2005 , 105, 2836-44	144
2198	The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. 2005 , 105, 1383-95	277
2197	Rapamycin induces tumor-specific thrombosis via tissue factor in the presence of VEGF. 2005 , 105, 4463-9	117
2196	Erratum for vol. 104, p. 2368. 2005 , 105, 1395-1395	
2195	Impact of adjuvant inhibition of vascular endothelial growth factor receptor tyrosine kinases on tumor growth delay and local tumor control after fractionated irradiation in human squamous cell carcinomas in nude mice. 2005 , 61, 908-14	39
2194	Enhancement of radiation effects by pXLG-mEndo in a lung carcinoma model. 2005 , 63, 553-64	19
2193	RO4383596, an orally active KDR, FGFR, and PDGFR inhibitor: synthesis and biological evaluation. 2005 , 13, 4835-41	19
2192	Identification of novel angiogenesis inhibitors. 2005 , 15, 4125-9	10
2191	Design, synthesis, and evaluation of original carriers for targeting vascular endothelial growth factor receptor interactions. 2005 , 22, 1411-21	22
2190	Angiogenesis inhibitors in the treatment of cancer. 2005 , 6, 1701-11	39
2189	Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression. 2005 , 92, 94-101	188
2188	The realisation of targeted antitumour therapy. 2005 , 92 Suppl 1, S2-5	16
2187	Real-time PCR of CD146 mRNA in peripheral blood enables the relative quantification of circulating endothelial cells and is an indicator of angiogenesis. 2005 , 93, 793-8	39
2186	PDGFRbeta+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival. 2005 , 7, 870-9	468
2185	The contributions of Santiago Ramón y Cajal to cancer research - 100 years on. <i>Nature Reviews Cancer</i> , 2005 , 5, 904-9	313 10
2184	Endogenous angiogenin in endothelial cells is a general requirement for cell proliferation and angiogenesis. 2005 , 24, 445-56	247
2183	Reduction in the requirement of oncogenic Ras signaling to activation of PI3K/AKT pathway during tumor maintenance. 2005 , 8, 381-92	154

2182	In silico analysis of angiogenesis associated gene expression identifies angiogenic stage related profiles. 2005 , 1755, 121-34	14
2181	Current management of advanced non-small cell lung cancer: targeted therapy. 2005 , 32, 315-28	39
2180	Matrix metalloproteinases and angiogenesis. 2005 , 9, 267-85	672
2179	Bone marrow expression of vascular endothelial growth factor in myelofibrosis with myeloid metaplasia. 2005 , 74, 35-9	10
2178	Expression analysis of secreted and cell surface genes of five transformed human cell lines and derivative xenograft tumors. 2005 , 6, 55	8
2177	Evaluation of stromal metalloproteinases and vascular endothelial growth factors in a spontaneous metastasis model. 2005 , 79, 259-64	9
2176	In vivo efficacy of HSV-TK transcriptionally targeted to the tumour vasculature is augmented by combination with cytotoxic chemotherapy. 2005 , 7, 263-75	20
2175	Antiangiogenic and antitumoral properties of a polysaccharide isolated from the seaweed <i>Sargassum stenophyllum</i> . 2005 , 56, 436-46	70
2174	The anti-angiogenic effect of sinomenine. 2005 , 8, 3-12	76
2173	Inhibition of p53 during physiological angiogenesis in the hamster ovary does not affect extent of new vessel formation but delays vessel maturation. 2005 , 320, 427-35	2
2172	The merits of vascular targeting for gynecologic malignancies. 2005 , 7, 444-50	2
2171	Cancer as a programmed death of an organism. 2005 , 70, 1055-64	10
2170	Biological significance of c-erbB family oncogenes in head and neck cancer. 2005 , 24, 47-69	142
2169	On evolutionary origin of cancer. 2005 , 5, 5	20
2168	New approaches for modelling cancer mechanisms in the mouse. 2005 , 205, 181-93	43
2167	Coexpression of Angiogenic Factors in Brain Arteriovenous Malformations. 2005 ,	0
2166	Contribution of bone marrow-derived pericyte precursor cells to corneal vasculogenesis. 2005 , 46, 3502-6	69
2165	Development of angiogenesis inhibitors to vascular endothelial growth factor receptor 2. Current status and future perspective. 2005 , 10, 1415-39	50

2164	Application of RNAi to cancer research and therapy. 2005 , 10, 1946-60	19
2163	Angiogenesis. 2005 , 257-265	
2162	Multimodality tumor imaging targeting integrin alphavbeta3. 2005 , 39, S14-25	51
2161	Combination of interferon and angiotensin-converting enzyme inhibitor, perindopril, suppresses liver carcinogenesis and angiogenesis in mice. 2005 , 13, 491	4
2160	Molecular pathways of endothelial cell activation for (targeted) pharmacological intervention of chronic inflammatory diseases. 2005 , 3, 11-39	62
2159	Cutaneous metastasis from glioblastoma. 2005 , 19, 65-8	25
2158	Angiogenesis in lymphoma: a short review. 2005 , 5, 609-13	3
2157	Molecular consequences of silencing mutant K-ras in pancreatic cancer cells: justification for K-ras-directed therapy. 2005 , 3, 413-23	160
2156	Detection of early antiangiogenic effects in human colon adenocarcinoma xenografts: in vivo changes of tumor blood volume in response to experimental VEGFR tyrosine kinase inhibitor. 2005 , 65, 9253-60	24
2155	Overexpression of platelet-derived growth factor receptor alpha in endothelial cells of hepatocellular carcinoma associated with high metastatic potential. 2005 , 11, 8557-63	85
2154	The role of pericytes in blood-vessel formation and maintenance. 2005 , 7, 452-64	1001
2153	Decreased expression of angiogenic factors in placentas with chorioamnionitis after preterm birth. 2005 , 58, 607-12	40
2152	Tumor Vasculature as a Target for Cancer Therapy. 2005 , 415-428	
2151	Soluble Robo4 receptor inhibits in vivo angiogenesis and endothelial cell migration. 2005 , 19, 121-3	150
2150	Proliferation of endothelial and tumor epithelial cells by progestin-induced vascular endothelial growth factor from human breast cancer cells: paracrine and autocrine effects. 2005 , 146, 3632-41	61
2149	In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models. 2005 , 11, 3633-41	156
2148	Angiogenic inhibitors: a new therapeutic strategy in oncology. 2005 , 2, 562-77	166
2147	New insights into intussusceptive angiogenesis. 2005 , 17-33	17

2146	A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. 2005 , 23, 939-52	449
2145	Id2 mediates tumor initiation, proliferation, and angiogenesis in Rb mutant mice. 2005 , 25, 3563-74	101
2144	AP23846, a novel and highly potent Src family kinase inhibitor, reduces vascular endothelial growth factor and interleukin-8 expression in human solid tumor cell lines and abrogates downstream angiogenic processes. 2005 , 4, 1900-11	76
2143	Integrins. 2005 , 201-227	
2142	Bone Metastasis. 2005 ,	1
2141	Molecularly-targeted therapies for non-small cell lung cancer. 2005 , 6, 2667-79	5
2140	Integration/Interaction of Oncologic Growth. 2005 ,	3
2139	Enhanced susceptibility of irradiated tumor vessels to vascular endothelial growth factor receptor tyrosine kinase inhibition. 2005 , 65, 5374-9	47
2138	Neamine inhibits xenografic human tumor growth and angiogenesis in athymic mice. 2005 , 11, 8745-52	38
2137	Headpin: a serpin with endogenous and exogenous suppression of angiogenesis. 2005 , 65, 11501-9	23
2136	Targeting invasion induction as a therapeutic strategy for the treatment of cancer. 2005 , 5, 489-503	16
2135	Liposomal targeting of angiogenic vasculature. 2005 , 2, 363-8	10
2134	Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions. 2005 , 23, 1295-311	169
2133	Cyclooxygenase-2 inhibitors decrease vascular endothelial growth factor expression in colon cancer cells by enhanced degradation of Sp1 and Sp4 proteins. 2005 , 68, 317-29	103
2132	Matrix Metalloproteinases: Mediators of Tumour-Host Cell Interactions. 2005 , 81-126	
2131	Introduction. Critical role of anti-angiogenesis and VEGF inhibition in colorectal cancer. 2005 , 69 Suppl 3, 1-3	30
2130	Managing patients treated with bevacizumab combination therapy. 2005 , 69 Suppl 3, 25-33	232
2129	Anti-angiogenic strategies for cancer therapy (Review). 2005 , 27, 563	2

2128	VEGF profiling and angiogenesis in human microtissues. 2005 , 118, 213-29	75
2127	Imaging angiogenesis: applications and potential for drug development. 2005 , 97, 172-87	276
2126	Mechanisms of Angiogenesis. 2005 ,	5
2125	PET imaging of tumor integrin expression.	
2124	Novel therapeutics in adult malignant brain gliomas. 2005 , 14, 643-58	4
2123	Time-resolved optical mammography between 637 and 985 nm: clinical study on the detection and identification of breast lesions. 2005 , 50, 2469-88	95
2122	Combination of vitamin K2 and the angiotensin-converting enzyme inhibitor, perindopril, attenuates the liver enzyme-altered preneoplastic lesions in rats via angiogenesis suppression. 2005 , 42, 687-93	62
2121	p53-dependent inhibition of progestin-induced VEGF expression in human breast cancer cells. 2005 , 93, 173-82	28
2120	Immunohistochemical analysis of tumor angiogenic factors in human pituitary adenomas. 2005 , 36, 1090-5	54
2119	Endogenous thrombospondin-1 is not necessary for proliferation but is permissive for vascular smooth muscle cell responses to platelet-derived growth factor. 2005 , 24, 110-23	50
2118	Tumstatin, the NC1 domain of alpha3 chain of type IV collagen, is an endogenous inhibitor of pathological angiogenesis and suppresses tumor growth. 2005 , 333, 292-8	92
2117	Platelet-derived growth factor receptor (PDGFR): a target for anticancer therapeutics. 2005 , 8, 75-83	100
2116	Long-term observation reveals time-course-dependent characteristics of tumour vascularisation. 2005 , 41, 1073-85	17
2115	VEGF, FGF2, TGFB1 and TGFBR1 mRNA expression levels correlate with the malignant transformation of the uterine cervix. 2005 , 221, 105-18	59
2114	[New strategies to interfere with radiation response: "biomodulation" of radiation therapy]. 2005 , 9, 69-76	6
2113	Angiogenetic signaling through hypoxia: HMGB1: an angiogenetic switch molecule. 2005 , 166, 1259-63	190
2112	VEGF as a key mediator of angiogenesis in cancer. 2005 , 69 Suppl 3, 4-10	1006
2111	Using intrathecal colistin for multidrug resistant shunt infection. 2005 , 19, 51-2	19

2110	Synthesis of chiral 2-(4-phenoxyphenylsulfonylmethyl)thiiranes as selective gelatinase inhibitors. 2005 , 7, 4463-5	53
2109	Antineovascular therapy, a novel antiangiogenic approach. 2005 , 9, 63-76	17
2108	The future development of bevacizumab in colorectal cancer. 2005 , 69 Suppl 3, 34-45	9
2107	Regulation of the pathological vasculature of malignant astrocytomas by angiopoietin-1. 2005 , 7, 1081-90	18
2106	Spontaneous human adult stem cell transformation. 2005 , 65, 3035-9	899
2105	Tyrosine kinase inhibitors and the dawn of molecular cancer therapeutics. 2005 , 45, 357-84	107
2104	Molecular Biology of Human Cancers. 2005 ,	4
2103	Mechanisms of disease: Oncogene addiction--a rationale for molecular targeting in cancer therapy. 2006 , 3, 448-57	552
2102	Angiogenesis in Chronic Lymphocytic Leukemia: An Emerging Target. 2006 , 1, 118-122	4
2101	Breast Cancer and Molecular Medicine. 2006 ,	2
2100	Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. 2006 , 82, 699-757	506
2099	Chemokine Biology [Basic Research and Clinical Application. 2006 ,	2
2098	Metronomic dosing of chemotherapy: applications in pediatric oncology. 2006 , 24, 432-43	28
2097	Antiprotease therapy in cancer: hot or not?. 2006 , 6, 257-79	75
2096	ICS-283: a system for targeted intravenous delivery of siRNA. 2006 , 3, 445-54	17
2095	A multitargeted receptor tyrosine kinase inhibitor, SU6668, does not affect the healing of cutaneous full-thickness incisional wounds in SKH-1 mice. 2006 , 19, 245-54	7
2094	Mechanisms of disease: angiogenesis in urologic malignancies. 2006 , 3, 157-69	44
2093	Potential use of humanized antibodies in the treatment of breast cancer. 2006 , 6, 1065-74	14

2092	The tumor microenvironment: key to early detection. 2006 , 43, 393-425	50
2091	Mastic oil from <i>Pistacia lentiscus</i> var. <i>chia</i> inhibits growth and survival of human K562 leukemia cells and attenuates angiogenesis. 2006 , 55, 86-93	65
2090	Side reaction of significance in preparation of peptide- or peptidomimetic-based hydroxamate enzyme inhibitors. 2006 , 71, 2885-7	2
2089	Macrophages regulate the angiogenic switch in a mouse model of breast cancer. 2006 , 66, 11238-46	813
2088	A review on pro- and anti-angiogenic factors as targets of clinical intervention. 2006 , 53, 89-103	126
2087	INGN 201 (Advexin): adenoviral p53 gene therapy for cancer. 2006 , 6, 823-32	48
2086	Targeting the expression of platelet-derived growth factor receptor by reactive stroma inhibits growth and metastasis of human colon carcinoma. 2006 , 169, 2054-65	87
2085	Molecular cross-talk between the NFkappaB and STAT3 signaling pathways in head and neck squamous cell carcinoma. 2006 , 8, 733-46	137
2084	Bioavailability of VEGF in tumor-shed vesicles depends on vesicle burst induced by acidic pH. 2006 , 8, 96-103	143
2083	Sustained angiopoietin-2 expression disrupts vessel formation and inhibits glioma growth. 2006 , 8, 419-28	35
2082	Tumor stroma and regulation of cancer development. 2006 , 1, 119-50	750
2081	Peptide-labeled near-infrared quantum dots for imaging tumor vasculature in living subjects. 2006 , 6, 669-76	836
2080	Tumor stroma fosters neovascularization by recruitment of progenitor cells into the tumor bed. 2006 , 10, 806-814	78
2079	Macrophage inflammatory protein-2 promotes angiogenesis, cell migration, and tumor growth in hepatic metastasis. 2006 , 13, 263-75	33
2078	Anti-angiogenic therapy: Prospects for treatment of ocular tumors. 2006 , 21, 151-60	22
2077	Circulating endothelial cells and angiogenic serum factors during neoadjuvant chemotherapy of primary breast cancer. 2006 , 94, 524-31	192
2076	Hypoxic induction of human visfatin gene is directly mediated by hypoxia-inducible factor-1. 2006 , 580, 4105-13	101
2075	Identification of the angiogenesis signaling domain in pleiotrophin defines a mechanism of the angiogenic switch. 2006 , 343, 653-8	32

2074	Over-expression of p53 mutants in LNCaP cells alters tumor growth and angiogenesis in vivo. 2006 , 345, 1207-14	12
2073	Characterization of the human EDF-1 minimal promoter: involvement of NFY and Sp1 in the regulation of basal transcription. 2006 , 374, 87-95	11
2072	Involvement of hepatocyte growth factor in the development of bone metastasis of a mouse mammary cancer cell line, BALB/c-MC. 2006 , 39, 27-34	28
2071	TWEAK and Fn14: new molecular targets for cancer therapy?. 2006 , 235, 11-7	54
2070	Transcriptional deregulation of VEGF, FGF2, TGF-beta1, 2, 3 and cognate receptors in breast tumorigenesis. 2006 , 235, 100-13	17
2069	The tumor microenvironment in the post-PAGET era. 2006 , 242, 1-10	109
2068	Targeting the stromal microenvironment in chronic inflammation. 2006 , 6, 393-400	31
2067	Targeted therapies in melanoma. 2006 , 32, 524-31	16
2066	Angiopoietin 1 (Ang-1), angiopoietin 2 (Ang-2) and Tie-2 (a receptor tyrosine kinase) concentrations in peripheral blood of patients with thyroid cancers. 2006 , 36, 291-5	27
2065	Microtubule-targeting agents in angiogenesis: where do we stand?. 2006 , 9, 74-86	70
2064	Angiogenesis in multiple myeloma. 2006 , 42, 1581-90	118
2063	Effect of sinomenine on gene expression of the IL-1 beta-activated human synovial sarcoma. 2006 , 79, 665-73	25
2062	Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1. 2006 , 79, 2370-81	130
2061	Angiogenic profile of soft tissue sarcomas based on analysis of circulating factors and microarray gene expression. 2006 , 135, 282-90	49
2060	Angiogenesis inhibition plus chemotherapy for metastatic hormone refractory prostate cancer: history and rationale. 2006 , 24, 250-3	32
2059	Inhibition of microvascular endothelial cell apoptosis by angiopoietin-1 and the involvement of cytochrome C. 2006 , 119, 725-730	5
2058	Protein Tyrosine Kinases as Targets for Cancer and Other Indications. 2006 , 1-29	3
2057	Molecular Imaging in Cancer. 705-727	1

2056	Polymeric Conjugates for Angiogenesis-Targeted Tumor Imaging and Therapy. 2006 , 159-184	
2055	Proangiogenic role of neutrophil-like inflammatory heterophils during neovascularization induced by growth factors and human tumor cells. 2006 , 107, 317-27	60
2054	Zebrafish G protein gamma2 is required for VEGF signaling during angiogenesis. 2006 , 108, 160-6	48
2053	Tumor Angiogenesis. 1087-1106	0
2052	Signal Transduction Therapy with Rationally Designed Kinase Inhibitors. 2006 , 1, 67-95	36
2051	Review of selected patents for cancer therapy targeting tumor angiogenesis. 2006 , 1, 153-61	4
2050	Cytokines and chemokines as regulators of angiogenesis in health and disease. 2006 , 12, 3101-15	97
2049	Curcumin inhibits hypoxia-induced angiogenesis via down-regulation of HIF-1. 2006 , 15, 1557	19
2048	Antiangiogenic cancer therapies get their act together: current developments and future prospects of growth factor- and growth factor receptor-targeted approaches. 2006 , 15, 175-86	37
2047	Peptide-based molecules in angiogenesis. 2006 , 67, 115-26	81
2046	VEGF controls endothelial-cell permeability by promoting the beta-arrestin-dependent endocytosis of VE-cadherin. 2006 , 8, 1223-34	768
2045	New signals from the invasive front. 2006 , 441, 444-50	780
2044	Liposome-DNA complexes infused intravenously inhibit tumor angiogenesis and elicit antitumor activity in dogs with soft tissue sarcoma. 2006 , 13, 306-17	44
2043	Tissue factor as an effector of angiogenesis and tumor progression in hematological malignancies. 2006 , 20, 1331-40	60
2042	Involvement of RB gene family in tumor angiogenesis. 2006 , 25, 5326-32	45
2041	MicroRNAs and the hallmarks of cancer. 2006 , 25, 6170-5	291
2040	Microarray expression profiles of angiogenesis-related genes predict tumor cell response to artemisinins. 2006 , 6, 269-78	102
2039	Enzymatic esterification of flavonoids with unsaturated fatty acids: Effect of the novel esters on vascular endothelial growth factor release from K562 cells. 2006 , 41, 2029-2034	101

2038	Ultrasound assessment of angiogenesis in a matrigel model in rats. 2006 , 32, 673-81	33
2037	Tumor growth or regression: powered by inflammation. 2006 , 80, 685-90	49
2036	Selective blockade of vascular endothelial growth factor receptor 2 with an antibody against tumor-derived vascular endothelial growth factor controls the growth of human pancreatic adenocarcinoma xenografts. 2006 , 13, 1145-55	27
2035	TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility. 2006 , 11, 397-408	510
2034	Longitudinal microPET imaging of brain tumor growth with F-18-labeled RGD peptide. 2006 , 8, 9-15	30
2033	Transfer of siRNA against XIAP induces apoptosis and reduces tumor cells growth potential in human breast cancer in vitro and in vivo. 2006 , 96, 267-77	32
2032	Matrix metalloproteinases and tumor metastasis. 2006 , 25, 9-34	1555
2031	MT1-MMP: universal or particular player in angiogenesis?. 2006 , 25, 77-86	112
2030	Inhibitors of growth factor receptors, signaling pathways and angiogenesis as therapeutic molecular agents. 2006 , 25, 243-52	24
2029	Metastasis: cell-autonomous mechanisms versus contributions by the tumor microenvironment. 2006 , 63, 449-68	190
2028	The application of NMR in tumor angiogenesis research. 2006 , 49, 27-44	12
2027	Targeted therapies in colorectal cancer: Complications and management. 2006 , 2, 125-133	2
2026	The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma. 2006 , 102, 425-8	104
2025	Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. 2006 , 10, 159-70	351
2024	Role of haematopoietic cells and endothelial progenitors in tumour angiogenesis. 2006 , 1766, 159-66	49
2023	Assessing responses to cancer therapy using molecular imaging. 2006 , 1766, 242-61	45
2022	Molecular pathways in renal cell carcinoma--rationale for targeted treatment. 2006 , 33, 588-95	55
2021	Notch signaling in the regulation of tumor angiogenesis. 2006 , 16, 293-300	97

2020	Development of antibody-based therapeutics for oncology indications. 2006 , 67, 699-728	2
2019	Differential effects of matrix and growth factors on endothelial and fibroblast motility: application of a modified cell migration assay. 2006 , 99, 1536-52	53
2018	Bystander effects are induced by CENU treatment and associated with altered protein secretory activity of treated tumor cells: a relay for chemotherapy?. 2006 , 119, 992-1004	35
2017	Outgrowth of human liver metastases after resection of the primary colorectal tumor: a shift in the balance between apoptosis and proliferation. 2006 , 119, 1249-53	106
2016	Expression of activated platelet-derived growth factor receptor in stromal cells of human colon carcinomas is associated with metastatic potential. 2006 , 119, 2567-74	82
2015	Breast cancer cells secreted platelet-derived growth factor-induced motility of vascular smooth muscle cells is mediated through neuropilin-1. 2006 , 45, 871-80	74
2014	Piecing together the HIF-1 puzzle: the role of the CTGF as a molecular mechanism of HIF-1 regulation. 2006 , 5, 1443-4	3
2013	Inhibiting vascular endothelial growth factor receptor-2 signaling reduces tumor burden in the ApcMin/+ mouse model of early intestinal cancer. 2006 , 27, 2133-9	52
2012	Systemic induction of the angiogenesis switch by the tetraspanin D6.1A/CO-029. 2006 , 66, 7083-94	182
2011	Temporal targeting in cancer: combined chemotherapy and antiangiogenic therapy. 2006 , 1, 359-63	
2010	Multimodality imaging of tumor integrin $\alpha v \beta 3$ expression. 2006 , 6, 227-34	93
2009	The bone marrow constitutes a reservoir of pericyte progenitors. 2006 , 80, 677-81	102
2008	Moderate antiangiogenic activity by local, transgenic expression of endostatin in Rip1Tag2 transgenic mice. 2006 , 80, 669-76	2
2007	The inflammatory tumor microenvironment and its impact on cancer development. 2006 , 13, 118-137	161
2006	Biological assays and genomic analysis reveal lipoic acid modulation of endothelial cell behavior and gene expression. 2007 , 28, 1008-20	26
2005	An oriental herbal cocktail, ka-mi-kae-kyuk-tang, exerts anti-cancer activities by targeting angiogenesis, apoptosis and metastasis. 2006 , 27, 2455-63	63
2004	Mechanisms regulating tumor angiogenesis by 12-lipoxygenase in prostate cancer cells. 2006 , 281, 18601-9	80
2003	Magnitude of stromal hemangiogenesis correlates with histologic subtype of non-Hodgkin's lymphoma. 2006 , 12, 5622-31	66

2002	Vascular proliferation is important for clinical progress of endometrial cancer. 2006 , 66, 3303-9	102
2001	The role of the vascular endothelial growth factor-Delta-like 4 ligand/Notch4-ephrin B2 cascade in tumor vessel remodeling and endothelial cell functions. 2006 , 66, 8501-10	138
2000	Tumor cell populations differ in angiogenic activity: a model system for spontaneous angiogenic switch can tell us why. 2006 , 98, 294-5	10
1999	Alleviating the burden of cancer: a perspective on advances, challenges, and future directions. 2006 , 15, 2049-55	18
1998	Hepatocyte growth factor and inducible nitric oxide synthase are involved in multidrug resistance-induced angiogenesis in hepatocellular carcinoma cell lines. 2006 , 66, 2673-82	52
1997	Essential role of Vav family guanine nucleotide exchange factors in EphA receptor-mediated angiogenesis. 2006 , 26, 4830-42	109
1996	Vascular endothelial growth factor induces proliferation of breast cancer cells and inhibits the anti-proliferative activity of anti-hormones. 2006 , 13, 905-19	106
1995	How molecular imaging is speeding up antiangiogenic drug development. 2006 , 5, 2624-33	178
1994	The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis. 2006 , 12, 1839-49	51
1993	Antiangiogenic activity of 4'-thio-beta-D-arabinofuranosylcytosine. 2006 , 5, 2218-24	12
1992	Proteolytically processed soluble tumor endothelial marker (TEM) 5 mediates endothelial cell survival during angiogenesis by linking integrin alpha(v)beta3 to glycosaminoglycans. 2006 , 281, 34179-88	59
1991	Quantitative Evaluation of Bone Marrow Angiogenesis in Idiopathic Myelofibrosis. 2006 , 126, 241-247	30
1990	Characterization of a von Hippel Lindau pathway involved in extracellular matrix remodeling, cell invasion, and angiogenesis. 2006 , 66, 1313-9	103
1989	Imatinib inhibits c-Kit-induced hypoxia-inducible factor-1alpha activity and vascular endothelial growth factor expression in small cell lung cancer cells. 2006 , 5, 1415-22	91
1988	Molekulare Pharmakologie und Toxikologie. 2006 ,	
1987	Effect of connective tissue growth factor on hypoxia-inducible factor 1alpha degradation and tumor angiogenesis. 2006 , 98, 984-95	65
1986	Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor promote malignant growth of cells from head and neck squamous cell carcinomas in vivo. 2006 , 66, 8026-36	101
1985	In vitro and in vivo characterization of 64Cu-labeled Abegrin, a humanized monoclonal antibody against integrin alpha v beta 3. 2006 , 66, 9673-81	176

1984	Improvement by solid dispersion of the bioavailability of KRN633, a selective inhibitor of VEGF receptor-2 tyrosine kinase, and identification of its potential therapeutic window. 2006 , 5, 80-8	7
1983	Giving blood: a new role for CD40 in tumorigenesis. 2006 , 203, 2409-12	28
1982	NG2/HMP proteoglycan as a cancer therapeutic target. 2007 , 361, 93-117	5
1981	Target Discovery and Validation Reviews and Protocols. 2006 ,	1
1980	Semaphorin 4D provides a link between axon guidance processes and tumor-induced angiogenesis. 2006 , 103, 9017-22	170
1979	Anti-VEGF therapy: a new approach to colorectal cancer therapy. 2006 , 6, 1385-96	13
1978	Hypoxic regulation of vascular endothelial growth factor through the induction of phosphatidylinositol 3-kinase/Rho/ROCK and c-Myc. 2006 , 281, 13957-63	72
1977	Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies. 2006 , 66, 11520-39	211
1976	Genomics and proteomics approaches in understanding tumor angiogenesis. 2007 , 7, 133-47	9
1975	Expression of the hypoxia marker carbonic anhydrase 9 is associated with anaplastic phenotypes in meningiomas. 2007 , 13, 68-75	24
1974	Angiopoietin-2 serum levels are elevated in patients with liver cirrhosis and hepatocellular carcinoma. 2007 , 102, 2471-81	43
1973	Deletion of tetraspanin Cd151 results in decreased pathologic angiogenesis in vivo and in vitro. 2007 , 109, 1524-32	141
1972	Back to basics: how natural products can provide the basis for new therapeutics. 2007 , 16, 1753-73	103
1971	New approaches in systemic treatment of advanced colorectal cancer: the molecular targets era. 2007 , 7, 1027-41	2
1970	Upregulated expression of PDGF receptor beta in endocrine pancreatic tumors and metastases compared to normal endocrine pancreas. 2007 , 46, 741-6	54
1969	Altered protein expression at early-stage rat hepatic neoplasia. 2007 , 292, G1272-82	12
1968	Monitoring response to anticancer therapy by targeting microbubbles to tumor vasculature. 2007 , 13, 323-30	228
1967	The biochemical, biological, and pathological kaleidoscope of cell surface substrates processed by matrix metalloproteinases. 2007 , 42, 113-85	282

1966	Angiogenesis inhibitors. Drug selectivity and target specificity. 2007 , 13, 2795-809	37
1965	Targeted in vivo imaging of angiogenesis: present status and perspectives. 2007 , 13, 17-31	43
1964	Renin-angiotensin system inhibitors as therapeutic alternatives in the treatment of chronic liver diseases. 2007 , 14, 2749-54	31
1963	VEGF-specific short hairpin RNA-expressing oncolytic adenovirus elicits potent inhibition of angiogenesis and tumor growth. 2007 , 15, 295-302	118
1962	Clinical and biological significance of vascular endothelial growth factor in endometrial cancer. 2007 , 13, 7487-95	150
1961	Molecular and cellular regulators of cancer angiogenesis. 2007 , 7, 743-58	55
1960	A phase I clinical trial of an adenovirus-mediated endostatin gene (E10A) in patients with solid tumors. 2007 , 6, 648-53	28
1959	PI-88 and novel heparan sulfate mimetics inhibit angiogenesis. 2007 , 33, 557-68	121
1958	Biological therapy update in colorectal cancer. 2007 , 7, 509-19	8
1957	Insights into the mechanisms involved in magnesium-dependent inhibition of primary tumor growth. 2007 , 59, 192-8	25
1956	Rapidly acting antitumoral antiangiogenic therapies. 2007 , 76, 031920	13
1955	The potential of antiangiogenic therapy in non-small cell lung cancer. 2007 , 13, 1961-70	57
1954	The NC1 domain of type XIX collagen inhibits in vivo melanoma growth. 2007 , 6, 506-14	31
1953	A chronic grey matter penumbra, lateral microvascular intussusception and venous peduncular avulsion underlie diabetic vitreous haemorrhage. 2007 , 91, 677-89	17
1952	Phenethyl isothiocyanate inhibits angiogenesis in vitro and ex vivo. 2007 , 67, 2239-46	132
1951	Human neutrophils uniquely release TIMP-free MMP-9 to provide a potent catalytic stimulator of angiogenesis. 2007 , 104, 20262-7	369
1950	Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer. 2007 , 67, 281-8	124
1949	NeuropeptideY: Neurogenic Mediator of Angiogenesis and Arteriogenesis. 2007 , 91-117	

1948	In vivo imaging of the systemic recruitment of fibroblasts to the angiogenic rim of ovarian carcinoma tumors. 2007 , 67, 9180-9	82
1947	Identification of mRNAs that continue to associate with polysomes during hypoxia. 2007 , 13, 1116-31	76
1946	Interference of macrophage migration inhibitory factor expression in a mouse melanoma inhibits tumor establishment by up-regulating thrombospondin-1. 2007 , 5, 1225-31	10
1945	Th1- and Th2-dependent endothelial progenitor cell recruitment and angiogenic switch in asthma. 2007 , 178, 6482-94	71
1944	Vandetanib, A Dual Inhibitor of VEGFR and EGFR Tyrosine Kinase Activity. 2007 , 3, 236-241	
1943	Dominant-negative activator protein 1 (TAM67) targets cyclooxygenase-2 and osteopontin under conditions in which it specifically inhibits tumorigenesis. 2007 , 67, 2430-8	37
1942	Distinctive features of angiogenesis and lymphangiogenesis determine their functionality during de novo tumor development. 2007 , 67, 5211-20	28
1941	Review: monoclonal antibodies to the vascular endothelial growth factor receptor-2 in cancer therapy. 2007 , 13, 5544s-5548s	64
1940	The homeobox gene GAX activates p21WAF1/CIP1 expression in vascular endothelial cells through direct interaction with upstream AT-rich sequences. 2007 , 282, 507-17	30
1939	Bevacizumab (Avastin). 2008 , 779-812	
1938	Inhibition of hypoxia-induced angiogenesis by sodium butyrate, a histone deacetylase inhibitor, through hypoxia-inducible factor-1 β suppression. 2007 , 17, 793	3
1937	Proteomic characterization of angiogenic endothelial cells stimulated with cancer cell-conditioned medium. 2007 , 30, 2300-7	20
1936	Re-activation of the p53 pathway inhibits in vivo and in vitro growth of hormone-dependent human breast cancer cells. 2007 ,	1
1935	Enhanced expression of asparagine synthetase under glucose-deprived conditions protects pancreatic cancer cells from apoptosis induced by glucose deprivation and cisplatin. 2007 , 67, 3345-55	69
1934	Vascular endothelial growth factor and its receptor as drug targets in hematological malignancies. 2007 , 8, 257-68	42
1933	Overexpression of VEGF and TGF- β mRNA in Pap smears correlates with progression of cervical intraepithelial neoplasia to cancer: Implication of YY1 in cervical tumorigenesis and HPV infection. 2007 ,	2
1932	Therapeutic options for hormone-refractory prostate cancer in 2007. 2007 , 25, 413-9	52
1931	Targeting metastatic and advanced breast cancer. 2007 , 23, 37-45	7

1930	Magnesium and neoplasia: from carcinogenesis to tumor growth and progression or treatment. 2007 , 458, 24-32	70
1929	Modulation of in vitro and in vivo angiogenesis by alternagin-C, a disintegrin-like protein from Bothrops alternatus snake venom and by a peptide derived from its sequence. 2007 , 461, 1-6	27
1928	Quantification of angiogenesis by the Chalkley method and its prognostic significance in epithelial ovarian cancer. 2007 , 43, 1300-7	16
1927	A novel angiogenesis inhibitor, Ki23057, is useful for preventing the progression of colon cancer and the spreading of cancer cells to the liver. 2007 , 43, 2612-20	13
1926	CXCR4/CXCL12 axis promotes VEGF-mediated tumor angiogenesis through Akt signaling pathway. 2007 , 359, 716-22	241
1925	Corticotropin-releasing factor family and its receptors: tumor therapeutic targets?. 2007 , 362, 785-8	18
1924	Multipotent Adult Progenitor Cells (MAPC) contribute to hepatocarcinoma neovasculature. 2007 , 364, 92-9	11
1923	Effects of anti-hypertensive drugs on vessel rarefaction. 2007 , 7, 151-7	45
1922	Neuropeptide Y in neural crest-derived tumors: effect on growth and vascularization. 2007 , 245, 293-302	15
1921	A conjugate of camptothecin and a somatostatin analog against prostate cancer cell invasion via a possible signaling pathway involving PI3K/Akt, alphaVbeta3/alphaVbeta5 and MMP-2/-9. 2007 , 246, 157-66	50
1920	Mutant p53 facilitates pro-angiogenic, hyperproliferative phenotype in response to chronic relative hypoxia. 2007 , 249, 209-19	42
1919	The emerging role of pituitary tumour transforming gene (PTTG) in endocrine tumourigenesis. 2007 , 278, 1-6	13
1918	A hypoxia-controlled cap-dependent to cap-independent translation switch in breast cancer. 2007 , 28, 501-12	221
1917	Molecular-functional imaging of cancer: to image and imagine. 2007 , 13, 287-97	62
1916	Metastasis: recent discoveries and novel treatment strategies. 2007 , 369, 1742-57	558
1915	Targeting the vascular endothelial growth factor pathway in the treatment of multiple myeloma. 2007 , 7, 551-66	11
1914	Tumor cell-organ microenvironment interactions in the pathogenesis of cancer metastasis. 2007 , 28, 297-321	278
1913	Kinase Inhibitors for Cancer. 2007 , 183-220	1

1912	Behavioral Interventions: Immunologic Mediators and Disease Outcomes. 2007 , 675-703	2
1911	Trends in therapeutic monoclonal antibodies of cancer. 2007 , 17, 1047-59	2
1910	Development of Angiogenesis Inhibitors to Vascular Endothelial Growth Factor Receptor 2 for Cancer Therapy. 2007 , 333-382	
1909	Dynamics of tumor growth and combination of anti-angiogenic and cytotoxic therapies. 2007 , 52, 3665-77	48
1908	Anginex-conjugated liposomes for targeting of angiogenic endothelial cells. 2007 , 18, 785-90	39
1907	Islet cell carcinoma: neuroendocrine tumors of the pancreas and periampullary region. 2007 , 21, 457-73; viii	12
1906	Bronchoscopy for bevacizumab-related hemoptysis. 2007 , 56, 465-8	14
1905	The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. 2007 , 5, 203-20	323
1904	Cancer cell: using inflammation to invade the host. 2007 , 6, 29	39
1903	Characterization of thimet oligopeptidase and neurolysin activities in B16F10-Nex2 tumor cells and their involvement in angiogenesis and tumor growth. 2007 , 6, 44	33
1902	Enhancing the anti-angiogenic action of histone deacetylase inhibitors. 2007 , 6, 68	22
1901	Plaque neovascularization and antiangiogenic therapy for atherosclerosis. 2007 , 49, 2073-80	190
1900	Mathematical models of the VEGF receptor and its role in cancer therapy. 2007 , 4, 283-304	20
1899	Inhibition of angiogenesis and invasion in malignant gliomas. 2007 , 7, 1537-60	44
1898	Markers of angiogenesis in ovarian cancer. 2007 , 23, 419-31	20
1897	CD31 and CD34 expression as immunohistochemical markers of endothelial transdifferentiation in human cutaneous melanoma. 2007 , 29, 59-66	20
1896	Characterization and clinical relevance of circulating and biopsy-derived endothelial progenitor cells in lymphoma patients. 2007 , 92, 469-77	55
1895	Multimodality imaging of vascular endothelial growth factor and vascular endothelial growth factor receptor expression. 2007 , 12, 4267-79	82

1894	Anti-angiogenic therapy for metastatic colorectal cancer. 2007 ,	
1893	Angiogenesis. 1444-1456	
1892	Angiogenesis. 2007 ,	1
1891	6-(1-Oxobutyl)-5,8-dimethoxy-1,4-naphthoquinone inhibits lewis lung cancer by antiangiogenesis and apoptosis. 2007 , 120, 2481-90	21
1890	The Dickkopf-homolog 3 is expressed in tumor endothelial cells and supports capillary formation. 2008 , 122, 1539-47	53
1889	The role of the organ microenvironment in the biology and therapy of cancer metastasis. 2007 , 101, 927-36	110
1888	Sinusoidal remodeling and angiogenesis: a new function for the liver-specific pericyte?. 2007 , 45, 817-25	185
1887	Nitric oxide, a double edged sword in cancer biology: searching for therapeutic opportunities. 2007 , 27, 317-52	351
1886	In vivo growth inhibitory and anti-angiogenic effects of synthetic novel dienone cyclopropoxy curcumin analogs on mouse Ehrlich ascites tumor. 2007 , 15, 7696-703	45
1885	Vascular damaging agents. 2007 , 19, 443-56	114
1884	Development of a one-step embryonic stem cell-based assay for the screening of sprouting angiogenesis. 2007 , 7, 20	13
1883	Pharmacogenomics and the Yin/Yang actions of ginseng: anti-tumor, angiomodulating and steroid-like activities of ginsenosides. 2007 , 2, 6	145
1882	[Angiogenesis inhibitors in cancer therapy. Bevacizumab against colon carcinoma]. 2007 , 36, 442-5	1
1881	Loss of vascular endothelial growth factor expression reduces vascularization, but not growth, of tumors lacking the Von Hippel-Lindau tumor suppressor gene. 2007 , 26, 4531-40	9
1880	Conditional activation of FGFR1 in the prostate epithelium induces angiogenesis with concomitant differential regulation of Ang-1 and Ang-2. 2007 , 26, 4897-907	39
1879	Models, mechanisms and clinical evidence for cancer dormancy. <i>Nature Reviews Cancer</i> , 2007 , 7, 834-46	313 1157
1878	Molecular basis for sunitinib efficacy and future clinical development. 2007 , 6, 734-45	522
1877	High-grade clear cell renal cell carcinoma has a higher angiogenic activity than low-grade renal cell carcinoma based on histomorphological quantification and qRT-PCR mRNA expression profile. 2007 , 96, 1888-95	62

1876	Early increase in serum levels of the angiogenesis-inhibitor endostatin and of basic fibroblast growth factor in melanoma patients during disease progression. 2007 , 156, 653-8	22
1875	Bevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancer. 2007 , 32, 1-14	90
1874	Fibroblast growth factor-2-induced host stroma reaction during initial tumor growth promotes progression of mouse melanoma via vascular endothelial growth factor A-dependent neovascularization. 2007 , 98, 541-8	53
1873	Metabolism of a highly selective gelatinase inhibitor generates active metabolite. 2007 , 70, 371-82	37
1872	Intermittent hypoxia changes HIF-1alpha phosphorylation pattern in endothelial cells: unravelling of a new PKA-dependent regulation of HIF-1alpha. 2007 , 1773, 1558-71	48
1871	Glioma-associated endothelial cells show evidence of replicative senescence. 2007 , 313, 1192-202	21
1870	Synergistic up-regulation of Hexokinase-2, glucose transporters and angiogenic factors in pancreatic cancer cells by glucose deprivation and hypoxia. 2007 , 313, 3337-48	64
1869	Vascular endothelial growth factor (VEGF) pathway as a therapeutic target in gynecologic malignancies. 2007 , 104, 768-78	59
1868	Challenges of antiangiogenic cancer therapy: trials and errors, and renewed hope. 2007 , 11, 374-82	43
1867	Cancer stem cells: the lessons from pre-cancerous stem cells. 2008 , 12, 67-96	71
1866	Signal transducers and activators of transcription 3 up-regulates vascular endothelial growth factor production and tumor angiogenesis in head and neck squamous cell carcinoma. 2007 , 43, 785-90	25
1865	Highlights from: The 2007 Prostate Cancer Symposium, February 22-24, 2007; Orlando, FL. 2007 , 5, 249-55	3
1864	Progestin-dependent progression of human breast tumor xenografts: a novel model for evaluating antitumor therapeutics. 2007 , 67, 9929-36	67
1863	Non-invasive assessment of vessel morphology and function in tumors by magnetic resonance imaging. 2007 , 17, 2136-48	57
1862	Mechanisms of disease: angiogenesis and the management of breast cancer. 2007 , 4, 536-50	93
1861	Inhibition of tumor angiogenesis by p53: a new role for the guardian of the genome. 2007 , 85, 1175-86	175
1860	Neue Therapieansätze in der pädiatrischen Onkologie. 2007 , 155, 127-133	
1859	Challenges for patient selection with VEGF inhibitors. 2007 , 60, 151-70	72

1858	Hepatocyte growth factor in invasive growth of carcinomas. 2007 , 64, 1341-54	44
1857	Hypoxia: a key regulator of angiogenesis in cancer. 2007 , 26, 281-90	551
1856	Tumor-host interaction in the optimization of paclitaxel-based combination therapies with vascular targeting compounds. 2007 , 26, 481-8	10
1855	Lipoxygenase metabolism: roles in tumor progression and survival. 2007 , 26, 503-24	219
1854	Transcriptome analysis of endothelial cell gene expression induced by growth on matrigel matrices: identification and characterization of MAGP-2 and lumican as novel regulators of angiogenesis. 2007 , 10, 197-216	83
1853	Angiogenic response of endothelial cells seeded dispersed versus on beads in fibrin gels. 2007 , 10, 269-77	23
1852	Duffy antigen/receptor for chemokines (DARC) attenuates angiogenesis by causing senescence in endothelial cells. 2007 , 10, 307-18	18
1851	Angiogenesis in cancer: molecular mechanisms, clinical impact. 2007 , 392, 371-9	72
1850	Gen- und Stammzelltherapie der peripheren arteriellen Verschlusskrankheit. 2007 , 2, IV30-IV37	
1849	Current status of signal transduction modulators in the treatment of gynecologic malignancies. 2007 , 8, 383-92	5
1848	The platelet-derived growth factor receptor as a therapeutic target. 2007 , 9, 89-95	8
1847	Monoclonal antibody mechanisms of action in cancer. 2007 , 39, 271-8	86
1846	VEGF immunopositivity related to malignancy degree, proliferative activity and angiogenesis in ENU-induced gliomas. 2007 , 33, 163-72	14
1845	TWEAK and the central nervous system. 2007 , 35, 255-65	33
1844	Metronomic chemotherapy: an antiangiogenic scheduling. 2007 , 9, 93-8	51
1843	Lymph node metastasis as a new target for cancer treatment. 2007 , 2, 49-57	1
1842	New multitargeted treatments with antiangiogenic and antitumor activity: focus on sunitinib. 2007 , 2, 17-29	
1841	VEGF: a key therapeutic target for the treatment of cancer-insights into its role and pharmacological inhibition. 2007 , 2, 153-164	8

1840	New angiogenic agents and non-small cell lung cancer: current results and future development. 2007 , 2, 211-223	2
1839	Combining targeted therapies. 2007 , 2, 241-252	1
1838	Suppression of VEGF-mediated autocrine and paracrine interactions between prostate cancer cells and vascular endothelial cells by soy isoflavones. 2007 , 18, 408-17	80
1837	Immune cells as mediators of solid tumor metastasis. 2008 , 27, 11-8	281
1836	Targeting the EGFR, VEGFR, and PDGFR on colon cancer cells and stromal cells is required for therapy. 2008 , 25, 477-89	33
1835	Antiangiogenic and growth inhibitory effects of synthetic novel 1, 5-diphenyl-1,4 pentadiene-3-one-3-yl-ethanone pyridine curcumin analogues on Ehrlich ascites tumor in vivo. 2008 , 17, 515-529	7
1834	Connective tissue growth factor (CTGF) and cancer progression. 2008 , 15, 675-85	105
1833	A new era in prostate cancer therapy: new targets and novel therapeutics. 2008 , 3, 31-39	
1832	Advanced non-small cell lung cancer therapy: historical and future perspectives. 2008 , 3, 135-147	2
1831	Microenvironment changes (in pH) affect VEGF alternative splicing. 2008 , 1, 131-9	43
1830	HIV-1 Tat mimetic of VEGF correlates with increased microvessels density in AIDS-related diffuse large B-cell and Burkitt lymphomas. 2008 , 1, 3-10	10
1829	Following up tumour angiogenesis: from the basic laboratory to the clinic. 2008 , 10, 468-77	6
1828	The tumor microenvironment and its contribution to tumor evolution toward metastasis. 2008 , 130, 1091-103	359
1827	Inter-cellular adhesion disruption and the RAS/RAF and beta-catenin signalling in lung cancer progression. 2008 , 8, 7	9
1826	Structural characterization and anti-angiogenic properties of prostate-specific antigen isoforms in seminal fluid. 2008 , 68, 945-54	39
1825	Vasculature-targeted tumor necrosis factor-alpha increases the therapeutic index of doxorubicin against prostate cancer. 2008 , 68, 1105-15	41
1824	Potentially functional polymorphisms of the vascular endothelial growth factor gene and risk of gastric cancer. 2008 , 47, 647-51	36
1823	Design, synthesis and iodination of an Arg-Arg-Leu peptide for potential use as an imaging agent for human prostate carcinoma. 2008 , 51, 374-378	8

1822	Application of cryobiopsy to morphological and immunohistochemical analyses of xenografted human lung cancer tissues and functional blood vessels. 2008 , 113, 1068-79	36
1821	Reduced tumor growth in a mouse model of schizophrenia, lacking the dopamine transporter. 2008 , 123, 511-8	31
1820	In vivo activity of ABT-869, a multi-target kinase inhibitor, against acute myeloid leukemia with wild-type FLT3 receptor. 2008 , 32, 1091-100	22
1819	Surface specific peptide immobilization on radiografted polymers as potential screening assays for antiangiogenic immunotherapy. 2008 , 68, 77-90	2
1818	Dynamic contrast-enhanced susceptibility-weighted perfusion MRI (DSC-MRI) in a glioma model of the rat brain using a conventional receive-only surface coil with a inner diameter of 47 mm at a clinical 1.5 T scanner. 2008 , 172, 168-72	15
1817	Correlation between tumor growth delay and expression of cancer and host VEGF, VEGFR2, and osteopontin in response to radiotherapy. 2008 , 72, 918-26	37
1816	Effective delivery of an angiogenesis inhibitor by neovessel-targeted liposomes. 2008 , 360, 219-24	30
1815	Identification of amino acids essential for the antiangiogenic activity of tumstatin and its use in combination antitumor activity. 2008 , 105, 15040-5	50
1814	Regulation of endothelial junctional permeability. 2008 , 1123, 134-45	428
1813	Proliferaci3n vascular en las extremidades isqu3micas: una revisi3n de los mecanismos y posible estimulaci3n terap3utica. 2008 , 22, 635-652	
1812	Cancer micrometastasis and tumour dormancy. 2008 , 116, 754-70	133
1811	Melatonin modulates the expression of VEGF and HIF-1 alpha induced by CoCl2 in cultured cancer cells. 2008 , 44, 121-6	91
1810	Intermittent hypoxia is a key regulator of cancer cell and endothelial cell interplay in tumours. 2008 , 275, 2991-3002	112
1809	Short hairpin RNA-expressing oncolytic adenovirus-mediated inhibition of IL-8: effects on antiangiogenesis and tumor growth inhibition. 2008 , 15, 635-51	80
1808	A new terrein glucoside, a novel inhibitor of angiogenin secretion in tumor angiogenesis. 2008 , 61, 442-8	40
1807	Signal pathway profiling of epithelial and stromal compartments of colonic carcinoma reveals epithelial-mesenchymal transition. 2008 , 27, 323-31	51
1806	Hypoxia upregulates expression of human endosialin gene via hypoxia-inducible factor 2. 2008 , 99, 1348-56	46
1805	Oxytocin stimulates migration and invasion in human endothelial cells. 2008 , 153, 728-36	55

1804	Preparation of peptide-conjugated quantum dots for tumor vasculature-targeted imaging. 2008 , 3, 89-96	203
1803	The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting. 2008 , 7, 411-25	402
1802	Pharmacokinetic and pharmacodynamic study of intratumoral injection of an adenovirus encoding endostatin in patients with advanced tumors. 2008 , 15, 247-56	33
1801	Neoangiogenesis and expression of hypoxia-inducible factor 1alpha, vascular endothelial growth factor, and glucose transporter-1 in endometrioid type endometrium adenocarcinomas. 2008 , 108, 603-8	36
1800	Emerging safety data for bevacizumab in advanced non-small-cell lung cancer. 2008 , 9 Suppl 2, S62-70	6
1799	New options for integrating antiangiogenic therapy and platinum-based first-line chemotherapy for advanced non-small-cell lung cancer. 2008 , 9 Suppl 3, S100-8	3
1798	Sphingosine-1-phosphate induces the association of membrane-type 1 matrix metalloproteinase with p130Cas in endothelial cells. 2008 , 582, 399-404	37
1797	Targeting angiogenesis in head and neck cancer. 2008 , 35, 274-85	66
1796	Peritumor injections of purified tumstatin delay tumor growth and lymphatic metastasis in an orthotopic oral squamous cell carcinoma model. 2008 , 44, 1118-26	18
1795	The role of tissue inhibitors of metalloproteinases in tumorigenesis and metastasis. 2008 , 45, 291-338	96
1794	Immune Cells and Inflammatory Mediators as Regulators of Tumor Angiogenesis. 2008 , 225-237	4
1793	Serum vascular endothelial growth factor is related to systemic oxidative stress in patients with lung cancer. 2008 , 60, 271-6	29
1792	Elevated expression of carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM-1) is associated with increased angiogenic potential in non-small-cell lung cancer. 2008 , 60, 426-33	51
1791	Myeloid cells functioning in tumor vascularization as a novel therapeutic target. 2008 , 151, 59-67	21
1790	Antiangiogenic effects of flavonoids and chalcones. 2008 , 57, 259-65	163
1789	Bevacizumab in the Management of Epithelial Ovarian Cancer. 2008 , 1, 116-119	
1788	[Current strategies in the treatment of renal-cell cancer: targeted therapies]. 2008 , 130, 380-92	2
1787	[Intracellular mechanisms involved in the angiogenic process in hematological malignancies]. 2008 , 130, 585-90	

1786	Plasmalemmal vesicle associated protein-1 (PV-1) is a marker of blood-brain barrier disruption in rodent models. 2008 , 9, 29	70
1785	Novel therapies in genitourinary cancer: an update. 2008 , 1, 11	1
1784	Endoscopic imaging of angiogenesis in vivo. 2008 , 134, 915-8	27
1783	VEGF and angiogenesis: implications for breast cancer therapy. 2008 , 6, 7-13	14
1782	Clinical data for anti-angiogenic agents in previously treated advanced breast cancer. 2008 , 6, 14-20	
1781	Combining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model. 2008 , 10, 1383-92	93
1780	Thymoquinone inhibits tumor angiogenesis and tumor growth through suppressing AKT and extracellular signal-regulated kinase signaling pathways. 2008 , 7, 1789-96	257
1779	Cancer: shift of the paradigm. 2008 , 71, 839-50	8
1778	A polysaccharide isolated from the brown seaweed <i>Sargassum stenophyllum</i> exerts antivascuogenic effects evidenced by modified morphogenesis. 2008 , 75, 34-44	35
1777	The low molecular weight S-nitrosothiol, S-nitroso-N-acetylpenicillamine, promotes cell cycle progression in rabbit aortic endothelial cells. 2008 , 18, 241-55	35
1776	Metastatic cancer cell. 2008 , 3, 221-47	191
1775	Redox signaling and cancer: the role of "labile" iron. 2008 , 266, 21-9	222
1774	The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: clinical experience with anti-angiogenic agents, focusing on bevacizumab. 2008 , 44, 912-20	50
1773	A family of models of angiogenesis and anti-angiogenesis anti-cancer therapy. 2009 , 26, 63-95	53
1772	Combination of Antiangiogenic Therapy with Other Anticancer Therapies. 2008 , 431-449	
1771	Increased survivin expression confers chemoresistance to tumor-associated endothelial cells. 2008 , 173, 575-85	77
1770	Nuclear interleukin-33 is generally expressed in resting endothelium but rapidly lost upon angiogenic or proinflammatory activation. 2008 , 173, 1229-42	174
1769	Provascular strategy: targeting functional adaptations of mature blood vessels in tumors to selectively influence the tumor vascular reactivity and improve cancer treatment. 2008 , 86, 300-13	41

1768	Transformation by oncogenic Ras expands the early genomic response to transforming growth factor beta in intestinal epithelial cells. 2008 , 10, 1073-82	4
1767	Vascular growth in ischemic limbs: a review of mechanisms and possible therapeutic stimulation. 2008 , 22, 582-97	59
1766	Croissance vasculaire des membres ischémiques : revue des mécanismes et possible stimulation thérapeutique. 2008 , 22, 632-649	
1765	Celecoxib analogs that lack COX-2 inhibitory function: preclinical development of novel anticancer drugs. 2008 , 17, 197-208	64
1764	Angiogenesis and vascular targeting: relevance for hyperthermia. 2008 , 24, 57-65	15
1763	Antiangiogenic blockage: a new treatment for glioblastoma. 2008 , 8, 1449-53	7
1762	Antitumor agents. 261. 20(S)-protopanaxadiol and 20(s)-protopanaxatriol as antiangiogenic agents and total assignment of (1)H NMR spectra. 2008 , 71, 478-81	44
1761	VEGF-A165 induces human aortic smooth muscle cell migration by activating neuropilin-1-VEGFR1-PI3K axis. 2008 , 47, 3345-51	46
1760	The role of endothelial progenitor cells in tumour vasculogenesis. 2008 , 75, 265-73	41
1759	z-Guggulsterone, a constituent of Ayurvedic medicinal plant Commiphora mukul, inhibits angiogenesis in vitro and in vivo. 2008 , 7, 171-80	79
1758	Urocortin's inhibition of tumor growth and angiogenesis in hepatocellular carcinoma via corticotrophin-releasing factor receptor 2. 2008 , 26, 359-68	38
1757	Multimodality molecular imaging of tumor angiogenesis. 2008 , 49 Suppl 2, 113S-28S	444
1756	Targeted therapies for pancreatic cancer. 2008 , 87, 97-130	23
1755	Distinct angiogenic mediators are required for basic fibroblast growth factor- and vascular endothelial growth factor-induced angiogenesis: the role of cytoplasmic tyrosine kinase c-Abl in tumor angiogenesis. 2008 , 19, 2278-88	40
1754	VEGF Trap induces antiglioma effect at different stages of disease. 2008 , 10, 940-5	83
1753	Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab. 2008 , 14, 7554-63	163
1752	Tumor microenvironment genesis and implications on cancer immune response. 2008 , 25-43	4
1751	Angiogenesis. 2008 ,	25

1750	Effect of PTK/ZK on the angiogenic switch in head and neck tumors. 2008 , 87, 1166-71	4
1749	Dual inhibition of VEGFR and EGFR signaling reduces the incidence and size of intestinal adenomas in Apc(Min/+) mice. 2008 , 7, 590-8	30
1748	Reversal of cellular roles in angiogenesis: implications for anti-angiogenic therapy. 2008 , 45, 129-31	15
1747	Regulating the angiogenic balance in tissues. 2008 , 7, 2056-70	51
1746	Antiangiogenic therapy with mammalian target of rapamycin inhibitor RAD001 (Everolimus) increases radiosensitivity in solid cancer. 2008 , 14, 892-900	92
1745	Regulation of angiogenesis through a microRNA (miR-130a) that down-regulates antiangiogenic homeobox genes GAX and HOXA5. 2008 , 111, 1217-26	385
1744	Polymorphisms in VEGF and IL-8 predict tumor recurrence in stage III colon cancer. 2008 , 19, 1734-41	100
1743	Chapter 7. Molecular imaging of tumor vasculature. 2008 , 445, 141-76	36
1742	Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. 2008 , 14, 7272-83	467
1741	Antiangiogenesis: biology and utility in the treatment of gliomas. 2008 , 8, 1419-23	9
1740	Bevacizumab for the treatment of advanced non-small-cell lung cancer. 2008 , 8, 689-99	29
1739	Principles of Molecular Oncology. 2008 ,	1
1738	Bortezomib is ineffective in an orthotopic mouse model of pancreatic adenocarcinoma. 2008 , 7, 3624-31	29
1737	Systemic chemotherapy and new experimental approaches in the treatment of metastatic prostate cancer. 2008 , 19 Suppl 7, vii91-5	24
1736	Innovative Leukemia and Lymphoma Therapy. 2008 ,	
1735	Enhanced antitumor efficacy of clinical-grade vasculature-targeted liposomal doxorubicin. 2008 , 14, 7320-9	71
1734	Stress chaperone GRP78/BiP confers chemoresistance to tumor-associated endothelial cells. 2008 , 6, 1268-75	129
1733	Atu027, a liposomal small interfering RNA formulation targeting protein kinase N3, inhibits cancer progression. 2008 , 68, 9788-98	250

1732	Neuropilin-2: a new molecular target for antiangiogenic and antitumor strategies. 2008 , 100, 81-3	9
1731	Potent systemic anticancer activity of adenovirally expressed EGFR-selective TRAIL fusion protein. 2008 , 16, 1919-26	26
1730	Antiangiogenic metronomic chemotherapy. 2008 , 31, 161-2	18
1729	Novel anti-myeloma agents and angiogenesis. 2008 , 49, 677-89	35
1728	Dual-targeted contrast agent for US assessment of tumor angiogenesis in vivo. 2008 , 248, 936-44	175
1727	Targeted therapy in advanced non-small-cell lung cancer. 2008 , 29, 291-301	24
1726	Chapter 11. The role of bone marrow-derived cells in tumor angiogenesis and metastatic progression. 2008 , 444, 255-69	5
1725	Nm23-H1/nucleoside diphosphate kinase as a key molecule in breast tumor angiogenesis. 2008 , 12, 1419-30	9
1724	Managing patients with metastatic colorectal cancer on bevacizumab. 2008 , 17, 944-9	15
1723	Combination of Endostatin Gene Transfer and Radiation Therapy Against Lung Adenocarcinoma Model. 2008 ,	1
1722	Determining tumor blood flow parameters from dynamic image measurements. 2008 , 135, 012062	2
1721	Targeted gene therapy in radiotherapy. 2008 , 42,	6
1720	Promising novel cytotoxic agents and combinations in metastatic prostate cancer. 2008 , 14, 15-9	10
1719	Dll4 activation of Notch signaling reduces tumor vascularity and inhibits tumor growth. 2008 , 112, 1904-11	43
1718	Trans-resveratrol inhibits early blood vessel formation (vasculogenesis) without impairment of embryonic growth. 2008 , 107, 118-27	7
1717	Angiogenesis and gliomas: current issues and development of surrogate markers. 2008 , 62, 31-50; discussion 50-2	46
1716	Tumor growth-promoting properties of macrophage migration inhibitory factor. 2008 , 14, 3790-801	60
1715	Targeted therapy for advanced renal cell cancer: cytokines and beyond. 2008 , 14, 2229-51	11

1714	Anti-angiogenic targets in the treatment of advanced renal cell carcinoma. 2008 , 8, 676-82	36
1713	Individualized treatment planning in oncology: role of PET and radiolabelled anticancer drugs in predicting tumour resistance. 2008 , 14, 2914-31	24
1712	Imaging of integrins as biomarkers for tumor angiogenesis. 2008 , 14, 2943-73	174
1711	New Concepts in Targeting and Imaging Liver Cancer. 202-212	
1710	Invasion Program of Normal and Cancer Stem Cells. 167-195	
1709	Antiangiogenic therapy in nonsmall cell lung cancer. 2008 , 20, 176-82	18
1708	Interferon-alpha in combination with chemotherapy has potent antiangiogenic properties in an orthotopic mouse model for pancreatic adenocarcinoma. 2008 , 31, 28-33	30
1707	. 2008 ,	20
1706	. 2008 ,	
1705	What Helps Tumors evade vascular targeting treatment?. 2008 , 121, 844-849	4
1704	Galectin-1, Cancer Cell Migration, Angiogenesis, and Chemoresistance. 157-191	2
1703	PET and SPECT Imaging of Tumor Biology: New Approaches towards Oncology Drug Discovery and Development. 2008 , 4, 46-53	29
1702	Tumor Angiogenesis. 2008 , 241-251	2
1701	A novel tumor-promoting function residing in the 5' non-coding region of vascular endothelial growth factor mRNA. 2008 , 5, e94	14
1700	Precancerous stem cells can serve as tumor vasculogenic progenitors. 2008 , 3, e1652	81
1699	Role of peroxisome proliferator-activated receptor alpha in the control of cyclooxygenase 2 and vascular endothelial growth factor: involvement in tumor growth. 2008 , 2008, 352437	10
1698	Peroxisome Proliferator-Activated Receptor-gamma Ligands: Potential Pharmacological Agents for Targeting the Angiogenesis Signaling Cascade in Cancer. 2008 , 2008, 431763	23
1697	Tumor microenvironment and angiogenesis. 2008 , 13, 6537-53	147

1696	Tyrosine kinase inhibitors and the thyroid as both an unintended and an intended target. 2008 , 14, 618-24	14
1695	. 2009 ,	19
1694	[The surgeon and anti-angiogenics]. 2009 , 203, 193-5	
1693	Blood vessel maturation in retinoblastoma tumors: spatial distribution of neovessels and mature vessels and its impact on ocular treatment. 2009 , 50, 1020-4	19
1692	Irinotecan therapy and molecular targets in colorectal cancer: a systemic review. 2009 , 15, 3597-602	44
1691	[Therapeutic consequences of molecular biology advances in oncology]. 2009 , 96, 59-71	2
1690	[Radiotherapy and targeted therapies in non-small-cell lung cancer]. 2009 , 96, 311-9	0
1689	Bevacizumab: Its Place in the Treatment of Advanced Non-small Cell Lung Cancer. 2009 , 1, CMT.S1949	
1688	Vascular endothelial growth factor expression and neovascularization in non--small cell lung carcinoma. 2009 , 17, 390-5	2
1687	Hemoglobin-based oxygen carriers combined with anticancer drugs may enhance sensitivity of radiotherapy and chemotherapy to solid tumors. 2009 , 37, 163-5	34
1686	Gap junction communication between autologous endothelial and tumor cells induce cross-recognition and elimination by specific CTL. 2009 , 182, 2654-64	25
1685	Angiogenesis is associated with the onset of hyperplasia in human ductal breast disease. 2009 , 101, 666-72	63
1684	Mathematical Modelling of Tumour Dormancy. 2009 , 4, 68-96	5
1683	Renal Cell Carcinoma. 2009 ,	3
1682	Dynamic contrast-enhanced and T2-weighted magnetic resonance imaging study of the correlation between tumour angiogenesis and growth kinetics. 2009 , 43, 53-9	6
1681	Peptides targeting angiogenesis related growth factor receptors. 2009 , 15, 2414-29	32
1680	Nitric oxide: cancer target or anticancer agent?. 2009 , 9, 214-36	45
1679	Blood vessel maturation in human uveal melanoma: spatial distribution of neovessels and mature vasculature. 2009 , 41, 160-9	15

1678	Imaging of tumor angiogenesis: functional or targeted?. 2009 , 193, 304-13	79
1677	Chalcones in cancer: understanding their role in terms of QSAR. 2009 , 16, 1062-81	65
1676	Potential role of vascular targeted therapy to combat against tumor. 2009 , 6, 719-26	6
1675	Angiogenesis inhibitors and vascular disrupting agents in non-small cell lung cancer. 2009 , 16, 3919-30	12
1674	Vessel growth and function: depiction with contrast-enhanced MR imaging. 2009 , 251, 317-35	43
1673	Angiogenesis inhibition in the treatment of prostate cancer. 2009 , 9, 1070-8	6
1672	Paths of FGFR-driven tumorigenesis. 2009 , 8, 580-8	115
1671	The angiogenic switch: implications in the regulation of tumor dormancy. 2009 , 9, 935-41	46
1670	Interferon-alpha counteracts the angiogenic switch and reduces tumor cell proliferation in a spontaneous model of prostatic cancer. 2009 , 30, 851-60	25
1669	The Kunitz-like modulatory protein haemangin is vital for hard tick blood-feeding success. 2009 , 5, e1000497	43
1668	Radiosensitization of solid tumors by Z-VAD, a pan-caspase inhibitor. 2009 , 8, 1270-9	35
1667	Cell and molecular biology of the novel protein tyrosine-phosphatase-interacting protein 51. 2009 , 275, 183-246	24
1666	Phospholipase Cepsilon promotes intestinal tumorigenesis of Apc(Min/+) mice through augmentation of inflammation and angiogenesis. 2009 , 30, 1424-32	95
1665	The cyclin-dependent kinase inhibitor, p21(WAF1), promotes angiogenesis by repressing gene transcription of thioredoxin-binding protein 2 in cancer cells. 2009 , 30, 1865-71	16
1664	Role of Notch signaling in colorectal cancer. 2009 , 30, 1979-86	109
1663	Anti-angiogenic therapy against gastrointestinal tract cancers. 2009 , 39, 543-51	19
1662	FOXO3a promotes tumor cell invasion through the induction of matrix metalloproteinases. 2009 , 29, 4906-17	114
1661	Snail promotes CXCR2 ligand-dependent tumor progression in non-small cell lung carcinoma. 2009 , 15, 6820-9	98

1660	Curcumin inhibits COPD-like airway inflammation and lung cancer progression in mice. 2009 , 30, 1949-56	78
1659	Angiogenic activity of nicotinic acetylcholine receptors: implications in tobacco-related vascular diseases. 2009 , 121, 205-23	62
1658	The angiogenic switch in carcinogenesis. 2009 , 19, 329-37	339
1657	Oxytocin stimulates in vitro angiogenesis via a Pyk-2/Src-dependent mechanism. 2009 , 315, 3210-9	40
1656	Ginkgo biloba extract EGb 761 exerts anti-angiogenic effects via activation of tyrosine phosphatases. 2009 , 13, 2122-2130	16
1655	Metastasis mechanisms. 2009 , 1796, 293-308	230
1654	Inhibition of invasion and migration of salivary gland adenocarcinoma cells by 5'-nitro-indirubinoxime (5'-NIO). 2010 , 32, 619-25	3
1653	CXCR4 and CXCR7 regulate angiogenesis and CT26.WT tumor growth independent from SDF-1. 2010 , 126, 1302-15	51
1652	MMP-2 alters VEGF expression via alphaVbeta3 integrin-mediated PI3K/AKT signaling in A549 lung cancer cells. 2010 , 127, 1081-95	155
1651	The dual role of thymidine phosphorylase in cancer development and chemotherapy. 2009 , 29, 903-53	143
1650	Inhibitory effects of a gradient static magnetic field on normal angiogenesis. 2009 , 30, 446-53	41
1649	Evidence of multiexponential T2 in rat glioblastoma. 2009 , 22, 609-18	13
1648	Branched-chain amino acids suppress insulin-resistance-based hepatocarcinogenesis in obese diabetic rats. 2009 , 44, 483-91	54
1647	New chemotherapy strategies and biological agents in the treatment of childhood ependymoma. 2009 , 25, 1275-82	26
1646	Use of dynamic susceptibility-contrast MRI (DSC-MRI) to assess perfusion changes in the ipsilateral brain parenchyma from glioblastoma. 2009 , 91, 213-20	12
1645	The role of antiangiogenesis therapy: bevacizumab and beyond. 2009 , 11, 349-55	20
1644	Optical tomography of breast cancer-monitoring response to primary medical therapy. 2009 , 4, 219-33	32
1643	Molecular imaging in clinical trials. 2009 , 4, 151-68	36

1642	Non-invasive Monitoring of Angiogenesis in Cardiology. 2009 , 2, 59-66	6
1641	Stem-like ovarian cancer cells can serve as tumor vascular progenitors. 2009 , 27, 2405-13	134
1640	Angioarchitecture of squamous cell carcinoma from hamster buccal pouch: a scanning electron microscopy study. 2009 , 31, 188-94	5
1639	Monotherapy with thalidomide for treatment of spinal cord hemangioblastomas in a patient with von Hippel-Lindau disease. 2009 , 53, 464-7	20
1638	Neutrophils: key mediators of tumour angiogenesis. 2009 , 90, 222-31	212
1637	Angiogenic growth factors in tissue homogenates of HNSCC: expression pattern, prognostic relevance, and interrelationships. 2009 , 100, 1210-8	30
1636	Carcinogenesis: evolution of concepts. 2009 , 74, 353-61	7
1635	A potent gelatinase inhibitor with anti-tumor-invasive activity and its metabolic disposition. 2009 , 73, 189-202	30
1634	Synthesis, kinetic characterization and metabolism of diastereomeric 2-(1-(4-phenoxyphenylsulfonyl)ethyl)thiiranes as potent gelatinase and MT1-MMP inhibitors. 2009 , 74, 535-46	11
1633	A bi-parametric model for the tumour angiogenesis and antiangiogenesis therapy. 2009 , 49, 1156-1163	13
1632	Vascular endothelial growth factor (VEGF), matrix metalloproteinase-9 (MMP-9), and thrombospondin-1 (TSP-1) expression in urothelial carcinomas. 2009 , 205, 854-7	35
1631	Coordination of intratumoral immune reaction and human colorectal cancer recurrence. 2009 , 69, 2685-93	200
1630	Inhibitive effect of artemether on tumor growth and angiogenesis in the rat C6 orthotopic brain gliomas model. 2009 , 8, 88-92	24
1629	Pancreatic endocrine tumors: tumor blood flow assessed with perfusion CT reflects angiogenesis and correlates with prognostic factors. 2009 , 250, 407-16	201
1628	Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAIL. 2009 , 27, 1227-34	1207
1627	Pharmaceutical Perspectives of Cancer Therapeutics. 2009 ,	11
1626	Survivin: a new target for anti-cancer therapy. 2009 , 35, 553-62	314
1625	Stat3 activation is required for the growth of U87 cell-derived tumours in mice. 2009 , 45, 677-84	35

1624	Nitric oxide delivery to cancer: why and how?. 2009 , 45, 1352-69	70
1623	Angiogenesis in pre-malignant conditions. 2009 , 45, 1924-34	139
1622	Cinnamon extract suppresses tumor progression by modulating angiogenesis and the effector function of CD8+ T cells. 2009 , 278, 174-182	69
1621	Decursin and decursinol inhibit VEGF-induced angiogenesis by blocking the activation of extracellular signal-regulated kinase and c-Jun N-terminal kinase. 2009 , 280, 86-92	45
1620	Antiangiogenic liposomal gene therapy with 16K human prolactin efficiently reduces tumor growth. 2009 , 284, 222-8	17
1619	Clinical implications of hypoxia inducible factor in renal cell carcinoma. 2009 , 27, 238-45	47
1618	[Metronomic chemotherapy in pediatric oncology: hype or hope?]. 2009 , 16, 1158-65	4
1617	RNA interference as an anticancer therapy: a patent perspective. 2009 , 19, 475-91	22
1616	Diffuse reflectance spectroscopy detects increased hemoglobin concentration and decreased oxygenation during colon carcinogenesis from normal to malignant tumors. 2009 , 17, 2805-17	56
1615	The pathogenesis of cancer metastasis: relevance to therapy. 2009 , 17-40	2
1614	In situ imaging of metals in cells and tissues. 2009 , 109, 4780-827	461
1613	Advances in anti-VEGF and anti-EGFR therapy for advanced non-small cell lung cancer. 2009 , 63, 1-9	32
1612	Angiogenesis in Waldenström's macroglobulinemia. 2009 , 9, 46-9	9
1611	Antiangiogenic therapies for high-grade glioma. 2009 , 5, 610-20	204
1610	Overexpression of RRM2 decreases thrombospondin-1 and increases VEGF production in human cancer cells in vitro and in vivo: implication of RRM2 in angiogenesis. 2009 , 8, 11	72
1609	Breast cancer cells stimulate osteoprotegerin (OPG) production by endothelial cells through direct cell contact. 2009 , 8, 49	29
1608	ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside. 2009 , 2, 33	50
1607	Cyclooxygenase-2 in cancer and angiogenesis. 2009 , 60, 242-53	60

1606	Angiogenesis and anti-angiogenic molecularly targeted therapies in malignant gliomas. 2009 , 77, 1-11	55
1605	Inhibition of B16 melanoma growth and metastasis in C57BL mice by vaccination with a syngeneic endothelial cell line. 2009 , 28, 13	17
1604	Haploinsufficiency for p190B RhoGAP inhibits MMTV-Neu tumor progression. 2009 , 11, R61	22
1603	Multitarget drugs: the present and the future of cancer therapy. 2009 , 10, 589-600	53
1602	siRNA and miRNA Gene Silencing. 2009 ,	3
1601	Mechanisms of Brain Tumor Angiogenesis. 2009 , 461-506	
1600	PET Imaging of Angiogenesis. 2009 , 4, 17-38	45
1599	Expression of cyclooxygenase-2, glucose transporter-1 and angiogenesis in gallbladder carcinomas and their impact on prognosis. 2009 , 44, 1101-8	13
1598	Solid tumours arising from differently pre-oxygenated cells: comparable growth rates despite dissimilar tissue oxygenation. 2009 , 85, 981-8	1
1597	Sunitinib: a multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies. 2009 , 23, 377-89	119
1596	Somatostatin and somatostatin receptors: implications for neoplastic growth and cancer biology. 2009 , 18, 1297-316	21
1595	Transforming growth factor-beta signaling and tumor angiogenesis. 2009 , 14, 4848-61	93
1594	Recent advances in tumor vasculature targeting using liposomal drug delivery systems. 2009 , 6, 1297-309	25
1593	[Bevacizumab and non-small cell lung cancer: a new step?]. 2009 , 26, 125-38	1
1592	Angiogenesis in adrenocortical physiology and tumor development. 2009 , 70, 153-5	8
1591	In vivo antitumor and antimetastatic activity of sunitinib in preclinical neuroblastoma mouse model. 2009 , 11, 426-35	61
1590	Pancreatic islet and stellate cells are the main sources of endocrine gland-derived vascular endothelial growth factor/prokineticin-1 in pancreatic cancer. 2009 , 9, 165-72	29
1589	Magnetic resonance perfusion and permeability imaging in brain tumors. 2009 , 19, 527-57	109

1588	Polymorphisms in interleukin 1 beta and interleukin 1 receptor antagonist associated with tumor recurrence in stage II colon cancer. 2009 , 19, 95-102	39
1587	Surrogate markers predict angiogenic potential and survival in patients with glioblastoma multiforme. 2009 , 64, 819-26; discussion 826-7	28
1586	Angiogenesis-inhibitors for metastatic thyroid cancer. 2009 ,	
1585	Spatial registration of temporally separated whole breast 3D ultrasound images. 2009 , 36, 4288-300	8
1584	Gastric cancer: current trends and future opportunities. 195-212	
1583	(-)-Epigallocatechin-3-gallate inhibits invasion and migration of salivary gland adenocarcinoma cells. 2009 , 23,	
1582	Anti-angiogenic therapies for metastatic colorectal cancer. 2009 , CD005392	69
1581	Monocytes promote tumor cell survival in T-cell lymphoproliferative disorders and are impaired in their ability to differentiate into mature dendritic cells. 2009 , 114, 2936-44	118
1580	Road to ABT-869: A Multitargeted Receptor Tyrosine Kinase Inhibitor. 79-112	1
1579	Structure-Based Design and Characterization of Axitinib. 167-201	8
1578	[The vascular endothelial growth factor (VEGF): a model of gene regulation and a marker of tumour aggressiveness. An obvious therapeutic target?]. 2009 , 203, 181-92	1
1577	Recent advances in targeted anti-vasculature therapy: the neuroblastoma model. 2009 , 10, 1021-7	12
1576	A material decomposition method for dual energy micro-CT. 2009 ,	
1575	Recent developments of targeted therapies in the treatment of non-small cell lung cancer. 2009 , 6, 91-102	24
1574	Targeted therapy for nonsmall cell lung cancer: focusing on angiogenesis, the epidermal growth factor receptor and multikinase inhibitors. 2010 , 21, 151-68	9
1573	Macrophage heterogeneity: relevance and functional implications in atherosclerosis. 2010 , 8, 233-48	38
1572	Vascular endothelial growth factor receptor as target for advanced non-small cell lung cancer therapy. 2010 , 11, 865-8784	3
1571	Periodic Control in Antiangiogenic and Combined Anticancer Therapies. 2010 , 43, 1-6	1

1570	Characterization of molecular and functional alterations of tumor endothelial cells to design anti-angiogenic strategies. 2010 , 8, 220-32	31
1569	Sorafenib Decreases Extrahepatic Collaterals in Hepatocellular Carcinoma: Implication of the Synergistic Effect of Sorafenib and Transcatheter Chemoembolization. 2010 , 6, 191-193	
1568	[Interests in angiogenesis inhibitor drugs approved for the treatment of cancers]. 2010 , 65, 95-105	1
1567	Nanoparticles for Cancer Detection and Therapy. 2010 , 51	5
1566	Abnormal expression of Endoglin and its receptor complex (TGF- β and TGF- β receptor II) as early angiogenic switch indicator in premalignant lesions of the colon mucosa. 2010 , 37, 1153-65	21
1565	Phenoptosis hypothesis as a concept of evolutionary oncology. 2010 , 80, 1447-1454	
1564	Tumor vasculature as target for therapeutic intervention. 2010 , 19, 1321-38	16
1563	Molecular interactions in cancer cell metastasis. 2010 , 112, 3-25	218
1562	Survivin as an immunotherapeutic target for adult and pediatric malignant brain tumors. 2010 , 59, 183-93	14
1561	Beneficial effect of metronomic chemotherapy on tumor suppression and survival in a rat model of hepatocellular carcinoma with liver cirrhosis. 2010 , 65, 1029-37	19
1560	Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action?. 2010 , 13, 1-14	330
1559	Molecular ultrasound assessment of tumor angiogenesis. 2010 , 13, 175-88	67
1558	Anti-angiogenic effects of resveratrol mediated by decreased VEGF and increased TSP1 expression in melanoma-endothelial cell co-culture. 2010 , 13, 305-15	81
1557	A digest on the role of the tumor microenvironment in gastrointestinal cancers. 2010 , 3, 167-76	23
1556	Cancer: evolutionary, genetic and epigenetic aspects. 2010 , 1, 85-100	12
1555	Study on biodistribution and imaging of radioiodinated arginine-arginine-leucine peptide in nude mice bearing human prostate carcinoma. 2010 , 24, 13-9	14
1554	The expanding role of bevacizumab in the treatment of human epidermal growth factor receptor 2-negative breast cancer. 2010 , 12, 22-5	5
1553	The tumor stromal microenvironment as modulator of malignant behavior. 2010 , 15, 377-9	9

1552	Potential of cell invasion and matrix metalloproteinase production by alpha3beta1 integrin-mediated adhesion of gastric carcinoma cells to laminin-5. 2010 , 27, 197-205	27
1551	Targeting anticancer drugs to tumor vasculature using cationic liposomes. 2010 , 27, 1171-83	68
1550	The PG500 series: novel heparan sulfate mimetics as potent angiogenesis and heparanase inhibitors for cancer therapy. 2010 , 28, 276-83	84
1549	Quantitative and qualitative investigation into the impact of focused ultrasound with microbubbles on the triggered release of nanoparticles from vasculature in mouse tumors. 2010 , 146, 291-8	50
1548	To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. 2010 , 148, 135-46	1900
1547	Angiogenesis inhibitors: current strategies and future prospects. 2010 , 60, 222-43	350
1546	PGF2F-prostanoid receptor signalling via ADAMTS1 modulates epithelial cell invasion and endothelial cell function in endometrial cancer. 2010 , 10, 488	27
1545	Neoadjuvant multidrug chemotherapy including high-dose methotrexate modifies VEGF expression in osteosarcoma: an immunohistochemical analysis. 2010 , 11, 34	22
1544	Abalone visceral extract inhibit tumor growth and metastasis by modulating Cox-2 levels and CD8+ T cell activity. 2010 , 10, 60	10
1543	Cancer models, genomic instability and somatic cellular Darwinian evolution. 2010 , 5, 19; discussion 19	45
1542	Angiogenesis inhibitors in the treatment of prostate cancer. 2010 , 3, 26	39
1541	Variations in surgical procedures for hind limb ischaemia mouse models result in differences in collateral formation. 2010 , 40, 796-803	74
1540	Pleiotropic roles of matrix metalloproteinases in tumor angiogenesis: contrasting, overlapping and compensatory functions. 2010 , 1803, 103-20	171
1539	Oxidative stress, inflammation, and cancer: how are they linked?. 2010 , 49, 1603-16	3065
1538	Change in fibroblast growth factor 2 expression as an early phase radiotherapy-responsive marker in sequential biopsy samples from patients with cervical cancer during fractionated radiotherapy. 2010 , 116, 5082-92	4
1537	Tumor angiogenesis and novel antiangiogenic strategies. 2010 , 126, 1777-1787	89
1536	Targeting Gene-ViroTherapy for prostate cancer by DD3-driven oncolytic virus-harboring interleukin-24 gene. 2010 , 127, 707-17	28
1535	Investigation of a plasmid containing a novel immunotoxin VEGF165-PE38 gene for antiangiogenic therapy in a malignant glioma model. 2010 , 127, 2222-9	13

1534	Cancer antineovascular therapy with liposome drug delivery systems targeted to BiP/GRP78. 2010 , 127, 2685-98	69
1533	Multi-photon resonance enhancement of third harmonic generation in human oxyhemoglobin and deoxyhemoglobin. 2010 , 3, 678-85	21
1532	Angiogenesis as a strategic target for prostate cancer therapy. 2010 , 30, 23-66	30
1531	Iodine(III)-mediated ring expansion: an efficient and green pathway in the synthesis of a key precursor for the design of aminopeptidase (APN or CD13) inhibitors. 2010 , 66, 8722-8728	7
1530	Effects of focused ultrasound and microbubbles on the vascular permeability of nanoparticles delivered into mouse tumors. 2010 , 36, 1460-9	31
1529	8-THP-DHI analogs as potent Type I dual TIE-2/VEGF-R2 receptor tyrosine kinase inhibitors. 2010 , 20, 3356-60	9
1528	F-Prostaglandin receptor regulates endothelial cell function via fibroblast growth factor-2. 2010 , 11, 8	16
1527	Metabolic alteration of HepG2 in scaffold-based 3-D culture: proteomic approach. 2010 , 10, 3896-904	18
1526	Proteomic characterization of Her2/neu-overexpressing breast cancer cells. 2010 , 10, 3800-10	28
1525	Engineering nanocomposite materials for cancer therapy. 2010 , 6, 2336-57	205
1524	Dysregulation of protein synthesis and disease. 2010 , 220, 140-51	68
1523	Melatonin suppresses tumor angiogenesis by inhibiting HIF-1alpha stabilization under hypoxia. 2010 , 48, 178-84	137
1522	It takes two to tango: combinations of conventional cytotoxics with compounds targeting the vascular endothelial growth factor-vascular endothelial growth factor receptor pathway in patients with solid malignancies. 2010 , 101, 7-15	24
1521	Pigpen, a nuclear coiled body component protein, is involved in angiogenesis. 2010 , 101, 1170-6	3
1520	Immune infiltration in human tumors: a prognostic factor that should not be ignored. 2010 , 29, 1093-102	725
1519	Inhibitor of DNA binding-4 promotes angiogenesis and growth of glioblastoma multiforme by elevating matrix GLA levels. 2010 , 29, 3793-802	33
1518	Human stem cells expressing novel TSP-1 variant have anti-angiogenic effect on brain tumors. 2010 , 29, 3185-95	63
1517	Issues on fit-for-purpose validation of a panel of ELISAs for application as biomarkers in clinical trials of anti-Angiogenic drugs. 2010 , 102, 1524-32	11

1516	Angiogenesis in superficial esophageal squamous cell carcinoma: magnifying endoscopic observation and molecular analysis. 2010 , 22, 259-67	30
1515	Systemic therapies in metastatic non-small-cell lung cancer with emphasis on targeted therapies: the rational approach. 2010 , 17, 13-23	26
1514	The "two-faced" effects of reactive oxygen species and the lipid peroxidation product 4-hydroxynonenal in the hallmarks of cancer. 2010 , 2, 338-63	62
1513	Angiogenesis: from chronic liver inflammation to hepatocellular carcinoma. 2010 , 2010, 272170	39
1512	The role and therapeutic potential of endothelial progenitor cells in tumor neovascularization. 2010 , 10, 1088-99	48
1511	Molecular mechanisms of resistance to tumour anti-angiogenic strategies. 2010 , 2010, 835680	57
1510	Angiogenesis inhibition in prostate cancer: current uses and future promises. 2010 , 2010, 361836	24
1509	Rosuvastatin counteracts vessel arterialisation and sinusoid capillarisation, reduces tumour growth, and prolongs survival in murine hepatocellular carcinoma. 2010 , 2010, 640797	10
1508	Bevacizumab suppression of establishment of micrometastases in experimental ocular melanoma. 2010 , 51, 2835-42	63
1507	A reduction in the interstitial fluid pressure per se, does not enhance the uptake of the small molecule weight compound 5-fluorouracil into 4T1 mammary tumours. 2010 , 1, 5	2
1506	Regulation of tumor angiogenesis by the local environment. 2010 , 15, 195-212	31
1505	Defective p53 antiangiogenic signaling in glioblastoma. 2010 , 12, 894-907	14
1504	Minireview: Won't get fooled again: the nonmetabolic roles of peroxisome proliferator-activated receptors (PPARs) in the heart. 2010 , 24, 1111-9	30
1503	Myricetin inhibits UVB-induced angiogenesis by regulating PI-3 kinase in vivo. 2010 , 31, 911-7	52
1502	Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma. 2010 , 70, 1053-62	182
1501	Antiangiogenic activities of 2,5-dimethyl-celecoxib on the tumor vasculature. 2010 , 9, 631-41	20
1500	Regulation of VEGF-A in uveal melanoma. 2010 , 51, 2329-37	50
1499	Applications of molecular imaging. 2010 , 95, 237-98	16

1498	Angiopoietin-4 promotes glioblastoma progression by enhancing tumor cell viability and angiogenesis. 2010 , 70, 7283-93	47
1497	Quantitative parametric perfusion images using 15O-labeled water and a clinical PET/CT scanner: test-retest variability in lung cancer. 2010 , 51, 1684-90	36
1496	Regulation of angiogenesis by histone chaperone HIRA-mediated incorporation of lysine 56-acetylated histone H3.3 at chromatin domains of endothelial genes. 2010 , 285, 41567-77	47
1495	Anti-tumour activity of fotemustine and protons in combination with bevacizumab. 2010 , 56, 214-22	4
1494	Antitumor activity of targeting SRC kinases in endothelial and myeloid cell compartments of the tumor microenvironment. 2010 , 16, 924-35	48
1493	Knockout of HIF-1 β in tumor-associated macrophages enhances M2 polarization and attenuates their pro-angiogenic responses. 2010 , 31, 1863-72	114
1492	Toward brain tumor gene therapy using multipotent mesenchymal stromal cell vectors. 2010 , 18, 1067-75	85
1491	Targeting angiogenesis with multitargeted tyrosine kinase inhibitors in the treatment of non-small cell lung cancer. 2010 , 15, 436-46	49
1490	Oxygen-controlled three-dimensional cultures to analyze tumor angiogenesis. 2010 , 16, 2133-41	84
1489	New dimensions in vascular engineering: opportunities for cancer biology. 2010 , 16, 2157-9	3
1488	HIF, hypoxia and the role of angiogenesis in non-small cell lung cancer. 2010 , 14, 1047-57	52
1487	Memory T Cells. 2010 ,	1
1486	Regulation of the expression and activity of the antiangiogenic homeobox gene GAX/MEOX2 by ZEB2 and microRNA-221. 2010 , 30, 3902-13	67
1485	CXCR4/YY1 inhibition impairs VEGF network and angiogenesis during malignancy. 2010 , 107, 14484-9	90
1484	(Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor. 2010 , 15, 539-47	104
1483	Genetically engineered mouse models in cancer research. 2010 , 106, 113-64	127
1482	Optical molecular imaging and its emerging role in colorectal cancer. 2010 , 299, G807-20	17
1481	Oncogenic engagement of the Met receptor is sufficient to evoke angiogenic, tumorigenic, and metastatic activities in rat intestinal epithelial cells. 2010 , 299, G677-86	10

1480	Genetic variations in angiogenesis pathway genes associated with clinical outcome in localized gastric adenocarcinoma. 2010 , 21, 78-86	36
1479	ARF suppresses tumor angiogenesis through translational control of VEGFA mRNA. 2010 , 70, 4749-58	29
1478	Hypoxic and highly angiogenic non-tumor tissues surrounding hepatocellular carcinoma: the 'niche' of endothelial progenitor cells. 2010 , 11, 2901-9	32
1477	Increased angiogenesis in Cdk4(R24C/R24C):Apc(+/-Min) intestinal tumors. 2010 , 9, 2456-63	12
1476	Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis. 2010 , 79, 27-38	139
1475	Too much of a good thing: suicide prevention promotes chemoresistance in ovarian carcinoma. 2010 , 10, 575-83	8
1474	Lung cancer therapeutics that target signaling pathways: an update. 2010 , 4, 631-45	19
1473	Current devices for high-performance whole-body hyperthermia therapy. 2010 , 7, 407-23	15
1472	Mechanisms of drug resistance to vascular endothelial growth factor (VEGF) inhibitors. 2010 , 10, 593-600	1
1471	Stat3 orchestrates tumor development and progression: the Achilles' heel of head and neck cancers?. 2010 , 10, 117-26	48
1470	Recent advances in cancer therapy: an overview. 2010 , 16, 3-10	232
1469	PDGF and vessel maturation. 2010 , 180, 103-14	183
1468	HIF-1alpha and cancer therapy. 2010 , 180, 15-34	57
1467	Biological applications of microfluidic gradient devices. 2010 , 2, 584-603	269
1466	In vivo photoacoustic tomography of chemicals: high-resolution functional and molecular optical imaging at new depths. 2010 , 110, 2756-82	601
1465	Angiogenesis-inhibitors for metastatic thyroid cancer. 2010 , CD007958	9
1464	Antiangiogenic agents in the treatment of prostate cancer. 2010 , 7, 9-15	0
1463	Thromboxane receptor alpha mediates tumor growth and angiogenesis via induction of vascular endothelial growth factor expression in human lung cancer cells. 2010 , 69, 26-32	34

1462	Use of anti-VEGF adjuvant therapy in cancer: challenges and rationale. 2010 , 16, 122-32	61
1461	Targeting of VEGF-dependent transendothelial migration of cancer cells by bevacizumab. 2010 , 4, 150-60	28
1460	Tumour and dendrimers: a review on drug delivery aspects. 2008 , 60, 671-88	44
1459	Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors. 2010 , 9, 107	69
1458	Poor prognostic clinicopathologic features correlate with VEGF expression but not with PTEN expression in squamous cell carcinoma of the larynx. 2010 , 5, 35	22
1457	Intravital spectral imaging as a tool for accurate measurement of vascularization in mice. 2010 , 2, 22	
1456	Targeted therapies as adjuvant treatment for early-stage colorectal cancer: first impressions and clinical questions. 2010 , 9 Suppl 1, S28-35	3
1455	Vascular endothelial growth factor and epidermal growth factor signaling pathways as therapeutic targets for colorectal cancer. 2010 , 138, 2163-76	74
1454	Tumor uptake of the RGD dimeric probe (99m)Tc-G3-2P4-RGD2 is correlated with integrin $\alpha_5\beta_1$ expressed on both tumor cells and neovasculature. 2010 , 21, 548-55	55
1453	Antiangiogenic cancer therapy: monitoring with molecular US and a clinically translatable contrast agent (BR55). 2010 , 256, 519-27	140
1452	Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers. 2010 , 28, 4316-23	163
1451	Metronomic chemotherapy: new rationale for new directions. 2010 , 7, 455-65	457
1450	Cancer du sein mÉastatique: progrÉ dans la prise en charge et limites actuelles. 2010 , 34, 52-57	1
1449	In vivo modulation of angiogenesis by beta 2 glycoprotein I. 2010 , 35, 232-40	22
1448	Glioblastoma and endothelial cells cross-talk, mediated by SDF-1, enhances tumour invasion and endothelial proliferation by increasing expression of cathepsins B, S, and MMP-9. 2010 , 289, 53-61	66
1447	Interferon alpha inhibits hepatocellular carcinoma growth through inducing apoptosis and interfering with adhesion of tumor endothelial cells. 2010 , 290, 204-10	22
1446	Purinergic mechanisms in breast cancer support intravasation, extravasation and angiogenesis. 2010 , 291, 131-41	21
1445	Matrix metalloproteinase-9 is required for tubular network formation and migration of resistant breast cancer cells MCF-7 through PKC and ERK1/2 signalling pathways. 2010 , 295, 242-51	26

1444	Targeted therapies of cancer: angiogenesis inhibition seems not enough. 2010 , 299, 1-10	48
1443	Impact of tumor microenvironment on oncolytic viral therapy. 2010 , 21, 127-34	65
1442	The Yin and Yang of bone morphogenetic proteins in cancer. 2010 , 21, 299-313	67
1441	Tumors as organs: complex tissues that interface with the entire organism. 2010 , 18, 884-901	827
1440	Autocrine VEGF signaling synergizes with EGFR in tumor cells to promote epithelial cancer development. 2010 , 140, 268-79	270
1439	Pericyte deficiencies lead to aberrant tumor vascularization in the brain of the NG2 null mouse. 2010 , 344, 1035-46	111
1438	Synthesis and biological evaluation of polysulfated oligosaccharide glycosides as inhibitors of angiogenesis and tumor growth. 2010 , 53, 1686-99	63
1437	Changes in hepatic blood flow during whole body hyperthermia. 2010 , 26, 95-100	16
1436	Apoptosis initiation and angiogenesis inhibition: melanoma targets for nanosecond pulsed electric fields. 2010 , 23, 554-63	67
1435	Proteomic analysis of shear stress-mediated protection from TNF-alpha in endothelial cells. 2010 , 17, 259-70	13
1434	Clinical applications of VEGF-trap (aflibercept) in cancer treatment. 2010 , 73, 449-56	40
1433	Biomechanical and Nutrient Controls in the Growth of Mammalian Cell Populations. 2010 , 17, 166-187	13
1432	From Molecular to Modular Tumor Therapy. 2010 ,	5
1431	Ocular Angiogenesis. 2010 , 103-121	50
1430	The role of bevacizumab in colorectal cancer: understanding its benefits and limitations. 2011 , 11, 405-13	28
1429	Destruction of tumor vasculature and abated tumor growth upon VEGF blockade is driven by proapoptotic protein Bim in endothelial cells. 2011 , 208, 1351-8	24
1428	Targeted delivery of antisense inhibitor of miRNA for antiangiogenesis therapy using cRGD-functionalized nanoparticles. 2011 , 8, 250-9	89
1427	Microparticles in angiogenesis: therapeutic potential. 2011 , 109, 110-9	137

1426	Brivanib alaninate for cancer. 2011 , 20, 577-86	35
1425	Place des anti-angiogéniques dans le traitement des gliomes. 2011 , 2, 71-76	
1424	Antitumor efficacy of a thrombospondin 1 mimetic CovX-body. 2011 , 4, 249-57	19
1423	Cancer du sein métastatique : progrès dans la prise en charge et limites actuelles. 2011 ,	
1422	Cancer-targeted optical imaging with fluorescent zinc oxide nanowires. 2011 , 11, 3744-50	171
1421	Tyrosine kinase inhibitors with antiangiogenic properties for the treatment of non-small cell lung cancer. 2011 , 20, 61-74	9
1420	GM3 Upregulation of matrix metalloproteinase-9 possibly through PI3K, AKT, RICTOR, RHOGDI-2, and TNF- α pathways in mouse melanoma B16 cells. 2011 , 705, 335-48	3
1419	Toward an image-guided microbeam radiation therapy using gadolinium-based nanoparticles. 2011 , 5, 9566-74	186
1418	Drug delivery strategies for therapeutic angiogenesis and antiangiogenesis. 2011 , 8, 485-504	39
1417	Synthesis and characterization of a theranostic vascular disrupting agent for in vivo MR imaging. 2011 , 22, 879-86	23
1416	Improving anticancer activity and reducing systemic toxicity of doxorubicin by self-assembled polymeric micelles. 2011 , 22, 095102	25
1415	Distinct contributions of angiogenesis and vascular co-option during the initiation of primary microtumors and micrometastases. 2011 , 32, 1143-50	54
1414	Extracellular Matrix Degradation. 2011 ,	6
1413	Measuring angiogenesis in mice. 2011 , 769, 351-8	
1412	Engineered conformation-dependent VEGF peptide mimics are effective in inhibiting VEGF signaling pathways. 2011 , 286, 13612-25	51
1411	Targeted Therapies. 2011 ,	3
1410	Tumors of the Central Nervous System, Volume 2. 2011 ,	1
1409	Cancer Systems Biology, Bioinformatics and Medicine. 2011 ,	3

1408	Cell Migration. 2011 ,	7
1407	Semaphorin-plexin signalling genes associated with human breast tumourigenesis. 2011 , 489, 63-9	17
1406	Chaotic neovascularization induced by aggressive fibrosarcoma cells overexpressing S-adenosylmethionine decarboxylase. 2011 , 43, 441-54	9
1405	Targeting angiogenesis with compounds from the extracellular matrix. 2011 , 43, 1674-85	30
1404	Differential dependency of human cancer cells on vascular endothelial growth factor-mediated autocrine growth and survival. 2011 , 309, 145-50	27
1403	The evaluation of anti-angiogenic treatment effects for implanted rabbit VX2 breast tumors using functional multi-slice spiral computed tomography (f-MSCT). 2011 , 78, 277-81	6
1402	Characterization of neuritin as a novel angiogenic factor. 2011 , 415, 608-12	20
1401	Hydrogen sulfide in cell survival: a double-edged sword. 2011 , 4, 33-47	40
1400	Bone formation and neovascularization mediated by mesenchymal stem cells and endothelial cells in critical-sized calvarial defects. 2011 , 17, 311-21	101
1399	Blockade of vascular endothelial growth factor sensitizes tumor-associated vasculatures to angiolytic therapy with a high-frequency ultrashort pulsed laser. 2011 , 82, 141-6	8
1398	Growing tumor vessels: more than one way to skin a cat - implications for angiogenesis targeted cancer therapies. 2011 , 32, 71-87	79
1397	Macrophage regulation of tumor angiogenesis: implications for cancer therapy. 2011 , 32, 123-45	127
1396	The combination of VEGF inhibitors and anti-oestrogen therapies in breast cancer. 2011 , 76, 807-11	2
1395	The role of mast cells and angiogenesis in benign and malignant neoplasms of the uterus. 2011 , 207, 618-22	6
1394	Potential use of circulating endothelial cells as a biomarker of renal cell carcinoma. 2011 , 29, 237-43	4
1393	Evaluation of tumor microenvironment in an animal model using a nanoparticle contrast agent in computed tomography imaging. 2011 , 18, 20-30	72
1392	The ESTRO Breur Lecture 2010: toward a tailored patient approach in rectal cancer. 2011 , 100, 15-21	16
1391	Modulation of signaling between TM4SF5 and integrins in tumor microenvironment. 2011 , 16, 1752-8	24

1390	Vernolide-A inhibits radiation-induced hypoxia-mediated tumor angiogenesis by regulating HIF-1 β , MMP-2, MMP-9, and VEGF. 2011 , 30, 139-51	8
1389	Angiogenesis and Lung Cancer. 2011 , 17-41	0
1388	The Influence of Aging and Cellular Senescence on Metastasis. 105-116	
1387	Antivascular therapy in gynaecological cancers. 121-138	
1386	Stromal-Derived Factors That Dictate Organ-Specific Metastasis. 77-84	
1385	Advanced retinoblastoma treatment: targeting hypoxia by inhibition of the mammalian target of rapamycin (mTOR) in LH(BETA)T(AG) retinal tumors. 2011 , 5, 337-43	12
1384	Advances in the prevention and treatment of lung cancer. 2011 , 41, 142-9	5
1383	Integrin targeted delivery of radiotherapeutics. 2011 , 1, 201-10	36
1382	Radiolabeled Cyclic RGD Peptides as Radiotracers for Imaging Tumors and Thrombosis by SPECT. 2011 , 1, 58-82	109
1381	A novel peptide derived from human apolipoprotein E is an inhibitor of tumor growth and ocular angiogenesis. 2011 , 6, e15905	21
1380	Vessel arterial-venous plasticity in adult neovascularization. 2011 , 6, e27332	26
1379	MicroRNA-mediated regulation of the angiogenic switch. 2011 , 18, 171-6	48
1378	Proteasome inhibitors and modulators of angiogenesis in multiple myeloma. 2011 , 18, 5185-95	11
1377	Collateral damage control in cancer therapy: defining the stem identity in gliomas. 2011 , 17, 2370-85	1
1376	Soluble VEGF receptor-2 may be a predictive marker of anti-angiogenic therapy with clinically available safe agents. 2011 , 2, 69-73	3
1375	Targeting neuropilin-1 in human leukemia and lymphoma. 2011 , 117, 920-7	78
1374	Pathophysiological and Vascular Characteristics of Solid Tumors in Relation to Drug Delivery. 2011 , 33-64	1
1373	Molecular targets of selenium in prostate cancer prevention (Review). 2011 , 39, 301-9	7

1372	The Molecular Immunology of Complex Carbohydrates-3. 2011 ,	2
1371	Lentiviral-mediated siRNA targeted against osteopontin suppresses the growth and metastasis of gastric cancer cells. 2011 , 25, 997-1003	9
1370	Hispidulin, a small flavonoid molecule, suppresses the angiogenesis and growth of human pancreatic cancer by targeting vascular endothelial growth factor receptor 2-mediated PI3K/Akt/mTOR signaling pathway. 2011 , 102, 219-25	88
1369	YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo. 2011 , 102, 1374-80	326
1368	Hypoxia-inducible factors--regulation, role and comparative aspects in tumourigenesis. 2011 , 9, 16-37	13
1367	Towards novel paradigms for cancer therapy. 2011 , 30, 1-20	93
1366	CEACAM1 creates a pro-angiogenic tumor microenvironment that supports tumor vessel maturation. 2011 , 30, 4275-88	38
1365	Myricetin is a potent chemopreventive phytochemical in skin carcinogenesis. 2011 , 1229, 124-32	59
1364	Role of intimate interactions between endothelial cells and the surrounding accessory cells in the maturation of blood vessels. 2011 , 9 Suppl 1, 144-50	13
1363	Implications of understanding cancer stem cell (CSC) biology in head and neck squamous cell cancer. 2011 , 47, 237-43	53
1362	Positron emission tomography imaging of cancer biology: current status and future prospects. 2011 , 38, 70-86	81
1361	MicroRNAs in the pathogenesis of cancer. 2011 , 38, 724-33	168
1360	Angiogenesis and molecular markers in advanced epithelial ovarian cancer: a retrospective study. 2011 , 123, 301-7	7
1359	Glioblastoma-derived leptin induces tube formation and growth of endothelial cells: comparison with VEGF effects. 2011 , 11, 303	45
1358	Altered angiogenesis in the tumor microenvironment. 2011 , 61, 630-7	23
1357	The VEGF/Rho GTPase signalling pathway: a promising target for anti-angiogenic/anti-invasion therapy. 2011 , 16, 219-28	56
1356	The angiogenic process as a therapeutic target in cancer. 2011 , 81, 1183-91	66
1355	Hallmarks of cancer: the next generation. 2011 , 144, 646-74	39819

1354	A YKL-40-neutralizing antibody blocks tumor angiogenesis and progression: a potential therapeutic agent in cancers. 2011 , 10, 742-51	129
1353	Mathematical and Computational Models in Cancer. 2011 , 113-126	
1352	Molecular oncology in lung cancer I between biomarkers and clinical application. Relevance of the Ras/Raf/MEK/ERK pathway. 2011 , 4, 242-247	1
1351	Molecular imaging with SPECT as a tool for drug development. 2011 , 63, 547-54	67
1350	Targeting mutant p53 protein and the tumor vasculature: an effective combination therapy for advanced breast tumors. 2011 , 125, 407-20	21
1349	Eicosanoid signalling pathways in the development and progression of colorectal cancer: novel approaches for prevention/intervention. 2011 , 30, 363-85	61
1348	Pigment epithelium-derived factor expression is down-regulated in bladder tumors and correlates with vascular endothelial growth factor and matrix metalloproteinase-9. 2011 , 43, 383-90	16
1347	Multiplexed analysis of angiogenesis and lymphangiogenesis factors predicts outcome for non-small cell lung cancer patients. 2011 , 458, 331-40	9
1346	Bevacizumab enhances chemosensitivity of hepatocellular carcinoma to adriamycin related to inhibition of survivin expression. 2011 , 137, 505-12	11
1345	Nanomaterials for cancer therapy and imaging. 2011 , 31, 295-302	234
1344	Protein-based tumor molecular imaging probes. 2011 , 41, 1013-36	9
1343	Examining the role of Rac1 in tumor angiogenesis and growth: a clinically relevant RNAi-mediated approach. 2011 , 14, 457-66	36
1342	Reduced pathological angiogenesis and tumor growth in mice lacking GPR4, a proton sensing receptor. 2011 , 14, 533-44	56
1341	MET and VEGF: synergistic targets in castration-resistant prostate cancer. 2011 , 13, 703-9	34
1340	FP3: a novel VEGF blocker with antiangiogenic effects in vitro and antitumour effects in vivo. 2011 , 13, 878-84	10
1339	Angiogenesis and its modulation in the pathophysiology and treatment of endometrial carcinoma. 2011 , 5, 43-48	
1338	Angiogenesis and multiple myeloma. 2011 , 4, 325-37	78
1337	Nanoparticle-delivered VEGF-silencing cassette and suicide gene expression cassettes inhibit colon carcinoma growth in vitro and in vivo. 2011 , 32, 1103-11	12

1336	Expression of pigment epithelium-derived factor in bladder tumour is correlated with interleukin-8 yet not with interleukin-1 β . 2011 , 31, 21-25	12
1335	Development of second-generation VEGFR tyrosine kinase inhibitors: current status. 2011 , 13, 103-11	93
1334	Antiangiogenic properties of Koetjapic acid, a natural triterpene isolated from Sandoricum koetjaoe Merr. 2011 , 11, 12	19
1333	The utility of Aspirin in Dukes C and High Risk Dukes B Colorectal cancer--the ASCOLT study: study protocol for a randomized controlled trial. 2011 , 12, 261	47
1332	Jekyll and Hyde: the role of the microenvironment on the progression of cancer. 2011 , 223, 162-76	267
1331	Tumor-initiating cells and tumor vascularization. 2011 , 56, 335-40	10
1330	Antiangiogenic phytochemicals and medicinal herbs. 2011 , 25, 1-10	43
1329	Pigment epithelium-derived factor as an impending therapeutic agent against vascular epithelial growth factor-driven tumor-angiogenesis. 2011 , 50, 67-72	21
1328	Nanomaterials: applications in cancer imaging and therapy. 2011 , 23, H18-40	729
1327	Directed blood vessel growth using an angiogenic microfiber/microparticle composite patch. 2011 , 23, 3139-43	33
1326	Longitudinal study of tumor-associated macrophages during tumor expansion using MRI. 2011 , 24, 1353-60	27
1325	Cyclic 3',5'-guanosine monophosphate-dependent protein kinase inhibits colon cancer cell adaptation to hypoxia. 2011 , 117, 5282-93	4
1324	Lymphotoxin- β receptor activation by lymphotoxin- β (LT β) and LIGHT promotes tumor growth in an NF κ B-dependent manner. 2011 , 128, 1363-70	26
1323	Size effect in molecular imaging of vascular endothelial growth factor. 2011 , 18, 819-20	2
1322	Extending optogenetics to a Ca(2+)-selective channel. 2011 , 18, 820-1	
1321	Correlation of matrix metalloproteinases and their inhibitors with hypoxia and angiogenesis in premenopausal patients with adenocarcinoma of the breast. 2011 , 44, 969-74	5
1320	Is VEGF a predictive biomarker to anti-angiogenic therapy?. 2011 , 79, 103-11	25
1319	An innovative strategy for the synthesis of a new series of potent aminopeptidase (APN or CD13) inhibitors derived from the oxepin-4-one family. 2011 , 52, 2586-2589	7

1318	FKBPL and peptide derivatives: novel biological agents that inhibit angiogenesis by a CD44-dependent mechanism. 2011 , 17, 1044-56	41
1317	Vascular endothelial growth factor and vascular homeostasis. 2011 , 8, 508-11	40
1316	Preclinical development of novel anti-glioma drugs targeting the endoplasmic reticulum stress response. 2011 , 17, 2428-38	18
1315	Anti-angiogenic therapy in uveal melanoma. 2012 , 49, 117-136	21
1314	Tumor angiogenic marker expression levels during tumor growth: longitudinal assessment with molecularly targeted microbubbles and US imaging. 2011 , 258, 804-11	113
1313	The medicinal chemistry of novel iron chelators for the treatment of cancer. 2011 , 11, 483-99	66
1312	Oct-4+/Tenascin C+ neuroblastoma cells serve as progenitors of tumor-derived endothelial cells. 2011 , 21, 1470-86	55
1311	Effective conversion of irinotecan to SN-38 after intratumoral drug delivery to an intracranial murine glioma model in vivo. Laboratory investigation. 2011 , 114, 689-94	17
1310	Chemotherapy for non-small-cell lung carcinoma: from a blanket approach to individual therapy. 2011 , 32, 78-93	8
1309	Inhibition of tumor angiogenesis by antibodies, synthetic small molecules and natural products. 2011 , 18, 3136-55	57
1308	Mouse as a Model Organism. 2011 ,	3
1307	Antiangiogenic therapies: is VEGF-A inhibition alone enough?. 2011 , 11, 485-96	4
1306	Imaging tumor vascularization for detection and diagnosis of breast cancer. 2011 , 10, 607-23	46
1305	E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. 2011 , 71, 1396-405	116
1304	Angiogenesis and parasitic helminth-associated neovascularization. 2011 , 138, 426-39	15
1303	Emerging therapies for the treatment of neovascular age related macular degeneration. 2011 , 26, 149-55	13
1302	Targeting FGFR/PDGFR/VEGFR impairs tumor growth, angiogenesis, and metastasis by effects on tumor cells, endothelial cells, and pericytes in pancreatic cancer. 2011 , 10, 2157-67	99
1301	A critical role for GRP78/BiP in the tumor microenvironment for neovascularization during tumor growth and metastasis. 2011 , 71, 2848-57	108

1300	Transdifferentiation of glioblastoma cells into vascular endothelial cells. 2011 , 108, 4274-80	400
1299	Combined fluorescence and reflectance spectroscopy for in vivo quantification of cancer biomarkers in low- and high-grade glioma surgery. 2011 , 16, 116007	93
1298	Angiocrine factors modulate tumor proliferation and motility through EphA2 repression of Slit2 tumor suppressor function in endothelium. 2011 , 71, 976-87	48
1297	Naftopidil, a selective {alpha}1-adrenoceptor antagonist, suppresses human prostate tumor growth by altering interactions between tumor cells and stroma. 2011 , 4, 87-96	40
1296	Supplementation with alpha-tocopherol or beta-carotene reduces serum concentrations of vascular endothelial growth factor-D, but Not -A or -C, in male smokers. 2011 , 141, 2030-4	8
1295	Targeted Therapies for Renal Cell Carcinoma. 2011 ,	
1294	Regional and temporal differences in gene expression of LH(BETA)T(AG) retinoblastoma tumors. 2011 , 52, 5359-68	13
1293	GPR56 Regulates VEGF production and angiogenesis during melanoma progression. 2011 , 71, 5558-68	79
1292	SKLB610: a novel potential inhibitor of vascular endothelial growth factor receptor tyrosine kinases inhibits angiogenesis and tumor growth in vivo. 2011 , 27, 565-74	20
1291	SKLB1002, a novel potent inhibitor of VEGF receptor 2 signaling, inhibits angiogenesis and tumor growth in vivo. 2011 , 17, 4439-50	78
1290	Vascular pericyte density and angiogenesis associated with adenocarcinoma of the prostate. 2011 , 78, 24-34	11
1289	Pyruvate promotes tumor angiogenesis through HIF-1-dependent PAI-1 expression. 2011 , 38, 571-6	18
1288	Passive and active tumour targeting with nanocarriers. 2011 , 8, 188-96	121
1287	Correlation between glioblastoma stem-like cells and tumor vascularization. 2012 , 27, 45-50	16
1286	Front Matter. 2011 , I-LXXXV	
1285	Targeting activin receptor-like kinase 1 inhibits angiogenesis and tumorigenesis through a mechanism of action complementary to anti-VEGF therapies. 2011 , 71, 1362-73	98
1284	Emerging Role of Micro-RNAs in the Regulation of Angiogenesis. 2011 , 2, 1134-8	31
1283	Impact of renin-angiotensin system in hepatocellular carcinoma. 2011 , 11, 431-41	17

1282	The biology of HDAC in cancer: the nuclear and epigenetic components. 2011 , 206, 13-37	77
1281	Notch regulation of tumor angiogenesis. 2011 , 7, 569-88	48
1280	5-Formylhonokiol exerts anti-angiogenesis activity via inactivating the ERK signaling pathway. 2011 , 43, 146-52	17
1279	The Blood-Brain and Other Neural Barriers. 2011 ,	10
1278	Restraint of angiogenesis by zinc finger transcription factor CTCF-dependent chromatin insulation. 2011 , 108, 15231-6	15
1277	Stable differences in intrinsic mitochondrial membrane potential of tumor cell subpopulations reflect phenotypic heterogeneity. 2011 , 2011, 978583	33
1276	Treatment of painful hypertrophic osteoarthropathy associated with non-small cell lung cancer with octreotide: a case report and review of the literature. 2011 , 1, 189-92	5
1275	Novel tumor suppressive function of Smad4 in serum starvation-induced cell death through PAK1-PUMA pathway. 2011 , 2, e235	28
1274	Vascular endothelial growth factor inhibitor-induced hypertension: basics for primary care providers. 2011 , 2011, 816897	30
1273	Combating angiogenesis early: potential of targeting tumor-recruited neutrophils in cancer therapy. 2012 , 8, 5-8	13
1272	The Role of Cancer Stem Cells in the Organ Tropism of Breast Cancer Metastasis: A Mechanistic Balance between the "Seed" and the "Soil"?. 2012 , 2012, 209748	27
1271	Targeting angiogenesis in metastatic breast cancer. 2012 , 17, 1014-26	19
1270	The role of vascular endothelial growth factor a polymorphisms in breast cancer. 2012 , 13, 14845-64	28
1269	Inhibiting angiogenesis in malignant gliomas. 2012 , 104, 279-308	
1268	ALKBH3 contributes to survival and angiogenesis of human urothelial carcinoma cells through NADPH oxidase and tweak/Fn14/VEGF signals. 2012 , 18, 5247-55	41
1267	Remodeling of tumor stroma and response to therapy. 2012 , 4, 340-53	13
1266	Antiangiogenic effects of GFP08, an agaran-type polysaccharide isolated from Grateloupia filicina. 2012 , 22, 1343-52	21
1265	The proteasomal subunit Rpn6 is a molecular clamp holding the core and regulatory subcomplexes together. 2012 , 109, 149-54	118

1264	Mesothelin promotes invasion and metastasis in breast cancer cells. 2012 , 40, 2109-16	16
1263	Targeting angiogenesis for treatment of NSCLC brain metastases. 2012 , 12, 289-99	16
1262	Possible involvement of angiogenesis in chronic liver diseases: interaction among renin-angiotensin-aldosterone system, insulin resistance and oxidative stress. 2012 , 19, 1889-98	22
1261	Physiology, pharmacology and pathophysiology of the pH regulatory transport proteins NHE1 and NBCn1: similarities, differences, and implications for cancer therapy. 2012 , 18, 1345-71	103
1260	Combination of local transcatheter arterial chemoembolization and systemic anti-angiogenic therapy for unresectable hepatocellular carcinoma. 2012 , 1, 201-15	15
1259	The role of VEGF 165b in pathophysiology. 2012 , 6, 561-8	34
1258	Identification, functional characterization, and pathobiological significance of GLI1 isoforms in human cancers. 2012 , 88, 115-40	18
1257	Visualizing breast cancer using the Twente photoacoustic mammoscope: what do we learn from twelve new patient measurements?. 2012 , 20, 11582-97	147
1256	Therapy innovation for the treatment of pancreatic neuroendocrine tumors. 2012 , 16 Suppl 2, S91-102	5
1255	Ginsenoside Rg3 attenuates tumor angiogenesis via inhibiting bioactivities of endothelial progenitor cells. 2012 , 13, 504-15	66
1254	CTCF-dependent chromatin insulator as a built-in attenuator of angiogenesis. 2012 , 3, 73-7	7
1253	Tumor microenvironment and breast cancer progression: a complex scenario. 2012 , 13, 14-24	41
1252	Bevacizumab in endometrial cancer treatment. 2012 , 12, 649-58	14
1251	Biglycan is a specific marker and an autocrine angiogenic factor of tumour endothelial cells. 2012 , 106, 1214-23	74
1250	VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2. 2012 , 107, 1869-75	87
1249	Macrophage metalloelastase (MME) as adjuvant for intra-tumoral injection of oncolytic adenovirus and its influence on metastases development. 2012 , 19, 126-34	23
1248	MEDICINAL RADIOPHARMACEUTICAL CHEMISTRY OF METAL RADIOPHARMACEUTICALS. 2012 , 08, 11-81	3
1247	Forkhead transcription factor FOXO3a protein activates nuclear factor B through B-cell lymphoma/leukemia 10 (BCL10) protein and promotes tumor cell survival in serum deprivation. 2012 , 287, 17737-17745	45

1246	Targeting oncogenic serine/threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia. 2012 , 109, E353-9	42
1245	Radiotracers for SPECT imaging: current scenario and future prospects. 2012 , 100, 95-107	16
1244	Pazopanib in the treatment of soft tissue sarcoma. 2012 , 12, 711-23	28
1243	Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling. 2012 , 33, 1022-30	20
1242	Monoclonal antibodies at the Oncology Institute of Vojvodina: 5-year expenditure. 2012 , 20, 53-56	
1241	Active roles of tumor stroma in breast cancer metastasis. 2012 , 2012, 574025	57
1240	Angiogenic signalling pathways altered in gliomas: selection mechanisms for more aggressive neoplastic subpopulations with invasive phenotype. 2012 , 2012, 597915	19
1239	Stroma targeting nuclear imaging and radiopharmaceuticals. 2012 , 2012, 817682	3
1238	Late SV40 factor (LSF) enhances angiogenesis by transcriptionally up-regulating matrix metalloproteinase-9 (MMP-9). 2012 , 287, 3425-32	27
1237	Promyelocytic leukemia protein (PML) regulates endothelial cell network formation and migration in response to tumor necrosis factor α (TNF α) and interferon γ (IFN γ). 2012 , 287, 23356-67	32
1236	α 7 nicotinic acetylcholine receptor subunit in angiogenesis and epithelial to mesenchymal transition. 2012 , 13, 671-9	33
1235	Effect of an angiogenesis inhibitor on hepatic tumor perfusion and the implications for adjuvant cytotoxic therapy. 2012 , 264, 68-77	16
1234	Nuclear receptors as modulators of the tumor microenvironment. 2012 , 5, 3-10	22
1233	Endogenous ribosomal protein L29 (RPL29): a newly identified regulator of angiogenesis in mice. 2013 , 6, 115-24	10
1232	A concise review of current radiopharmaceuticals in tumor angiogenesis imaging. 2012 , 18, 1032-40	14
1231	Trial Watch: Immunostimulatory cytokines. 2012 , 1, 493-506	66
1230	Identification and functional study of cytokines and chemokines involved in tumorigenesis. 2012 , 15, 276-85	8
1229	PET and SPECT Imaging of Tumor Vasculature. 2012 , 341-371	

1228 Fluorescent Dye Conjugates for Optical Imaging of Cancer. **2012**, 451-482

1227 Multimeric Cyclic RGD Peptides Useful for Development of Integrin $\alpha_5\beta_1$ -Targeted SPECT Radiotracers. **2012**, 165-195

1226 A 47-year-old man with progressive shortness of breath and exercise intolerance. **2012**, 344, 407-12

1225 Grape seed proanthocyanidins inhibit colon cancer-induced angiogenesis through suppressing the expression of VEGF and Ang1. **2012**, 30, 1410-6 39

1224 Absence of Dickkopf (Dkk)-3 protein expression is correlated with longer disease-free survival and lower incidence of metastasis in head and neck squamous cell carcinoma. **2012**, 3, 273-280 13

1223 Antitumor effect of microbubbles enhanced by low frequency ultrasound cavitation on prostate carcinoma xenografts in nude mice. **2012**, 3, 187-191 15

1222 CDP-diacylglycerol synthetase-controlled phosphoinositide availability limits VEGFA signaling and vascular morphogenesis. **2012**, 120, 489-98 34

1221 The recombinant lectin-like domain of thrombomodulin inhibits angiogenesis through interaction with Lewis Y antigen. **2012**, 119, 1302-13 37

1220 Functional Gold Nanoparticles for Biointerfaces. **2012**, 147-176 2

1219 The Design of Hybrid Nanoparticles for Image-Guided Radiotherapy. **2012**, 95-143 1

1218 Multiscale imaging and computational modeling of blood flow in the tumor vasculature. **2012**, 40, 2425-41 40

1217 Patterning microscale extracellular matrices to study endothelial and cancer cell interactions in vitro. **2012**, 12, 4244-8 39

1216 Anti-angiogenic gene therapy in the treatment of malignant gliomas. **2012**, 527, 62-70 43

1215 The mesenchyme in malignancy: a partner in the initiation, progression and dissemination of cancer. **2012**, 136, 131-41 15

1214 Real-time visualization and characterization of tumor angiogenesis and vascular response to anticancer therapies. **2012**, 872, 115-27 2

1213 Synthesis and biological profile of the pan-vascular endothelial growth factor receptor/tyrosine kinase with immunoglobulin and epidermal growth factor-like homology domains 2 (VEGF-R/TIE-2) inhibitor 35

11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo[5,4-a]pyrrolo[3,4-c]carbazol-4-one (CFR-11981): a novel angiolytic therapeutic agent. **2012**, 55, 903-13
1212 Pro-metastatic tumor-stroma interactions in breast cancer. **2012**, 8, 1427-42 20

1211 Esophageal squamous cell carcinoma: assessing tumor angiogenesis using multi-slice CT perfusion imaging. **2012**, 57, 2195-202 13

1210	Early vascular deficits are correlated with delayed mammary tumorigenesis in the MMTV-PyMT transgenic mouse following genetic ablation of the NG2 proteoglycan. 2012 , 14, R67	50
1209	FHL family members suppress vascular endothelial growth factor expression through blockade of dimerization of HIF1 α and HIF1 β . 2012 , 64, 921-30	14
1208	Development of a multiplexed PCR-coupled liquid bead array assay for vascular endothelial growth factor (VEGF) splice variants. 2012 , 45, 475-82	4
1207	ADAMTS5 functions as an anti-angiogenic and anti-tumorigenic protein independent of its proteoglycanase activity. 2012 , 181, 1056-68	58
1206	Targeting angiogenesis as a promising modality for the treatment of prostate cancer. 2012 , 39, 547-60	7
1205	The apelin/APJ system induces maturation of the tumor vasculature and improves the efficiency of immune therapy. 2012 , 31, 3254-64	53
1204	Inflamed tumor-associated adipose tissue is a depot for macrophages that stimulate tumor growth and angiogenesis. 2012 , 15, 481-95	68
1203	SCF(E3RCP) suppresses angiogenesis and thyroid cancer cell migration by promoting ubiquitination and destruction of VEGF receptor 2. 2012 , 209, 1289-307	68
1202	An in vivo neovascularization assay for screening regulators of angiogenesis and assessing their effects on pre-existing vessels. 2012 , 15, 643-55	24
1201	The impact of tumor microenvironment on cancer treatment and its modulation by direct and indirect antivascular strategies. 2012 , 31, 823-42	56
1200	How intact is the basement membrane? Role of MMPs. 2012 , 749, 215-32	4
1199	Beyond bevacizumab: new anti-VEGF strategies in colorectal cancer. 2012 , 21, 949-59	18
1198	Aspirin as adjuvant therapy for colorectal cancer--reinterpreting paradigms. 2012 , 9, 561-70	82
1197	Endothelial Wnt/ β -catenin signaling inhibits glioma angiogenesis and normalizes tumor blood vessels by inducing PDGF-B expression. 2012 , 209, 1611-27	101
1196	Collagen VI ablation retards brain tumor progression due to deficits in assembly of the vascular basal lamina. 2012 , 180, 1145-1158	35
1195	Inhibition of endothelial/smooth muscle cell contact loss by the investigational angiopoietin-2 antibody MEDI3617. 2012 , 83, 290-7	9
1194	Determination of pazopanib (GW-786034) in mouse plasma and brain tissue by liquid chromatography-tandem mass spectrometry (LC/MS-MS). 2012 , 901, 85-92	34
1193	Blockade of VEGF-A suppresses tumor growth via inhibition of autocrine signaling through FAK and AKT. 2012 , 318, 221-5	29

1192	Chemopreventive effects of dietary phytochemicals against cancer invasion and metastasis: phenolic acids, monophenol, polyphenol, and their derivatives. 2012 , 38, 76-87	358
1191	Recent clinical developments and rationale for combining targeted agents in non-small cell lung cancer (NSCLC). 2012 , 38, 173-84	26
1190	Docetaxel combined with targeted therapies in metastatic breast cancer. 2012 , 38, 387-96	10
1189	Prognostic value of TP/PD-ECGF and thrombocytosis in gastric carcinoma. 2012 , 38, 568-73	18
1188	Microarray analysis revealing common and distinct functions of promyelocytic leukemia protein (PML) and tumor necrosis factor alpha (TNF) signaling in endothelial cells. 2012 , 13, 453	17
1187	Molecular target based combinational therapeutic approaches in thyroid cancer. 2012 , 10, 81	6
1186	Knockdown of aberrantly expressed nuclear localized decorin attenuates tumour angiogenesis related mediators in oral cancer progression model in vitro. 2012 , 4, 11	13
1185	Inhibition of lymphatic metastasis in neuroblastoma by a novel neutralizing antibody to vascular endothelial growth factor-D. 2012 , 103, 2144-52	17
1184	Combined chemotherapy delivered by nanoparticulate systems: an old concept with modern innovations. 2012 , 3, 1363-8	1
1183	AL3810, a multi-tyrosine kinase inhibitor, exhibits potent anti-angiogenic and anti-tumour activity via targeting VEGFR, FGFR and PDGFR. 2012 , 16, 2321-30	24
1182	The promise of mTOR inhibitors in the treatment of colorectal cancer. 2012 , 21, 1775-88	23
1181	Peptide vaccines and targeting HER and VEGF proteins may offer a potentially new paradigm in cancer immunotherapy. 2012 , 8, 961-87	38
1180	A Review of Mechanisms of Contrast for Diffuse Optical Imaging of Cancer. 2012 , 20, 185-202	6
1179	Cyclic RGDyk-conjugated LMWH-taurocholate derivative as a targeting angiogenesis inhibitor. 2012 , 164, 8-16	13
1178	An investigation of growth factors and lactoferrin in naturally occurring ovine pulmonary adenomatosis. 2012 , 147, 441-51	9
1177	The vascular-disrupting agent, combretastatin-A4-phosphate, enhances neurogenic vasoconstriction in rat small arteries. 2012 , 695, 104-11	8
1176	New concepts and best practices for management of pre- and post-transplantation cancer. 2012 , 26, 261-79	70
1175	Grape seed proanthocyanidins inhibit angiogenesis via the downregulation of both vascular endothelial growth factor and angiopoietin signaling. 2012 , 32, 530-6	22

1174	Advances and prospects of anginex as a promising anti-angiogenesis and anti-tumor agent. 2012 , 38, 457-62	21
1173	Synergistic effects of cell-penetrating peptide Tat and fusogenic peptide HA2-enhanced cellular internalization and gene transduction of organosilica nanoparticles. 2012 , 8, 833-41	48
1172	CD133 as a marker for regulation and potential for targeted therapies in glioblastoma multiforme. 2012 , 23, 391-405	24
1171	Correlational study of vascular endothelial growth factor expression and microvessel density in primary malignant gastric lymphoma. 2012 , 29, 1711-5	5
1170	Metronomic chemotherapy in progressive pediatric malignancies: old drugs in new package. 2012 , 79, 1617-22	21
1169	p16INK4A represses breast stromal fibroblasts migration/invasion and their VEGF-A-dependent promotion of angiogenesis through Akt inhibition. 2012 , 14, 1269-77	29
1168	Molecular Genetics and Personalized Medicine. 2012 ,	1
1167	Cell Signaling & Molecular Targets in Cancer. 2012 ,	1
1166	Cellular Trafficking of Cell Stress Proteins in Health and Disease. 2012 ,	3
1165	Angiopreventive efficacy of pure flavonolignans from milk thistle extract against prostate cancer: targeting VEGF-VEGFR signaling. 2012 , 7, e34630	41
1164	Ionizing radiation induces stemness in cancer cells. 2012 , 7, e43628	124
1163	CXCL17 expression by tumor cells recruits CD11b+Gr1 high F4/80- cells and promotes tumor progression. 2012 , 7, e44080	55
1162	Tumor endothelial inflammation predicts clinical outcome in diverse human cancers. 2012 , 7, e46104	38
1161	Dehydrocostuslactone suppresses angiogenesis in vitro and in vivo through inhibition of Akt/GSK-3 β and mTOR signaling pathways. 2012 , 7, e31195	33
1160	Evaluation of serum concentrations of vascular endothelial growth factor (VEGF) in breast cancer patients. 2012 , 63, 255-60	8
1159	Vascular Biomarkers and Imaging Studies. 2012 , 139-162	
1158	Targeting the tumor microenvironment: focus on angiogenesis. 2012 , 2012, 281261	76
1157	Bone Marrow Suppression by c-Kit Blockade Enhances Tumor Growth of Colorectal Metastases through the Action of Stromal Cell-Derived Factor-1. 2012 , 2012, 196957	

1156	Integrin-mediated cell-matrix interaction in physiological and pathological blood vessel formation. 2012 , 2012, 125278	24
1155	The critical role of vascular endothelial growth factor in tumor angiogenesis. 2012 , 12, 23-43	65
1154	Contrast Enhancement of the Brain by Folate-Conjugated Gadolinium Diethylenetriaminepentaacetic Acid Human Serum Albumin Nanoparticles by Magnetic Resonance Imaging. 2012 , 11, 7290.2011.00047	6
1153	Magnetic Nanoparticles in the Imaging of Tumor Angiogenesis. 2012 , 2, 525-534	7
1152	Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) in Preclinical Studies of Antivascular Treatments. 2012 , 4, 563-89	31
1151	Targeted Nanoparticles for Cancer Therapy. 2012 ,	10
1150	Targeting Tumor Microenvironments for Cancer Prevention and Therapy. 2012 ,	1
1149	Retinoblastoma treatment: utilization of the glycolytic inhibitor, 2-deoxy-2-fluoro-D-glucose (2-FG), to target the chemoresistant hypoxic regions in LH(BETA)T(AG) retinal tumors. 2012 , 53, 996-1002	12
1148	8.4 Targeting protein-glycan interactions at cell surface during EMT and hematogenous metastasis: consequences on tumor invasion and metastasis.	
1147	. 2012 ,	5
1146	Sonic Hedgehog in cancer stem cells: a novel link with autophagy. 2012 , 45, 223-30	38
1145	Retinoblastoma treatment: impact of the glycolytic inhibitor 2-deoxy-d-glucose on molecular genomics expression in LH(BETA)T(AG) retinal tumors. 2012 , 6, 817-30	2
1144	The effect of anti-VEGF drugs (bevacizumab and aflibercept) on the survival of patients with metastatic colorectal cancer (mCRC). 2012 , 5, 59-65	13
1143	Dietary restriction promotes vessel maturation in a mouse astrocytoma. 2012 , 2012, 264039	20
1142	Modeling Tumor Angiogenesis in Zebrafish. 2012 ,	1
1141	Prognostic significance of angiogenesis by Chalkley counting in node negative cancer of the ampulla of Vater. 2012 , 27, 495-9	0
1140	Operation 'p53 Hunt' to combat cancer: theaflavins in action. 2012 , 4, 300-20	1
1139	Molecular Mechanisms of Tumor Angiogenesis. 2012 ,	1

1138	Design, synthesis, and anti-proliferative evaluation of [1,1'-biphenyl]-4-ols as inhibitor of HUVEC migration and tube formation. 2012 , 17, 8091-104	8
1137	Central role of lactic acidosis in cancer cell resistance to glucose deprivation-induced cell death. 2012 , 227, 189-99	91
1136	Perspectives on the ARE as it turns 25 years old. 2012 , 3, 719-31	40
1135	Emerging insights into the molecular and cellular basis of glioblastoma. 2012 , 26, 756-84	388
1134	Molecular mechanism inhibiting human hepatocarcinoma cell invasion by 6-shogaol and 6-gingerol. 2012 , 56, 1304-14	68
1133	Targeted polymeric micelles for siRNA treatment of experimental cancer by intravenous injection. 2012 , 6, 5174-89	167
1132	Peptide targeted lipid nanoparticles for anticancer drug delivery. 2012 , 24, 3803-22, 3710	145
1131	Mechanisms of resistance to vascular endothelial growth factor blockade. 2012 , 118, 3455-67	56
1130	Ras homolog gene family, member A promotes p53 degradation and vascular endothelial growth factor-dependent angiogenesis through an interaction with murine double minute 2 under hypoxic conditions. 2012 , 118, 4105-16	16
1129	Generation of monoclonal antibodies to recombinant vascular endothelial growth factor. 2012 , 153, 139-42	5
1128	Microvessel density is high in clear-cell renal cell carcinomas of Ukrainian patients exposed to chronic persistent low-dose ionizing radiation after the Chernobyl accident. 2012 , 460, 611-9	10
1127	Flavonoids, a ubiquitous dietary phenolic subclass, exert extensive in vitro anti-invasive and in vivo anti-metastatic activities. 2012 , 31, 323-51	153
1126	A novel multi-targeted tyrosine kinase inhibitor, linifanib (ABT-869), produces functional and structural changes in tumor vasculature in an orthotopic rat glioma model. 2012 , 69, 911-21	22
1125	A phase I study of sunitinib combined with modified FOLFOX6 in patients with advanced solid tumors. 2012 , 70, 65-74	7
1124	Psoriasin (S100A7) increases the expression of ROS and VEGF and acts through RAGE to promote endothelial cell proliferation. 2012 , 134, 71-80	56
1123	Midkine expression in oral squamous cell carcinoma and leukoplakia. 2012 , 41, 21-6	10
1122	Combination or sequencing strategies to improve the outcome of metastatic renal cell carcinoma patients: a critical review. 2012 , 82, 323-37	29
1121	Tubular network formation by adriamycin-resistant MCF-7 breast cancer cells is closely linked to MMP-9 and VEGFR-2/VEGFR-3 over-expressions. 2012 , 685, 1-7	22

1120	Glioblastoma: therapeutic challenges, what lies ahead. 2012 , 1826, 338-49	75
1119	Antiangiogenic activity of 3,4-seco-cycloartane triterpenes from Thai Gardenia spp. and their semi-synthetic analogs. 2012 , 22, 512-7	11
1118	Actions of the Kunitz-type serine protease inhibitor Amblyomin-X on VEGF-A-induced angiogenesis. 2012 , 60, 333-40	22
1117	Cancer therapy and vaccination. 2012 , 382, 1-23	42
1116	The hypoxia-inducible factor-responsive proteins semaphorin 4D and vascular endothelial growth factor promote tumor growth and angiogenesis in oral squamous cell carcinoma. 2012 , 318, 1685-98	36
1115	Decreased lung carcinoma cell functions on select polymer nanometer surface features. 2012 , 100, 94-102	13
1114	The novel lupus antigen related protein acheron enhances the development of human breast cancer. 2012 , 130, 544-54	18
1113	VEGF directly suppresses activation of T cells from ovarian cancer patients and healthy individuals via VEGF receptor Type 2. 2012 , 130, 857-64	96
1112	DCE and DW-MRI monitoring of vascular disruption following VEGF-Trap treatment of a rat glioma model. 2012 , 25, 935-42	24
1111	Identification of CD146 expression, angiogenesis, and lymphangiogenesis as progression, metastasis, and poor-prognosis related markers for gallbladder adenocarcinoma. 2012 , 33, 173-82	26
1110	Evaluation of ⁶⁴ Cu labeled GX1: a phage display peptide probe for PET imaging of tumor vasculature. 2012 , 14, 96-105	38
1109	Therapeutic angiogenesis for myocardial ischemia revisited: basic biological concepts and focus on latest clinical trials. 2012 , 15, 1-22	99
1108	A Cy5.5-labeled phage-displayed peptide probe for near-infrared fluorescence imaging of tumor vasculature in living mice. 2012 , 42, 1329-37	36
1107	VEGF gene alternative splicing: pro- and anti-angiogenic isoforms in cancer. 2012 , 138, 363-70	65
1106	Microarray meta-analysis defines global angiogenesis-related gene expression signatures in human carcinomas. 2013 , 52, 29-38	10
1105	Oncogenes and angiogenesis: a way to personalize anti-angiogenic therapy?. 2013 , 70, 4131-40	16
1104	New Advances on Disease Biomarkers and Molecular Targets in Biomedicine. 2013 ,	
1103	Monocytes and macrophages in cancer: development and functions. 2013 , 6, 179-91	112

1102	Nanotechnological strategies for therapeutic targeting of tumor vasculature. 2013 , 8, 1209-22	30
1101	c-Myc enhances colon cancer cell-mediated angiogenesis through the regulation of HIF-1 β . 2013 , 430, 505-11	41
1100	C-X-C motif receptor 2, endostatin and proteinase-activated receptor 1 polymorphisms as prognostic factors in NSCLC. 2013 , 81, 123-9	10
1099	Cancer: Angiogenic awakening. 2013 , 500, 37-8	16
1098	3D numerical simulation of avascular tumour growth: effect of hypoxic micro-environment in host tissue. 2013 , 34, 1055-1068	3
1097	Molecular Imaging in Oncology. 2013 ,	3
1096	High circulating VEGF level predicts poor overall survival in lung cancer. 2013 , 139, 1157-67	21
1095	Pericytes on the tumor vasculature: jekyll or hyde?. 2013 , 6, 1-17	55
1094	p55PIK-PI3K stimulates angiogenesis in colorectal cancer cell by activating NF- κ B pathway. 2013 , 16, 561-73	29
1093	Microengineered tumor models: insights & opportunities from a physical sciences-oncology perspective. 2013 , 15, 583-593	33
1092	Hypoxia-induced decreases in SOCS3 increase STAT3 activation and upregulate VEGF gene expression. 2013 , 30, 135-43	23
1091	Pattern analysis accounts for heterogeneity observed in MRI studies of tumor angiogenesis. 2013 , 70, 1481-90	9
1090	Risk of hemoptysis in patients with resected squamous cell and other high-risk lung cancers treated with adjuvant bevacizumab. 2013 , 72, 453-61	11
1089	Correlation between response to chemotherapy with concomitant bevacizumab for hepatic metastasis of colorectal cancer and degree of enhancement using contrast-enhanced computed tomography. 2013 , 72, 209-15	4
1088	Polymeric Nanomedicines as a Promising Vehicle for Solid Tumor Therapy and Targeting. 2013 , 13, 179-204	20
1087	Mesoporous Silica Nanoparticles for Cancer Therapy. 2013 , 231-242	
1086	Evaluation of serum nitric oxide before and after local radiofrequency thermal ablation for hepatocellular carcinomaPeer review under responsibility of Alexandria University Faculty of Medicine.View all notesAvailable online 6 October 2012View all notes. 2013 , 49, 67-73	1
1085	Crosstalk between hydrogen sulfide and nitric oxide in endothelial cells. 2013 , 17, 879-88	115

1084	Angiotensin-converting enzyme and the tumor microenvironment: mechanisms beyond angiogenesis. 2013 , 305, R205-15	23
1083	Simultaneous progression of oxidative stress, angiogenesis, and cell proliferation in prostate carcinoma. 2013 , 31, 1561-6	9
1082	VEGF pathway polymorphisms as prognostic and pharmacogenetic factors in cancer: a 2013 update. 2013 , 14, 1659-67	12
1081	Integrin modulators: a patent review. 2013 , 23, 1273-95	58
1080	VEGF111b, a new member of VEGFxxx isoforms and induced by mitomycin C, inhibits angiogenesis. 2013 , 441, 18-24	11
1079	Implications of Glioblastoma Stem Cells in Chemoresistance. 2013 , 435-462	
1078	Angiogenic capacity of M1- and M2-polarized macrophages is determined by the levels of TIMP-1 complexed with their secreted proMMP-9. 2013 , 122, 4054-67	146
1077	Pericytes, mesenchymal stem cells and the wound healing process. 2013 , 2, 621-34	70
1076	Targeting the tumor microenvironment: from understanding pathways to effective clinical trials. 2013 , 73, 4965-77	191
1075	Cell and Molecular Biology of Breast Cancer. 2013 ,	8
1074	Transformed Drosophila cells evade diet-mediated insulin resistance through wingless signaling. 2013 , 154, 664-75	84
1073	Angiogenesis-related pathways in the pathogenesis of ovarian cancer. 2013 , 14, 15885-909	77
1072	Development of RGD-based radiotracers for tumor imaging and therapy: translating from bench to bedside. 2013 , 13, 1487-505	37
1071	An optimized ultrasound detector for photoacoustic breast tomography. 2013 , 40, 032901	36
1070	Proteases: Structure and Function. 2013 ,	25
1069	A morphometric tool applied to angiogenesis research based on vessel segmentation. 2013 , 8,	1
1068	Antiangiogenic effects of melatonin in endothelial cell cultures. 2013 , 87, 25-33	53
1067	Pancreatic-carcinoma-cell-derived pro-angiogenic factors can induce endothelial-cell differentiation of a subset of circulating CD34+ progenitors. 2013 , 11, 314	12

1066	Current evidence for the hepatoprotective activities of the medicinal mushroom <i>Antrodia cinnamomea</i> . 2013 , 8, 21	19
1065	Design, synthesis, biological evaluation, and molecular modeling study of 4-alkoxyquinazoline derivatives as potential VEGFR2 kinase inhibitors. 2013 , 11, 7676-86	23
1064	Systems Biology of Tumor Dormancy. 2013 ,	6
1063	Protease-activated receptor 2 signaling upregulates angiogenic growth factors in renal cell carcinoma. 2013 , 94, 91-7	12
1062	Micropatterned Surfaces for the Study of Cancer and Endothelial Cell Interactions with Hyaluronic Acid. 2013 , 53, n/a-n/a	1
1061	In vivo tumor targeting and image-guided drug delivery with antibody-conjugated, radiolabeled mesoporous silica nanoparticles. 2013 , 7, 9027-39	281
1060	Multiple FAS1 domains and the RGD motif of TGFBI act cooperatively to bind $\alpha 5 \beta 1$ integrin, leading to anti-angiogenic and anti-tumor effects. 2013 , 1833, 2378-88	31
1059	Monitoring tumor response to linifanib therapy with SPECT/CT using the integrin $\alpha 5 \beta 1$ -targeted radiotracer ^{99m}Tc -3P-RGD2. 2013 , 346, 251-8	24
1058	Parameter optimization of HIF-1 controller designed for tumor growth in the light of physiological aspects. 2013 ,	5
1057	Spatiotemporal assessments of dermal hyperemia enable accurate prediction of experimental cutaneous carcinogenesis as well as chemopreventive activity. 2013 , 73, 150-9	18
1056	Preclinical molecular imaging using PET and MRI. 2013 , 187, 257-310	13
1055	Loss of p53 in enterocytes generates an inflammatory microenvironment enabling invasion and lymph node metastasis of carcinogen-induced colorectal tumors. 2013 , 23, 93-106	203
1054	Glioblastoma, a brief review of history, molecular genetics, animal models and novel therapeutic strategies. 2013 , 61, 25-41	145
1053	Melatonin suppresses tumor progression by reducing angiogenesis stimulated by HIF-1 in a mouse tumor model. 2013 , 54, 264-70	71
1052	Regulation of vascular endothelial growth factor by melatonin in human breast cancer cells. 2013 , 54, 373-80	78
1051	The tumor microenvironment: characterization, redox considerations, and novel approaches for reactive oxygen species-targeted gene therapy. 2013 , 19, 854-95	79
1050	The high angiogenic activity in very early breast cancer enables reliable imaging with VEGFR2-targeted microbubbles (BR55). 2013 , 23, 468-75	49
1049	Diffusion-weighted imaging in rectal carcinoma patients without and after chemoradiotherapy: a comparative study with histology. 2013 , 82, 444-52	40

1048	Study on bladder cancer susceptibility and genetic polymorphisms of XPC, XPG, and CYP in smokers and non-smokers. 2013 , 37, 259-65	9
1047	Study of capillary network directionality and irrigation of hypoxic tissue in an angiogenesis lattice model. 2013 , 392, 6389-6399	
1046	Synthesis and anti-angiogenic activity evaluation of N-(3-aryl acryloyl)aminosaccharide derivatives. 2013 , 381, 83-92	3
1045	Study on bladder cancer susceptibility and genetic polymorphisms of XPC, XPG, and CYP in smokers and non-smokers. 2013 , 37, 259-265	4
1044	Antiangiogenic effects of marine sponge derived compounds on cancer. 2013 , 36, 1097-108	12
1043	Ellagic acid inhibits human pancreatic cancer growth in Balb c nude mice. 2013 , 337, 210-7	70
1042	Metastatic gastric cancer treatment: a little slow but worthy progress. 2013 , 30, 464	30
1041	Tumor dormancy and cancer stem cells: two sides of the same coin?. 2013 , 734, 145-79	88
1040	Emerging VEGF-receptor inhibitors for colorectal cancer. 2013 , 18, 25-37	24
1039	The Role of Tumor Exosomes in Tumorigenicity. 2013 , 169-179	
1038	Mechanisms of neovascularization and resistance to anti-angiogenic therapies in glioblastoma multiforme. 2013 , 91, 439-48	107
1037	Regulation of Angiogenesis by Tumour Suppressor Pathways. 2013 , 79-99	
1036	Models and discovery strategies for new therapies of retinoblastoma. 2013 , 8, 383-94	17
1035	Prostate cancer and physical activity: adaptive response to oxidative stress. 2013 , 60, 115-24	28
1034	Ecological photodynamic therapy: new trend to disrupt the intricate networks within tumor ecosystem. 2013 , 1835, 86-99	13
1033	A common and functional gene variant in the vascular endothelial growth factor a predicts clinical outcome in early-stage breast cancer. 2013 , 52 Suppl 1, E96-102	9
1032	Molecular markers to predict outcome to antiangiogenic therapies in colorectal cancer: current evidence and future perspectives. 2013 , 39, 908-24	31
1031	Key molecular mechanisms in lung cancer invasion and metastasis: a comprehensive review. 2013 , 87, 1-11	106

1030	Development of liposomal Ginsenoside Rg3: formulation optimization and evaluation of its anticancer effects. 2013 , 450, 250-8	36
1029	Identification of stromal differentially expressed proteins in the colon carcinoma by quantitative proteomics. 2013 , 34, 1679-92	36
1028	YB-1: oncoprotein, prognostic marker and therapeutic target?. 2013 , 449, 11-23	149
1027	Pancreatic adenocarcinoma upregulated factor, a novel endothelial activator, promotes angiogenesis and vascular permeability. 2013 , 32, 3638-47	31
1026	Inhibitory effect of paclitaxel and rapamycin individual and dual drug-loaded polymeric micelles in the angiogenic cascade. 2013 , 10, 2071-8	26
1025	Using functional nanomaterials to target and regulate the tumor microenvironment: diagnostic and therapeutic applications. 2013 , 25, 3508-25	127
1024	Mounting a strategic offense: fighting tumor vasculature with oncolytic viruses. 2013 , 19, 378-92	26
1023	Angiogenin expression in human kidneys and Wilms' tumours: relationship with hypoxia and angiogenic factors. 2013 , 94, 115-25	5
1022	Overexpression of PLCE1 in Kazakh esophageal squamous cell carcinoma: implications in cancer metastasis and aggressiveness. 2013 , 121, 908-18	33
1021	Cellular, Molecular, and Biological Perspective of Polyphenols in Chemoprevention and Therapeutic Adjunct in Cancer. 2013 , 2175-2254	4
1020	Investigation into the impact of diagnostic ultrasound with microbubbles on the capillary permeability of rat hepatomas. 2013 , 39, 628-37	19
1019	Nanoparticle PET/CT imaging of natriuretic peptide clearance receptor in prostate cancer. 2013 , 24, 196-204	38
1018	Neurotransmitters as regulators of tumor angiogenesis and immunity: the role of catecholamines. 2013 , 8, 7-14	45
1017	Elastin-based protein polymer nanoparticles carrying drug at both corona and core suppress tumor growth in vivo. 2013 , 171, 330-8	69
1016	Interplay between p53 and VEGF: how to prevent the guardian from becoming a villain. 2013 , 20, 852-4	9
1015	Incorporation of paramagnetic, fluorescent and PET/SPECT contrast agents into liposomes for multimodal imaging. 2013 , 34, 1179-92	62
1014	Angiogenesis: from molecular mechanisms to translational implications. 2013 , 54, 345-55	13
1013	Synthesis and evaluation of ⁶⁴ Cu-labeled monomeric and dimeric NGR peptides for MicroPET imaging of CD13 receptor expression. 2013 , 10, 417-27	56

1012	Incidental neuroendocrine tumors of the pancreas: MDCT findings and features of malignancy. 2013 , 200, 355-62	53
1011	Processing of VEGF-C and -D by the Proprotein Convertases: Importance in Angiogenesis, Lymphangiogenesis, and Tumorigenesis. 2013 , 2, 1-66	1
1010	. 2013 ,	4
1009	Induction of hypoxia by vascular disrupting agents and the significance for their combination with radiation therapy. 2013 , 52, 1320-6	22
1008	Design considerations for ultrasound detectors in photoacoustic breast imaging. 2013 ,	1
1007	Branched-chain amino acids suppress the cumulative recurrence of hepatocellular carcinoma under conditions of insulin-resistance. 2013 , 30, 545-52	12
1006	Molecular hierarchy of heparin-binding EGF-like growth factor-regulated angiogenesis in triple-negative breast cancer. 2013 , 11, 506-17	29
1005	The role of IL-1 β in the early tumor cell-induced angiogenic response. 2013 , 190, 3500-9	136
1004	Molecular MR imaging of neovascular progression in the Vx2 tumor with α -targeted paramagnetic nanoparticles. 2013 , 268, 470-80	33
1003	Design and evaluation of a laboratory prototype system for 3D photoacoustic full breast tomography. 2013 , 4, 2555-69	31
1002	Drosophila and the hallmarks of cancer. 2013 , 135, 79-110	6
1001	Progress of molecular targeted therapies for advanced renal cell carcinoma. 2013 , 2013, 419176	27
1000	Bevacizumab for glioblastoma-a promising drug or not?. 2013 , 5, 1456-68	4
999	Transgenic mouse models--a seminal breakthrough in oncogene research. 2013 , 2013, 1099-108	12
998	Oral naftopidil suppresses human renal-cell carcinoma by inducing G(1) cell-cycle arrest in tumor and vascular endothelial cells. 2013 , 6, 1000-6	16
997	Emerging Concepts of Tumor Exosome-Mediated Cell-Cell Communication. 2013 ,	5
996	μ -opioids inhibit tumor angiogenesis by suppressing VEGF signaling. 2013 , 3, 3213	34
995	Synergistic effect of cisplatin and synchrotron irradiation on F98 gliomas growing in nude mice. 2013 , 20, 777-84	7

994	Expression of angiogenic growth factors in laryngeal carcinoma. 2013 , 1, 1013-1018	3
993	Mitochondrial dysfunction in cancer. 2013 , 3, 292	293
992	Ziv-aflibercept in metastatic colorectal cancer. 2014 , 8, 13-25	25
991	Recent trends in multifunctional liposomal nanocarriers for enhanced tumor targeting. 2013 , 2013, 705265	149
990	Biochemical Basis and Therapeutic Implications of Angiogenesis. 2013 ,	2
989	. 2013 ,	
988	Angiogenesis inhibitors in cancer therapy: mechanistic perspective on classification and treatment rationales. 2013 , 170, 712-29	136
987	Heterogeneity of tumor endothelial cells. 2013 , 104, 1391-5	52
986	Dickkopf-related protein 3 promotes pathogenic stromal remodeling in benign prostatic hyperplasia and prostate cancer. 2013 , 73, 1441-52	20
985	RAC1: an emerging therapeutic option for targeting cancer angiogenesis and metastasis. 2013 , 12, 1925-34	169
984	Loss of epigenetic Kruppel-like factor 4 histone deacetylase (KLF-4-HDAC)-mediated transcriptional suppression is crucial in increasing vascular endothelial growth factor (VEGF) expression in breast cancer. 2013 , 288, 27232-27242	24
983	SC-535, a novel oral multikinase inhibitor, showed potent antitumor activity in human melanoma models. 2013 , 32, 138-53	6
982	Tumor-associated soluble uPAR-directed endothelial cell motility and tumor angiogenesis. 2013 , 2, e53	17
981	Single-cell clones of liver cancer stem cells have the potential of differentiating into different types of tumor cells. 2013 , 4, e857	33
980	A review of vascular disrupting agents as a concomitant anti-tumour modality with radiation. 2013 , 12, 255-262	4
979	A human thyroid cancer cell line, DH-14-3, newly established from poorly differentiated thyroid carcinoma. 2013 , 230, 75-82	3
978	Polymeric Biomaterials in Pulmonary Drug Delivery. 2013 , 572-599	
977	Erxian decoction, a traditional chinese herbal formula, inhibits angiogenesis in human umbilical vein endothelial cells. 2013 , 36, 754-63	3

976	Development of Novel Inhibitors Specific for Human Heparanase-1. 2013 , 42, 797-798	1
975	Synthesis of a Heparan Sulfate Disaccharide Fluoride for Detection of Heparanase Activity. 2013 , 42, 1168-1169	1
974	Imatinib disrupts lymphoma angiogenesis by targeting vascular pericytes. 2013 , 121, 5192-202	66
973	Combination therapy with VEGFR2 and EGFR siRNA enhances the antitumor effect of cisplatin in non-small cell lung cancer xenografts. 2013 , 29, 260-8	20
972	Studies on the anti-angiogenic effect of Marsdenia tenacissima extract in vitro and in vivo. 2013 , 5, 917-922	30
971	Non-invasive imaging for studying anti-angiogenic therapy effects. 2013 , 109, 375-90	69
970	Antitumor and anti-angiogenesis effects of thymoquinone on osteosarcoma through the NF- κ B pathway. 2013 , 29, 571-8	106
969	Physicochemical regulation of endothelial sprouting in a 3D microfluidic angiogenesis model. 2013 , 101, 2948-56	59
968	Effect of rapamycin-induced tumor vessel thrombosis combined with docetaxel in non-small-cell lung cancer. 2013 , 24, 406-14	6
967	Inhibition of angiopoietin 2 attenuates lumen formation of tumour-associated vessels in vivo. 2013 , 43, 1447-55	7
966	Use of Nanotechnology to Develop Multi-Drug Inhibitors For Cancer Therapy. 2013 , 4,	38
965	The role of tumor-associated macrophages in tumor vascularization. 2013 , 5, 20	76
964	[Microenvironment and colorectal liver metastases angiogenesis: surgical implications]. 2013 , 100, 343-50	3
963	Antitumor effect of bevacizumab in a xenograft model of canine hemangiopericytoma. 2013 , 121, 339-42	10
962	Anti- α 5 β 1 antibody guided three-step pretargeting approach using magnetoliposomes for molecular magnetic resonance imaging of breast cancer angiogenesis. 2013 , 8, 245-55	17
961	Integrin α 5 β 1-targeted radiotracer (99m Tc-3P-RGD) useful for noninvasive monitoring of breast tumor response to antiangiogenic linifanib therapy but not anti-integrin α 5 β 1 therapy. 2013 , 3, 816-30	23
960	Novel delivery system for T-oligo using a nanocomplex formed with an alpha helical peptide for melanoma therapy. 2014 , 9, 43-53	9
959	Brain Tumor-Induced Angiogenesis: Approaches and Bioassays. 2013 ,	2

958	Bevacizumab in high-grade gliomas: a review of its uses, toxicity assessment, and future treatment challenges. 2013 , 6, 371-89	24
957	TGF-Beta suppresses VEGFA-mediated angiogenesis in colon cancer metastasis. 2013 , 8, e59918	57
956	VEGF in tumor progression and targeted therapy. 2013 , 13, 423-43	65
955	Optical imaging of head and neck squamous cell carcinoma in vivo using arginine-glycine-aspartic acid peptide conjugated near-infrared quantum dots. 2013 , 6, 1779-87	13
954	TMA vessel segmentation based on color and morphological features: application to angiogenesis research. 2013 , 2013, 263190	9
953	Tumor angiogenesis, macrophages and mast cell microdensities in endometrioid endometrial carcinoma. 2013 , 6, 415-420	5
952	A review of tasquinimod in the treatment of advanced prostate cancer. 2013 , 7, 167-74	9
951	Immune suppression and evasion in patients with head and neck cancer. 2013 , 1, 21809	2
950	Prospective Role of Indian Medicinal Plants in Inhibiting Vascular Endothelial Growth Factor (VEGF) mediated Pathological Angiogenesis. 2013 , 02,	
949	Innovative Models to Assess Multiple Myeloma Biology and the Impact of Drugs. 2013 ,	4
948	Toxicity assessment of repeated intravenous injections of arginine-glycine-aspartic acid peptide conjugated CdSeTe/ZnS quantum dots in mice. 2014 , 9, 4809-17	13
947	Circulating Levels of Soluble Angiogenic Factors in Multiple Myeloma: Correlation with Parameters of Disease Activity and Prognosis. 2014 , 2, 76-95	4
946	Cancer Angiogenesis and Vasculogenesis. 2014 , 403-411	
945	Imaging circulating tumor cells in freely moving awake small animals using a miniaturized intravital microscope. 2014 , 9, e86759	28
944	Capsaicin-induced activation of p53-SMAR1 auto-regulatory loop down-regulates VEGF in non-small cell lung cancer to restrain angiogenesis. 2014 , 9, e99743	51
943	SHARP1 suppresses angiogenesis of endometrial cancer by decreasing hypoxia-inducible factor-1 β level. 2014 , 9, e99907	19
942	Lectin-like oxidized LDL receptor-1 is an enhancer of tumor angiogenesis in human prostate cancer cells. 2014 , 9, e106219	36
941	An in vitro cord formation assay identifies unique vascular phenotypes associated with angiogenic growth factors. 2014 , 9, e106901	6

940	Hyperplasia of pericytes is one of the main characteristics of microvascular architecture in malignant glioma. 2014 , 9, e114246	26
939	Mechanisms of Acquired Resistance to Tyrosine Kinase Inhibitors in Clear - Cell Renal Cell Carcinoma (ccRCC). 2014 , 8, 218-228	56
938	LPA-primed astrocytes induce axonal outgrowth of cortical progenitors by activating PKA signaling pathways and modulating extracellular matrix proteins. 2014 , 8, 296	16
937	Gliomas and the vascular fragility of the blood brain barrier. 2014 , 8, 418	166
936	Trabectedin and plitidepsin: drugs from the sea that strike the tumor microenvironment. 2014 , 12, 719-33	31
935	ELK3 suppresses angiogenesis by inhibiting the transcriptional activity of ETS-1 on MT1-MMP. 2014 , 10, 438-47	16
934	Reduced miR-126 expression facilitates angiogenesis of gastric cancer through its regulation on VEGF-A. 2014 , 5, 11873-85	104
933	. 2014 ,	12
932	. 2014 ,	5
931	Clinical Insights: Antiangiogenesis in Cancer Therapy. 2014 ,	
930	Role of hypoxia and vascular endothelial growth factors in lymphangiogenesis. 2014 , 1, e29907	7
929	Recent advances in vascular disrupting agents in cancer therapy. 2014 , 6, 1485-98	48
928	La réduction des volumes ou l'intensité de la réponse tumorale en cancérologie colorectale. 2014 , 16, 587-592	
927	Tissue-infiltrating neutrophils constitute the major in vivo source of angiogenesis-inducing MMP-9 in the tumor microenvironment. 2014 , 16, 771-88	161
926	Dendritic Polymers as Targeting Nanoscale Drug Delivery Systems for Cancer Therapy. 2014 , 29-60	
925	Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy. 2014 , 15, 1635-45	46
924	Regulation of invadopodia by the tumor microenvironment. 2014 , 8, 226-35	53
923	Platelet-rich plasma in surgical oncology. 2014 , 21, 441	11

922	Effect of vascular haemoglobin concentrations on ultrasound-guided diffuse optical tomography in differentiating benign from malignant breast lesions. 2014 , 24, 2848-56	5
921	Microvasculature: An essential component for organ-on-chip systems. 2014 , 39, 51-59	28
920	Solena amplexicaulis induces cell cycle arrest, apoptosis and inhibits angiogenesis in hepatocarcinoma cells and HUVECs. 2014 , 42, 1521-37	4
919	Kinase Inhibitors in Cancer. 2014 ,	2
918	Tumor Dormancy, Quiescence, and Senescence, Vol. 3. 2014 ,	1
917	Rho GTPases modulate malignant transformation of tumor cells. 2014 , 5, e29019	111
916	Therapeutic angiogenesis after ischemic stroke: Chinese medicines, bone marrow stromal cells (BMSCs) and their combinational treatment. 2014 , 42, 61-77	29
915	Study of microvessel density and the expression of vascular endothelial growth factors in adrenal gland pheochromocytomas. 2014 , 2014, 104129	7
914	Metastatic Breast Cancer: Clinical Considerations. 2014 , 963-970	
913	Role of VEGF-A and its receptors in sporadic and MEN2-associated pheochromocytoma. 2014 , 15, 5323-36	6
912	Evidence for G-quadruplex in the promoter of vegfr-2 and its targeting to inhibit tumor angiogenesis. 2014 , 42, 2945-57	36
911	Gelatinase B/MMP-9 in Tumour Pathogenesis and Progression. 2014 , 6, 240-96	129
910	Transcription Factor STAT3 as a Novel Molecular Target for Cancer Prevention. 2014 , 6, 926-57	196
909	Sorafenib-based therapy in HER2-negative advanced breast cancer: Results from a retrospective pooled analysis of randomized controlled trials. 2014 , 7, 1420-1426	6
908	The role of the RhoA/Rho kinase pathway in angiogenesis and its potential value in prostate cancer (Review). 2014 , 8, 1907-1911	34
907	Immunohistochemical analysis of IL-6, IL-8/CXCR2 axis, Tyr p-STAT-3, and SOCS-3 in lymph nodes from patients with chronic lymphocytic leukemia: correlation between microvascular characteristics and prognostic significance. 2014 , 2014, 251479	16
906	Development of Novel Anti-Cancer Strategies Based on Angiogenesis Inhibition. 2014 , 147-190	
905	MicroRNAs: promising new antiangiogenic targets in cancer. 2014 , 2014, 878450	43

904	Leucas aspera inhibits the Dalton's ascitic lymphoma in Swiss albino mice: A preliminary study exploring possible mechanism of action. 2014 , 10, 118-24	6
903	Metronomic chemotherapy. 2014 , 5, 186-92	76
902	Molecular Targets of Honokiol: A Promising Phytochemical for Effective Cancer Management. 2014 , 36, 175-93	9
901	Cancer Microenvironments as Therapeutic Targets. 2014 , 412-422	
900	ARF: a versatile DNA damage response ally at the crossroads of development and tumorigenesis. 2014 , 5, 236	11
899	Persistent viremia by a novel parvovirus in a slow loris (<i>Nycticebus coucang</i>) with diffuse histiocytic sarcoma. 2014 , 5, 655	13
898	Inhibition of tumor growth and angiogenesis by SP-2, an anti-lectin, galactoside-binding soluble 3 binding protein (LGALS3BP) antibody. 2014 , 13, 916-25	14
897	Magnetic fluid hyperthermia inhibits the growth of breast carcinoma and downregulates vascular endothelial growth factor expression. 2014 , 7, 1370-1374	13
896	VEGF-C and VEGF-D overexpression is more common in left-sided and well-differentiated colon adenocarcinoma. 2014 , 31, 125-30	8
895	Tumor site prediction using spatiotemporal detection of subclinical hyperemia in experimental photocarcinogenesis. 2014 ,	
894	Angiogenesis and acute myeloid leukemia. 2014 , 19, 311-23	16
893	Inhibition of CD73 stimulates the migration and invasion of B16F10 melanoma cells in vitro, but results in impaired angiogenesis and reduced melanoma growth in vivo. 2014 , 31, 819-27	29
892	Tumors in murine brains studied by grating-based phase contrast microtomography. 2014 ,	
891	Chemokines in cancer. 2014 , 2, 1125-31	299
890	A microfluidic platform for quantitative analysis of cancer angiogenesis and intravasation. 2014 , 8, 054102	85
889	Recent developments in dynamic contrast-enhanced ultrasound imaging of tumor angiogenesis. 2014 , 6, 41-52	37
888	A comparison of arterial spin labeling perfusion MRI and DCE-MRI in human prostate cancer. 2014 , 27, 817-25	12
887	Tyrosine kinase inhibitor-induced vasculopathy in clear cell renal cell carcinoma: an unrecognized antitumour mechanism. 2014 , 64, 484-93	13

886	The effect of the anti-angiogenic drug sunitinib malate on the vascular architecture of oral squamous cell carcinoma. 2014 , 77, 250-6	6
885	Maßgeschneiderte Nanopartikel für den Wirkstofftransport in der Krebstherapie. 2014 , 126, 12520-12568	75
884	The Lister Strain of Vaccinia Virus as an Anticancer Therapeutic Agent. 2014 , 225-238	
883	Long-term recurrence of soft tissue sarcomas: prognostic factors and implications for prolonged follow-up. 2014 , 120, 3003-6	30
882	Gastrointestinal stromal tumor associated with obliterative foam cell vasculopathy. 2014 , 210, 1117-22	1
881	Bacteriophage: From Bacteria to a Successful Targeted Systemic Gene Delivery for Cancer. 2014 , 479-490	
880	Quantitative fluorescent profiling of VEGFRs reveals tumor cell and endothelial cell heterogeneity in breast cancer xenografts. 2014 , 3, 225-44	41
879	In vivo modeling of malignant glioma: the road to effective therapy. 2014 , 121, 261-330	19
878	Targeting of tumor endothelial cells combining 2 Gy/day of X-ray with Everolimus is the effective modality for overcoming clinically relevant radioresistant tumors. 2014 , 3, 310-21	21
877	Clinical Imaging of Hypoxia. 2014 , 179-201	
876	Altered methylation and expression patterns of genes regulating placental angiogenesis in preterm pregnancy. 2014 , 21, 1508-17	27
875	Proteomic characterization of breast cancer xenografts identifies early and late bevacizumab-induced responses and predicts effective drug combinations. 2014 , 20, 404-12	27
874	E7080 (lenvatinib), a multi-targeted tyrosine kinase inhibitor, demonstrates antitumor activities against colorectal cancer xenografts. 2014 , 16, 972-81	15
873	Signaling pathways influencing tumor microenvironment and their exploitation for targeted drug delivery. 2014 , 3,	8
872	Effect of a 12-month exercise intervention on serum biomarkers of angiogenesis in postmenopausal women: a randomized controlled trial. 2014 , 23, 648-57	15
871	Emerging lung cancer therapeutic targets based on the pathogenesis of bone metastases. 2014 , 2014, 236246	12
870	Therapeutic targeting of angiogenesis with a recombinant CTT peptide-endostatin mimic-kringle 5 protein. 2014 , 13, 2674-87	6
869	Quercetin-nanostructured lipid carriers: characteristics and anti-breast cancer activities in vitro. 2014 , 113, 15-24	137

868	Pilot study of angiogenic response to yttrium-90 radioembolization with resin microspheres. 2014 , 25, 297-306.e1	22
867	Lung cancer neovascularisation: Cellular and molecular interaction between endothelial and lung cancer cells. 2014 , 219, 308-14	20
866	Interleukin-6: an angiogenic target in solid tumours. 2014 , 89, 129-39	93
865	Model-based angiogenic inhibition of tumor growth using modern robust control method. 2014 , 114, e98-110	36
864	Neutrophil dependence of vascular remodeling after Mycoplasma infection of mouse airways. 2014 , 184, 1877-89	9
863	Updates in the management of high-grade glioma. 2014 , 261, 651-4	16
862	The Semaphorin 4D-Plexin-B1-RhoA signaling axis recruits pericytes and regulates vascular permeability through endothelial production of PDGF-B and ANGPTL4. 2014 , 17, 261-74	42
861	Differential TIMP3 expression affects tumor progression and angiogenesis in melanomas through regulation of directionally persistent endothelial cell migration. 2014 , 17, 163-77	38
860	Dysphonia induced by anti-angiogenic compounds. 2014 , 32, 774-82	15
859	Combination of sorafenib and angiotensin-II receptor blocker attenuates preneoplastic lesion development in a non-diabetic rat model of steatohepatitis. 2014 , 49, 1421-9	15
858	VEGFA gene locus analysis across 80 human tumour types reveals gene amplification in several neoplastic entities. 2014 , 17, 519-27	16
857	Cell adhesion molecules and their relation to (cancer) cell stemness. 2014 , 35, 747-59	115
856	ARF tumor suppression in the nucleolus. 2014 , 1842, 831-9	51
855	Mesenchymal stem/stromal cells as a pharmacological and therapeutic approach to accelerate angiogenesis. 2014 , 143, 181-96	211
854	Current concepts in clinical radiation oncology. 2014 , 53, 1-29	109
853	Coupling of discrete random walks and continuous modeling for three-dimensional tumor-induced angiogenesis. 2014 , 53, 449-464	27
852	Diabetic retinopathy and pregnancy. 2014 , 34, 989-97	13
851	Studies on Respiratory Disorders. 2014 ,	1

850	Near-infrared fluorescence imaging of CD13 receptor expression using a novel Cy5.5-labeled dimeric NGR peptide. 2014 , 46, 1547-56	26
849	3D cell culture systems modeling tumor growth determinants in cancer target discovery. 2014 , 69-70, 29-41	312
848	Anti-angiogenic therapy in pediatric brain tumors: an effective strategy?. 2014 , 89, 418-32	16
847	Morphological characterization of sprouting and intussusceptive angiogenesis by SEM in oral squamous cell carcinoma. 2014 , 36, 293-300	4
846	Tumor models for prostate cancer exemplified by fibroblast growth factor 8-induced tumorigenesis and tumor progression. 2014 , 14, 16-24	10
845	Tenascins in stem cell niches. 2014 , 37, 112-23	120
844	Ultrasound Imaging of Cancer Therapy. 2014 , 127-137	3
843	Novel thalidomide analogs: Anti-angiogenic and apoptotic effects on Hep-G2 and MCF-7 cancer cell lines. 2014 , 4, 179-189	10
842	Inhibitors of Tumor Angiogenesis. 2014 , 275-317	1
841	Proteomic signatures of angiogenesis in androgen-independent prostate cancer. 2014 , 74, 260-72	22
840	Tumor vasculature targeting: a generally applicable approach for functionalized nanomaterials. 2014 , 10, 1887-93	57
839	MicroRNA-542-3p inhibits tumour angiogenesis by targeting angiopoietin-2. 2014 , 232, 499-508	78
838	MicroRNA in Development and in the Progression of Cancer. 2014 ,	6
837	GBM's multifaceted landscape: highlighting regional and microenvironmental heterogeneity. 2014 , 16, 1167-75	99
836	Role of translation initiation factor 4G in lifespan regulation and age-related health. 2014 , 13, 115-24	18
835	Perspectives in molecular imaging through translational research, human medicine, and veterinary medicine. 2014 , 44, 66-75	3
834	Novel anthraquinone based chalcone analogues containing an imine fragment: synthesis, cytotoxicity and anti-angiogenic activity. 2014 , 24, 65-71	32
833	Tissue-engineered 3D tumor angiogenesis models: potential technologies for anti-cancer drug discovery. 2014 , 79-80, 30-9	65

832	Effects of angiogenic factors and 3D-microenvironments on vascularization within sandwich cultures. 2014 , 35, 4739-48	74
831	Imaging aspects of the tumor stroma with therapeutic implications. 2014 , 141, 192-208	44
830	Rigid nanoparticle-based delivery of anti-cancer siRNA: challenges and opportunities. 2014 , 32, 831-43	59
829	Netrin-1 as a potential target for metastatic cancer: focus on colorectal cancer. 2014 , 33, 101-13	20
828	The molecular basis for the pharmacokinetics and pharmacodynamics of curcumin and its metabolites in relation to cancer. 2014 , 66, 222-307	327
827	Bradykinin promotes vascular endothelial growth factor expression and increases angiogenesis in human prostate cancer cells. 2014 , 87, 243-53	31
826	Contrast-enhanced CT and diffusion-weighted MR imaging: performance as a prognostic factor in patients with pancreatic ductal adenocarcinoma. 2014 , 83, 612-9	30
825	In vitro models of tumor vessels and matrix: engineering approaches to investigate transport limitations and drug delivery in cancer. 2014 , 69-70, 205-216	55
824	VEGF β -conjugated mesoporous silica nanoparticle: a tumor targeted drug delivery system. 2014 , 6, 21677-85	95
823	The extracellular matrix modulates the hallmarks of cancer. 2014 , 15, 1243-53	957
822	CD47 signaling regulates the immunosuppressive activity of VEGF in T cells. 2014 , 193, 3914-24	71
821	Material-mediated proangiogenic factor release pattern modulates quality of regenerated blood vessels. 2014 , 196, 363-9	11
820	PPemd26, an anthraquinone derivative, suppresses angiogenesis via inhibiting VEGFR2 signalling. 2014 , 171, 5728-42	10
819	Autophagy promotes radiation-induced senescence but inhibits bystander effects in human breast cancer cells. 2014 , 10, 1212-28	45
818	The β -integrin binding protein β -endonexin is a novel negative regulator of hypoxia-inducible factor-1. 2014 , 20, 1964-76	8
817	ADAM8 expression in invasive breast cancer promotes tumor dissemination and metastasis. 2014 , 6, 278-94	69
816	Principles of targeting endothelial cell metabolism to treat angiogenesis and endothelial cell dysfunction in disease. 2014 , 6, 1105-20	123
815	Increased angiogenesis and FGFR protein expression indicate a favourable prognosis in bladder cancer. 2014 , 465, 687-95	25

814	The Rb-E2F transcriptional regulatory pathway in tumor angiogenesis and metastasis. 2014 , 121, 147-182	55
813	Id proteins in the vasculature: from molecular biology to cardiopulmonary medicine. 2014 , 104, 388-98	20
812	A three-dimensional in vitro model of tumor cell intravasation. 2014 , 6, 603-10	146
811	Enalapril and ASS inhibit tumor growth in a transgenic mouse model of islet cell tumors. 2014 , 21, 813-24	13
810	Antimetastasis and antitumor efficacy promoted by sequential release of vascular disrupting and chemotherapeutic agents from electrospun fibers. 2014 , 475, 438-49	23
809	Engineered nanoparticles for drug delivery in cancer therapy. 2014 , 53, 12320-64	807
808	Therapeutic potential of siRNA and DNAzymes in cancer. 2014 , 35, 9505-21	24
807	FITC-conjugated cyclic RGD peptides as fluorescent probes for staining integrin $\alpha_5\beta_1$ in tumor tissues. 2014 , 25, 1925-41	51
806	Hydrogels to model 3D in vitro microenvironment of tumor vascularization. 2014 , 79-80, 19-29	105
805	Tumor Hypoxia. 2014 , 205-222	
804	Live cell integrated surface plasmon resonance biosensing approach to mimic the regulation of angiogenic switch upon anti-cancer drug exposure. 2014 , 86, 7305-10	15
803	Synthesis, antimitotic and antivascular activity of 1-(3',4',5'-trimethoxybenzoyl)-3-arylamino-5-amino-1,2,4-triazoles. 2014 , 57, 6795-808	39
802	Targeting Angiogenesis by Therapeutic Antibodies. 2014 , 823-850	
801	Convergence of nanotechnology and cancer prevention: are we there yet?. 2014 , 7, 973-92	9
800	CellBiomaterial interactions for blood vessel formation. 2014 , 350-388	1
799	New radiotracers for imaging of vascular targets in angiogenesis-related diseases. 2014 , 76, 2-20	36
798	MYC and the art of microRNA maintenance. 2014 , 4,	43
797	Multimodal magnetic resonance imaging evaluation of primary brain tumors. 2014 , 41, 478-495	10

796	Brain-derived neurotrophic factor increases vascular endothelial growth factor expression and enhances angiogenesis in human chondrosarcoma cells. 2014 , 91, 522-33	48
795	Oesophageal squamous cell carcinoma in high-risk Chinese populations: Possible role for vascular epithelial growth factor A. 2014 , 50, 2855-65	6
794	Protein kinase D2 induces invasion of pancreatic cancer cells by regulating matrix metalloproteinases. 2014 , 25, 324-36	38
793	Anginex lipoplexes for delivery of anti-angiogenic siRNA. 2014 , 472, 175-84	7
792	The role of targeted therapies in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline. 2014 , 118, 557-99	32
791	Beyond bevacizumab: investigating new angiogenesis inhibitors in ovarian cancer. 2014 , 23, 37-53	13
790	Dynamic contrast-enhanced magnetic resonance imaging: applications in oncology. 2014 , 26, e9-20	11
789	Autophagy inhibition suppresses the tumorigenic potential of cancer stem cell enriched side population in bladder cancer. 2014 , 1842, 2073-86	49
788	Cancer research: a hurdle race. 2014 , 79, 385-90	4
787	Bevacizumab terminates homeobox B9-induced tumor proliferation by silencing microenvironmental communication. 2014 , 13, 102	17
786	Hypoxia differentially regulated CXCR4 and CXCR7 signaling in colon cancer. 2014 , 13, 58	60
785	Vasohibin-2 modulates tumor onset in the gastrointestinal tract by normalizing tumor angiogenesis. 2014 , 13, 99	21
784	Imaging integrin $\alpha_5\beta_1$ on blood vessels with ^{111}In -RGD2 in head and neck tumor xenografts. 2014 , 55, 281-6	21
783	VEGF regulates region-specific localization of perivascular bone marrow-derived cells in glioblastoma. 2014 , 74, 3727-39	20
782	Preparation, antiangiogenic and antitumoral activities of the chemically sulfated glucan from <i>Phellinus ribis</i> . 2014 , 106, 42-8	23
781	Axitinib sensitization of high Single Dose Radiotherapy. 2014 , 111, 88-93	35
780	Angiogenic factors as potential drug target: efficacy and limitations of anti-angiogenic therapy. 2014 , 1846, 161-79	89
779	Heparin-binding epidermal growth factor-like growth factor (HB-EGF) and proteolytic processing by a disintegrin and metalloproteinases (ADAM): a regulator of several pathways. 2014 , 28, 22-30	36

778	Accumulation of nano-sized particles in a murine model of angiogenesis. 2014 , 443, 470-6	4
777	Soy isoflavones and prostate cancer: a review of molecular mechanisms. 2014 , 140, 116-32	189
776	Recent advances in molecular, multimodal and theranostic ultrasound imaging. 2014 , 72, 15-27	147
775	Microvesicles as mediators of intercellular communication in cancer. 2014 , 1165, 147-73	79
774	Chemopreventive Properties of Fruit Phenolic Compounds and Their Possible Mode of Actions. 2014 , 42, 229-266	11
773	Design, synthesis and biological evaluation of type-II VEGFR-2 inhibitors based on quinoxaline scaffold. 2014 , 56, 16-26	42
772	Andrographolide inhibits tumor angiogenesis via blocking VEGFA/VEGFR2-MAPKs signaling cascade. 2014 , 218, 99-106	36
771	Tumor dormancy at bedside: A late awakening. 2019 , 45, 61-63	6
770	MACC1 promotes angiogenesis in cholangiocarcinoma by upregulating VEGFA. 2019 , 12, 1893-1903	13
769	Deep-tissue optical imaging of near cellular-sized features. 2019 , 9, 3873	31
768	Novel multitarget inhibitors with antiangiogenic and immunomodulator properties. 2019 , 170, 87-98	4
767	The roles and role-players in thyroid cancer angiogenesis. 2019 , 66, 277-293	29
766	Endothelial Microparticles and Vascular Endothelial Growth Factor in Patients With Head and Neck Cancer Undergoing Radiotherapy or Radiochemotherapy. 2019 , 33, 581-586	
765	The Role of Brain Vasculature in Glioblastoma. 2019 , 56, 6645-6653	24
764	A nonlinear mathematical model of cell-mediated immune response for tumor phenotypic heterogeneity. 2019 , 471, 42-50	9
763	Enhancement of the Marginal Area in Colorectal Cancer Liver Metastasis on Computed Tomography Correlates With Microvessel Density and Clinicopathological Factors. 2019 , 39, 1301-1308	2
762	Tumor Neovascularization and Developments in Therapeutics. 2019 , 11,	46
761	Strategies of the War on Cancer: To Kill or to Neutralize?. 2018 , 8, 667	4

760	Andrographolide binds to ATP-binding pocket of VEGFR2 to impede VEGFA-mediated tumor-angiogenesis. 2019 , 9, 4073	17
759	Optimizing sequential treatment with anti-EGFR and VEGF mAb in metastatic colorectal cancer: current results and controversies. 2019 , 11, 1705-1716	12
758	Identification of highly potent and selective MMP2 inhibitors addressing the S1' subsite with d-proline-based compounds. 2019 , 27, 1891-1902	8
757	Inhibition of Sphingosine Phosphate Receptor 1 Signaling Enhances the Efficacy of VEGF Receptor Inhibition. 2019 , 18, 856-867	7
756	Nanotechnology in metastatic cancer treatment: Current Achievements and Future Research Trends. 2019 , 10, 1358-1369	17
755	Drug Delivery: Localized and Systemic Therapeutic Strategies with Polymer Systems. 2019 , 1-56	
754	Tumor-associated macrophages: a short compendium. 2019 , 76, 1447-1458	47
753	Risk Classification. 2019 , 61-77	
752	Gastrointestinal Stromal Tumor. 2019 ,	
751	CT Enhancement and 3D Texture Analysis of Pancreatic Neuroendocrine Neoplasms. 2019 , 9, 2176	36
750	Regulation of Blood and Lymphatic Vessels by Immune Cells in Tumors and Metastasis. 2019 , 81, 535-560	24
749	Knowledge and Context in Tibetan Medicine. 2019 ,	
748	ADAMTS-1 inhibits angiogenesis via the PI3K/Akt-eNOS-VEGF pathway in lung cancer cells.. 2019 , 8, 2725-27356	
747	The effect of histological subtypes on survival outcome in nasopharyngeal carcinoma after extensive follow up. 2019 , 7, 768	12
746	Interferon-Gamma and Tumor Necrosis Factor-Related Weak Inducer of Apoptosis Expression in Neoangiogenesis in Colorectal Polypoid Lesions. 2019 , 60, 186-195	2
745	Calreticulin regulates vascular endothelial growth factor-A mRNA stability in gastric cancer cells. 2019 , 14, e0225107	5
744	Yu Ping Feng San Exert Anti-Angiogenesis Effects through the Inhibition of TSLP-STAT3 Signaling Pathways in Hepatocellular Carcinoma. 2019 , 2019, 1947156	4
743	Insights into the Regulation of Tumor Angiogenesis by Micro-RNAs. 2019 , 8,	46

742	BMI, irAE, and gene expression signatures associate with resistance to immune-checkpoint inhibition and outcomes in renal cell carcinoma. 2019 , 17, 386	17
741	Antiangiogenic Effects of Coumarins against Cancer: From Chemistry to Medicine. 2019 , 24,	29
740	The use of apatinib in treating primary pleural synovial sarcoma: A case report. 2019 , 98, e18382	2
739	Cancer Drug Delivery Systems Based on the Tumor Microenvironment. 2019 ,	3
738	Chemokines and Chemokine Receptors: Orchestrating Tumor Metastasization. 2018 , 20,	75
737	Role of tumor-derived exosomes in cancer metastasis. 2019 , 1871, 12-19	48
736	Gold Nanoparticles in Cancer Treatment. 2019 , 16, 1-23	213
735	SCF β TrCP ubiquitinates CHK1 in an AMPK-dependent manner in response to glucose deprivation. 2019 , 13, 307-321	14
734	Do locally advanced and metastatic human epithelial cancers evolve in 'placental/decidual-like microenvironments'?. 2019 , 21, 160-166	0
733	Dormancy in cancer. 2019 , 110, 474-480	62
732	Cancer-Associated Intermediate Conductance Ca-Activated K ⁺ Channel K3.1. 2019 , 11,	29
731	Targeting Angiogenesis in Colorectal Carcinoma. 2019 , 79, 63-74	27
730	Optimizing immune cell therapies with artificial intelligence. 2019 , 461, 34-40	7
729	Ultrasmall bimodal nanomolecules enhanced tumor angiogenesis contrast with endothelial cell targeting and molecular pharmacokinetics. 2019 , 15, 252-263	10
728	Extracellular vesicles of multiple myeloma cells utilize the proteasome inhibitor mechanism to moderate endothelial angiogenesis. 2019 , 22, 185-196	43
727	Astrocytes and the TGF- β Pathway in the Healthy and Diseased Brain: a Double-Edged Sword. 2019 , 56, 4653-4679	43
726	Bimetallic titanocene-gold phosphane complexes inhibit invasion, metastasis, and angiogenesis-associated signaling molecules in renal cancer. 2019 , 161, 310-322	27
725	Type I interferon/IRF7 axis instigates chemotherapy-induced immunological dormancy in breast cancer. 2019 , 38, 2814-2829	45

724	New concepts in the diagnosis and management of choroidal metastases. 2019 , 68, 144-176	52
723	Angiogenesis-related gene expression profile in clinical cases of canine cancer. 2019 , 5, 19-29	2
722	Cytoskeletal remodeling induced by substrate rigidity regulates rheological behaviors in endothelial cells. 2019 , 107, 71-80	19
721	Role of VEGF, CD105, and CD31 in the Prognosis of Colorectal Cancer Cases. 2019 , 50, 23-34	37
720	Stimuli-responsive nanotherapeutics for precision drug delivery and cancer therapy. 2019 , 11, e1527	152
719	Non-coding RNAs as potential therapeutic targets in breast cancer. 2020 , 1863, 194378	43
718	Emerging roles of ECM remodeling processes in cancer. 2020 , 62, 192-200	63
717	Discovery of a highly selective VEGFR2 kinase inhibitor CHMFL-VEGFR2-002 as a novel anti-angiogenesis agent. 2020 , 10, 488-497	13
716	Laminin 332 in cancer: When the extracellular matrix turns signals from cell anchorage to cell movement. 2020 , 62, 149-165	39
715	Eukaryotic elongation factor 2 kinase promotes angiogenesis in hepatocellular carcinoma via PI3K/Akt and STAT3. 2020 , 146, 1383-1395	26
714	Cancer-associated fibroblast-derived WNT2 increases tumor angiogenesis in colon cancer. 2020 , 23, 159-177	61
713	Variation in energy metabolism arising from the effect of the tumor microenvironment on cell biological behaviors of bladder cancer cells and endothelial cells. 2020 , 46, 64-75	4
712	Immunohistochemical assessment of Eph/ephrin expression in oral squamous cell carcinoma and precursor lesions. 2020 , 108, 166-173	2
711	Synthesis, characterization, apoptosis, ROS, autophagy and western blotting studies of cyclometalated iridium(III) complexes. 2020 , 111, 107594	1
710	Therapeutic Targeting of the Colorectal Tumor Stroma. 2020 , 158, 303-321	23
709	Metastases to the ovary arising from endometrial, cervical and fallopian tube cancer: recent advances. 2020 , 76, 37-51	19
708	Venous contribution to sodium MRI in the human brain. 2020 , 83, 1331-1338	3
707	Importance of the Microbiota Inhibitory Mechanism on the Warburg Effect in Colorectal Cancer Cells. 2020 , 51, 738-747	22

706	Development of new food and pharmaceutical products: Nutraceuticals and food additives. 2020 , 92, 53-96	9
705	Parallels between wound healing, epimorphic regeneration and solid tumors. 2020 , 147,	9
704	In vitro evaluation of the antitumoral and antiangiogenic effects of extracts from <i>Spondias mombin</i> L. leaves. 2020 , 131, 110716	1
703	Molecular Mechanism and Approach in Progression of Meningioma. 2020 , 10, 538845	2
702	Hypoxia and proangiogenic proteins in human ameloblastoma. 2020 , 10, 17567	3
701	TGF- β suppresses type 2 immunity to cancer. 2020 , 587, 115-120	63
700	Relevance of EGFR Between Serum VEGF and MMP-9 in Primary Hepatocellular Carcinoma Patients with Transarterial Chemoembolization. 2020 , 13, 9407-9417	2
699	Concepts of extracellular matrix remodelling in tumour progression and metastasis. 2020 , 11, 5120	317
698	Variable Tumor Microenvironment-on-a-chip with Temporal Angiogenic Switching System by Diffusion Control. 2020 , 2020, 2227-2230	
697	Molecular Ultrasound Imaging. 2020 , 10,	15
696	Drug Targets in Cellular Processes of Cancer: From Nonclinical to Preclinical Models. 2020 ,	
695	Expression of angiogenic growth factors in canine squamous cell cancers. 2021 , 96, 450-459	2
694	Angiogenesis Analyzer for ImageJ - A comparative morphometric analysis of "Endothelial Tube Formation Assay" and "Fibrin Bead Assay". 2020 , 10, 11568	68
693	Neoangiogenesis in Melanoma: An Issue in Biology and Systemic Treatment. 2020 , 11, 584903	7
692	In vitro three-dimensional modeling for prostate cancer. 2020 , 251-286	
691	The Non-Coding Landscape of Cutaneous Malignant Melanoma: A Possible Route to Efficient Targeted Therapy. 2020 , 12,	9
690	miR-106a-5p Functions as a Tumor Suppressor by Targeting VEGFA in Renal Cell Carcinoma. 2020 , 2020, 8837941	7
689	Medicinal Chemistry Targeting Mitochondria: From New Vehicles and Pharmacophore Groups to Old Drugs with Mitochondrial Activity. 2020 , 21,	6

688	Forkhead Box Q1 Is Critical to Angiogenesis and Macrophage Recruitment of Colorectal Cancer. 2020 , 10, 564298	2
687	Environmental interplay: Stromal cells and biomaterial composition influence in the glioblastoma microenvironment. 2021 , 132, 421-436	0
686	Vascular Heterogeneity With a Special Focus on the Hepatic Microenvironment. 2020 , 11, 591901	3
685	Metastasis in three-dimensional biomaterials. 2020 , 191-216	1
684	Pomegranate () Fruit Extract Suppresses Cancer Progression and Tumor Angiogenesis of Pancreatic and Colon Cancer in Chick Chorioallantoic Membrane Model. 2021 , 73, 1350-1356	6
683	IQGAP1 causes choroidal neovascularization by sustaining VEGFR2-mediated Rac1 activation. 2020 , 23, 685-698	20
682	Assessment of pelvic lymph node metastasis in FIGO IB and IIA cervical cancer using quantitative dynamic contrast-enhanced MRI parameters. 2020 , 26, 382-389	
681	Enzyme catalysis powered micro/nanomotors for biomedical applications. 2020 , 8, 7319-7334	20
680	Effect of Physical Exercise on the Release of Microparticles with Angiogenic Potential. 2020 , 10, 4871	4
679	Targeting the Tumor Microenvironment in Neuroblastoma: Recent Advances and Future Directions. 2020 , 12,	17
678	Novel Nargenicin A1 Analog Inhibits Angiogenesis by Downregulating the Endothelial VEGF/VEGFR2 Signaling and Tumoral HIF-1 α /VEGF Pathway. 2020 , 8,	5
677	Stem cell programs in cancer initiation, progression, and therapy resistance. 2020 , 10, 8721-8743	46
676	Phase II trial of bevacizumab and sorafenib in recurrent ovarian cancer patients with or without prior-bevacizumab treatment. 2020 , 159, 88-94	3
675	MicroRNA-16 Inhibits Glioblastoma Growth in Orthotopic Model by Targeting Cyclin D1 and WIP1. 2020 , 13, 10807-10816	1
674	Characterization of the Tumor Immune Microenvironment Identifies M0 Macrophage-Enriched Cluster as a Poor Prognostic Factor in Hepatocellular Carcinoma. 2020 , 4, 1002-1013	7
673	Adipocytes: active facilitators in epithelial ovarian cancer progression?. 2020 , 13, 115	9
672	Resveratrol and Tumor Microenvironment: Mechanistic Basis and Therapeutic Targets. 2020 , 25,	15
671	Novel 2-indolinone thiazole hybrids as sunitinib analogues: Design, synthesis, and potent VEGFR-2 inhibition with potential anti-renal cancer activity. 2020 , 208, 112752	22

670	Noninvasive imaging of tumor hypoxia after nanoparticle-mediated tumor vascular disruption. 2020 , 15, e0236245	4
669	Usefulness of peroral cholangioscopy in the differential diagnosis of IgG4-related sclerosing cholangitis and extrahepatic cholangiocarcinoma: a single-center retrospective study. 2020 , 20, 287	3
668	Melatonin as a potential inhibitor of kidney cancer: A survey of the molecular processes. 2020 , 72, 2355-2365	5
667	The hallmarks of cancer are also the hallmarks of wound healing. 2020 , 13,	36
666	The Emerging Role of PPAR Beta/Delta in Tumor Angiogenesis. 2020 , 2020, 3608315	7
665	Retooling Cancer Nanotherapeutics' Entry into Tumors to Alleviate Tumoral Hypoxia. 2020 , 16, e2003000	19
664	Hypoxia-Mediated Decrease of Ovarian Cancer Cells Reaction to Treatment: Significance for Chemo- and Immunotherapies. 2020 , 21,	7
663	Impact of Angiogenesis- and Hypoxia-Associated Polymorphisms on Tumor Recurrence in Patients with Hepatocellular Carcinoma Undergoing Surgical Resection. 2020 , 12,	4
662	Cell-free DNA promotes malignant transformation in non-tumor cells. 2020 , 10, 21674	6
661	Optical coherence tomography angiography of choroidal neovascularization in immune choroiditis following acute retinal necrosis. 2020 , 1120672120977349	
660	Current Concepts in Multi-Modality Imaging of Solid Tumor Angiogenesis. 2020 , 12,	1
659	A multitarget angiogenesis inhibitor, CTT peptide-endostatin mimic-kringle 5, prevents diet-induced obesity. 2020 , 98, 1753-1765	1
658	A practical toolkit to study aspects of the metastatic cascade in vitro. 2020 , 122, 151654	1
657	High-throughput screening in multicellular spheroids for target discovery in the tumor microenvironment. 2020 , 15, 955-967	5
656	Mathematical Model Predicts Effective Strategies to Inhibit VEGF-eNOS Signaling. 2020 , 9,	6
655	Thymidine phosphorylase promotes angiogenesis and tumour growth in intrahepatic cholangiocarcinoma. 2020 , 38, 743-752	2
654	JMJD2B-induced amino acid alterations enhance the survival of colorectal cancer cells under glucose-deprivation via autophagy. 2020 , 10, 5763-5777	3
653	Oxygen Pathology and Oxygen-Functional Materials for Therapeutics. 2020 , 2, 1115-1147	6

652	Gold Nanoparticles Induce Tumor Vessel Normalization and Impair Metastasis by Inhibiting Endothelial Smad2/3 Signaling. 2020 , 14, 7940-7958	27
651	The Role of Metals and Metalloids in the Modulation of Angiogenesis. 2020 , 293-318	
650	Angiogenesis signaling in breast cancer models is induced by hexachlorobenzene and chlorpyrifos, pesticide ligands of the aryl hydrocarbon receptor. 2020 , 401, 115093	5
649	Random-forest algorithm based biomarkers in predicting prognosis in the patients with hepatocellular carcinoma. 2020 , 20, 251	11
648	Tumor cells derived-exosomes as angiogenic agents: possible therapeutic implications. 2020 , 18, 249	49
647	Architecture of Cancer-Associated Fibroblasts in Tumor Microenvironment: Mapping Their Origins, Heterogeneity, and Role in Cancer Therapy Resistance. 2020 , 24, 314-339	14
646	Molecular insights and novel approaches for targeting tumor metastasis. 2020 , 585, 119556	33
645	Pro-tumorigenic functions of macrophages at the primary, invasive and metastatic tumor site. 2020 , 69, 1673-1697	19
644	Resistance Mechanisms to Anti-angiogenic Therapies in Cancer. 2020 , 10, 221	94
643	Usefulness of melatonin as complementary to chemotherapeutic agents at different stages of the angiogenic process. 2020 , 10, 4790	13
642	Modulating tumor immunity by metronomic dosing of oxaliplatin incorporated in multiple oral nanoemulsion. 2020 , 322, 13-30	15
641	Improving tumor hypoxia and radiotherapy resistance via in situ nitric oxide release strategy. 2020 , 150, 96-107	7
640	A Dual Role of Type I Interferons in Antitumor Immunity. 2020 , 4, e1900237	5
639	Gibbs point field model quantifies disorder in microvasculature of U87-glioblastoma. 2020 , 494, 110230	2
638	Anti-angiogenic effects of VEGF stimulation on endothelium deficient in phosphoinositide recycling. 2020 , 11, 1204	8
637	Transcriptional suppression of AMPK β promotes breast cancer metastasis upon oncogene activation. 2020 , 117, 8013-8021	23
636	Chorioallantoic Membrane Assay as Model for Angiogenesis in Tissue Engineering: Focus on Stem Cells. 2020 , 26, 519-539	15
635	Case Study on Receptor Tyrosine Kinases EGFR, VEGFR, and PDGFR. 2020 , 155-201	

634	Decreased miR-200b-3p in cancer cells leads to angiogenesis in HCC by enhancing endothelial ERG expression. 2020 , 10, 10418	20
633	Hybrid Modelling of Transarterial Chemoembolisation Therapies (TACE) for Hepatocellular Carcinoma (HCC). 2020 , 10, 10571	3
632	Overcoming cancer therapeutic bottleneck by drug repurposing. 2020 , 5, 113	131
631	DNA polymerase beta modulates cancer progression via enhancing CDH13 expression by promoter demethylation. 2020 , 39, 5507-5519	5
630	Recapitulating the Vasculature Using Organ-On-Chip Technology. 2020 , 7,	15
629	Glioma-Derived miRNA-Containing Extracellular Vesicles Induce Angiogenesis by Reprogramming Brain Endothelial Cells. 2020 , 30, 2065-2074.e4	58
628	Development of an Automated Image Analyzer for Microvessel Density Measurement in Bone Marrow Biopsies. 2020 , 40, 312-316	
627	MiR-199b-5p Suppresses Tumor Angiogenesis Mediated by Vascular Endothelial Cells in Breast Cancer by Targeting ALK1. 2019 , 10, 1397	23
626	Tumor microenvironment-responsive intelligent nanoplatforms for cancer theranostics. 2020 , 32, 100851	118
625	Network Properties of Cancer Prognostic Gene Signatures in the Human Protein Interactome. 2020 , 11,	
624	Interactions Between Tumor Biology and Targeted Nanoplatforms for Imaging Applications. 2020 , 30, 1910402	15
623	miRNAs as Key Players in the Management of Cutaneous Melanoma. 2020 , 9,	13
622	Recent Advancements of Nanomedicine towards Antiangiogenic Therapy in Cancer. 2020 , 21,	39
621	SENP1/HIF-1 α axis works in angiogenesis of human dental pulp stem cells. 2020 , 34, e22436	5
620	Inorganic Biomaterials for Regenerative Medicine. 2020 , 12, 5319-5344	69
619	Organic Nanocarriers for Delivery and Targeting of Therapeutic Agents for Cancer Treatment. 2020 , 3, 1900136	13
618	Tumor Hypoxia: Impact on Radiation Therapy and Molecular Pathways. 2020 , 10, 562	54
617	Inhibition of Tumor VEGFR2 Induces Serine 897 EphA2-Dependent Tumor Cell Invasion and Metastasis in NSCLC. 2020 , 31, 107568	7

616	Diabetic Retinopathy and Ocular Melanoma: How Far We Are?. 2020 , 10, 2777	1
615	Nanobody-based therapeutics against colorectal cancer: Precision therapies based on the personal mutanome profile and tumor neoantigens. 2020 , 156, 104790	14
614	Immune escape mechanisms in head and neck squamous cell carcinoma and implication for new immunotherapy approach. 2020 , 32, 203-209	4
613	Cancer Stem Cells and Its Role in Angiogenesis and Vasculogenic Mimicry in Gastrointestinal Cancers. 2020 , 10, 413	17
612	Texture Analysis of Breast DCE-MRI Based on Intratumoral Subregions for Predicting HER2 2+ Status. 2020 , 10, 543	2
611	Virus-Like Particles Presenting the FGF-2 Protein or Identified Antigenic Peptides Promoted Antitumor Immune Responses in Mice. 2020 , 15, 1983-1996	5
610	Tunneling Nanotubes and Tumor Microtubes in Cancer. 2020 , 12,	31
609	Cerebral angiogenesis ameliorates pathological disorders in -deficient mice with small-vessel disease. 2021 , 41, 219-235	1
608	Tumor microenvironment as a therapeutic target in cancer. 2021 , 221, 107753	41
607	Engineering a photosensitizer nanoplatform for amplified photodynamic immunotherapy via tumor microenvironment modulation. 2021 , 6, 120-131	42
606	Gastric carcinogenesis: a comprehensive review of the angiogenic pathways. 2021 , 14, 14-25	8
605	Neuregulin Signaling in the Tumor Microenvironment. 2021 , 1270, 1-29	
604	Talin-dependent integrin activation is required for endothelial proliferation and postnatal angiogenesis. 2021 , 24, 177-190	6
603	Nintedanib plus mFOLFOX6 as second-line treatment of metastatic, chemorefractory colorectal cancer: The randomised, placebo-controlled, phase II TRICC-C study (AIO-KRK-0111). 2021 , 148, 1428-1437	
602	The effects of anticancer medicinal herbs on vascular endothelial growth factor based on pharmacological aspects: a review study. 2021 , 73, 1-15	13
601	Wounds Inhibit Tumor Growth In Vivo. 2021 , 273, 173-180	2
600	Continuing Cetuximab Bevacizumab plus chemotherapy after first progression in wild-type , and metastatic colorectal cancer: a randomized phase II trial. 2021 , 12, 5268-5274	0
599	Role of inflammatory microenvironment: potential implications for improved breast cancer nano-targeted therapy. 2021 , 78, 2105-2129	6

598	CXCL8 Signaling in the Tumor Microenvironment. 2021 , 1302, 25-39	7
597	The interaction between lipocalin 2 and dipyrindine ketone hydrazone dithiocarbamate may influence respective function in proliferation and metastasis-related gene expressions in HepG2 cell. 2021 , 26, 123-133	
596	Efficient Multitask Multiple Kernel Learning With Application to Cancer Research. 2021 , PP,	1
595	Radiomic analysis of HTR-DCE MR sequences improves diagnostic performance compared to BI-RADS analysis of breast MR lesions. 2021 , 31, 4848-4859	2
594	Gene co-expression in the interactome: moving from correlation toward causation via an integrated approach to disease module discovery. 2021 , 7, 3	29
593	F4, a collagen XIX-derived peptide, inhibits tumor angiogenesis through $\alpha 3$ and $\beta 1$ integrin interaction. 2021 , 15, 215-223	2
592	Gleevec and Rapamycin Synergistically Reduce Cell Viability and Inhibit Proliferation and Angiogenic Function of Mouse Bone Marrow-Derived Endothelial Progenitor Cells. 2021 , 58, 330-342	1
591	Endothelial Cells as Tools to Model Tissue Microenvironment in Hypoxia-Dependent Pathologies. 2021 , 22,	5
590	The tumorigenic and therapeutic functions of exosomes in colorectal cancer: Opportunity and challenges. 2021 , 39, 468-477	7
589	Opto-acoustic Image Reconstruction and Motion Tracking using Convex Optimization. 2021 , 1-1	0
588	Correlation between radiologic features on contrast-enhanced CT and pathological tumor grades in pancreatic neuroendocrine neoplasms. 2020 , 35, 179-188	1
587	Tuning Nanosiliceous Framework for Enhanced Cancer Theranostic Applications. 2021 , 4, 2000218	3
586	Engineered nanomedicines for tumor vasculature blockade therapy. 2021 , 13, e1691	5
585	Nanotechnology: A boon in cancer therapy: Review. 2021 , 001-006	
584	The Role of Anti-angiogenesis in the Treatment Landscape of Non-small Cell Lung Cancer - New Combinational Approaches and Strategies of Neovessel Inhibition. 2020 , 8, 610903	10
583	Assays and protocols for the detection of cancer metastasis. 2021 , 69-86	
582	The cancer cell secretome drives cooperative manipulation of the tumour microenvironment to accelerate tumourigenesis. 2021 , 10, 4	3
581	CCL25 Signaling in the Tumor Microenvironment. 2021 , 1302, 99-111	0

580	An in vivo model allowing continuous observation of human vascular formation in the same animal over time. 2021 , 11, 745	2
579	The Adhesome Network: Key Components Shaping the Tumour Stroma. 2021 , 13,	6
578	Non-flavonoids Targeting Cancer Stem Cells: A Promising Therapeutic Avenue for Cancer Treatment. 2021 , 289-334	2
577	A multilayered blood vessel/tumor tissue chip to investigate T cell infiltration into solid tumor tissues. 2021 , 21, 2142-2152	5
576	Novel matrix metalloproteinase inhibitors: an updated patent review (2014 - 2020). 2021 , 31, 509-523	5
575	The Role and Expression of Angiogenesis-Related miRNAs in Gastric Cancer. 2021 , 10,	6
574	An Insight into the Anti-Angiogenic and Anti-Metastatic Effects of Oridonin: Current Knowledge and Future Potential. 2021 , 26,	6
573	Strain-specific behavior of Mycobacterium tuberculosis in A549 lung cancer cell line. 2021 , 22, 154	0
572	Identification of Cyclophilin A as a Potential Anticancer Target of Novel Nargenicin A1 Analog in AGS Gastric Cancer Cells. 2021 , 22,	2
571	An updated review of mechanistic potentials of melatonin against cancer: pivotal roles in angiogenesis, apoptosis, autophagy, endoplasmic reticulum stress and oxidative stress. 2021 , 21, 188	10
570	Contribution of cell death signaling to blood vessel formation. 2021 , 78, 3247-3264	2
569	A bi-directional dialog between vascular cells and monocytes/macrophages regulates tumor progression. 2021 , 40, 477-500	1
568	Tumor Microenvironment in Prostate Cancer: Toward Identification of Novel Molecular Biomarkers for Diagnosis, Prognosis, and Therapy Development. 2021 , 12, 652747	12
567	The effects of vascularization on tumor development: A systematic review and meta-analysis of pre-clinical studies. 2021 , 159, 103245	1
566	The Role of Endoglin in Hepatocellular Carcinoma. 2021 , 22,	4
565	Effect of cell microenvironment on the drug sensitivity of hepatocellular cancer cells. 2021 , 12, 674-685	3
564	Correlation of Mast Cell and Angiogenesis in Oral Lichen Planus, Dysplasia (Leukoplakia), and Oral Squamous Cell Carcinoma. 2021 , 12,	3
563	The anti-angiogenic agent lenvatinib induces tumor vessel normalization and enhances radiosensitivity in hepatocellular tumors. 2021 , 38, 60	1

562	Novel combinatorial strategies for boosting the efficacy of immune checkpoint inhibitors in advanced breast cancers. 2021 , 23, 1979-1994	6
561	Microvascularized tumor organoids-on-chips: advancing preclinical drug screening with pathophysiological relevance. 2021 , 8, 12	18
560	Inhibitory effects of terrein on lung cancer cell metastasis and angiogenesis. 2021 , 45,	2
559	Anti-Cancer Treatment Strategies in the Older Population: Time to Test More?. 2021 , 6,	0
558	Risk stratification of cardiac metastases using late gadolinium enhancement cardiovascular magnetic resonance: prognostic impact of hypo-enhancement evidenced tumor avascularity. 2021 , 23, 42	2
557	The Cancer Cell Dissemination Machinery as an Immunosuppressive Niche: A New Obstacle Towards the Era of Cancer Immunotherapy. 2021 , 12, 654877	5
556	Angiogenesis Inhibitors. 1-66	
555	Engineering the early bone metastatic niche through human vascularized immuno bone minitissues. 2021 , 13,	0
554	The Hallmarks of Cancer as Ecologically Driven Phenotypes. 2021 , 9,	5
553	Melatonin in Cancer Treatment: Current Knowledge and Future Opportunities. 2021 , 26,	16
552	Cannabinoids orchestrate cross-talk between cancer cells and endothelial cells in colorectal cancer. 2021 ,	4
551	Liquid biopsy in cholangiocarcinoma: Current status and future perspectives. 2021 , 13, 332-350	12
550	Endoscopic Shielding With Platelet-rich Plasma After Resection of Large Colorectal Lesions: Stroma Microanatomy Raises Oncological Safety Issues. 2021 , 31, 511	
549	Disrupting tumour vasculature and recruitment of aPDL1-loaded platelets control tumour metastasis. 2021 , 12, 2773	13
548	Acacetin and pinostrobin as a promising inhibitor of cancer-associated protein kinases. 2021 , 151, 112091	7
547	RUNX2 Phosphorylation by Tyrosine Kinase ABL Promotes Breast Cancer Invasion. 2021 , 11, 665273	0
546	Targeting Neuroinflammation in Brain Cancer: Uncovering Mechanisms, Pharmacological Targets, and Neuropharmaceutical Developments. 2021 , 12, 680021	5
545	Are All Anti-Angiogenic Drugs the Same in the Treatment of Second-Line Metastatic Colorectal Cancer? Expert Opinion on Clinical Practice. 2021 , 11, 637823	4

544	Galectin-3: A factotum in carcinogenesis bestowing an archery for prevention. 2021 , 43, 77-96	1
543	Vascular Endothelial Growth Factor, a Key Modulator of the Anti-Tumor Immune Response. 2021 , 22,	11
542	Nano drug delivery system reconstruct tumour vasculature for the tumour vascular normalisation. 2021 , 1-12	3
541	Hypoxia-dependent drivers of melanoma progression. 2021 , 40, 159	11
540	Oncolytic virotherapy reverses the immunosuppressive tumor microenvironment and its potential in combination with immunotherapy. 2021 , 21, 262	9
539	Targeting tumor vascularization: promising strategies for vascular normalization. 2021 , 147, 2489-2505	2
538	Exosome-derived miR-let-7c promotes angiogenesis in multiple myeloma by polarizing M2 macrophages in the bone marrow microenvironment. 2021 , 105, 106566	5
537	Pro- and Antiangiogenic Factors in Gliomas: Implications for Novel Therapeutic Possibilities. 2021 , 22,	2
536	Immune Checkpoint and Anti-Angiogenic Antibodies for the Treatment of Non-Small Cell Lung Cancer in the European Union and United States. 2021 , 13,	0
535	Chemokine signaling in cancer-stroma communications. 2021 , 15, 361-381	3
534	Photodynamic Therapy-Current Limitations and Novel Approaches. 2021 , 9, 691697	54
533	Active Rap1-mediated inhibition of choroidal neovascularization requires interactions with IQGAP1 in choroidal endothelial cells. 2021 , 35, e21642	1
532	Preoperative histogram parameters of dynamic contrast-enhanced MRI as a potential imaging biomarker for assessing the expression of Ki-67 in prostate cancer. 2021 , 10, 4240-4249	1
531	Heterotypic Tumor Spheroids in Agitation-Based Cultures: A Scaffold-Free Cell Model That Sustains Long-Term Survival of Endothelial Cells. 2021 , 9, 649949	6
530	An updated patent review of VEGFR-2 inhibitors (2017-present). 2021 , 31, 989-1007	4
529	CAFs Interacting With TAMs in Tumor Microenvironment to Enhance Tumorigenesis and Immune Evasion. 2021 , 11, 668349	17
528	Lenvatinib Targets PDGFR-Pericytes and Inhibits Synergy With Thyroid Carcinoma Cells: Novel Translational Insights. 2021 , 106, 3569-3590	1
527	3D Tumor Models for Breast Cancer: Whither We Are and What We Need. 2021 , 7, 3470-3486	3

526	Vasculogenic Mimicry in Breast Cancer: Clinical Relevance and Drivers. 2021 , 10,	4
525	Consequences of Extracellular Matrix Remodeling in Headway and Metastasis of Cancer along with Novel Immunotherapies: A Great Promise for Future Endeavor. 2021 ,	0
524	Micro-positron emission tomography imaging of angiogenesis based on F-RGD for assessing liver metastasis of colorectal cancer. 2021 , 20, 345-351	
523	Targeted and Non-Targeted Mechanisms for Killing Hypoxic Tumour Cells-Are There New Avenues for Treatment?. 2021 , 22,	
522	microRNAs and bone tumours: Role of tiny molecules in the development and progression of chondrosarcoma, of giant cell tumour of bone and of Ewing's sarcoma. 2021 , 149, 115968	2
521	Engineering a Vascularized Hypoxic Tumor Model for Therapeutic Assessment. 2021 , 10,	1
520	Effect of PACAP on Hypoxia-Induced Angiogenesis and Epithelial-Mesenchymal Transition in Glioblastoma. 2021 , 9,	3
519	Challenges towards Targeted Drug Delivery in Cancer Nanomedicines. 2021 , 9, 1527	4
518	Glucose deprivation enhances resistance to paclitaxel via ELAVL2/4-mediated modification of glycolysis in ovarian cancer cells. 2021 ,	1
517	Engineering Chameleon Prodrug Nanovesicles to Increase Antigen Presentation and Inhibit PD-L1 Expression for Circumventing Immune Resistance of Cancer. 2021 , 33, e2102668	6
516	Gene editing and synthetically accessible inhibitors reveal role for TPC2 in HCC cell proliferation and tumor growth. 2021 , 28, 1119-1131.e27	17
515	ECaryophyllene Induces Apoptosis and Inhibits Angiogenesis in Colorectal Cancer Models. 2021 , 22,	2
514	Imaging of Tumor Hypoxia With Radionuclide-Labeled Tracers for PET. 2021 , 11, 731503	1
513	Effects of hypoxia and nanocarrier size on pH-responsive nano-delivery system to solid tumors. 2021 , 11, 19350	13
512	HSP47 contributes to angiogenesis by induction of CCL2 in bladder cancer. 2021 , 85, 110044	2
511	Angiogenesis and Anti-Angiogenic Treatment in Prostate Cancer: Mechanisms of Action and Molecular Targets. 2021 , 22,	10
510	Strategies for active tumor targeting-an update. 2021 , 915, 174512	4
509	Regulation of Rac1 Activation in Choroidal Endothelial Cells: Insights into Mechanisms in Age-Related Macular Degeneration. 2021 , 10,	2

508	KAI1(CD82) is a key molecule to control angiogenesis and switch angiogenic milieu to quiescent state. 2021 , 14, 148	1
507	Multiple genetic variants predict the progression-free survival of bevacizumab plus chemotherapy in advanced ovarian cancer: A retrospective study. 2021 , 100, e27130	1
506	Identification of new [1,2,4]triazolo[4,3-a]quinoxalines as potent VEGFR-2 tyrosine kinase inhibitors: Design, synthesis, anticancer evaluation, and in silico studies. 2021 , 46, 116384	2
505	Stress and cancer: mechanisms, significance and future directions. <i>Nature Reviews Cancer</i> , 2021 , 21, 767-785	14
504	Engineered platelets: Advocates for tumor immunotherapy. 2021 , 40, 101281	6
503	The functional cross talk between cancer cells and cancer associated fibroblasts from a cancer mechanics perspective. 2021 , 1868, 119103	3
502	Breast cancer fibroblasts and cross-talk. 2021 , 521, 158-169	3
501	A state-of-the-art review on the application of various pharmaceutical nanoparticles as a promising technology in cancer treatment. 2021 , 14, 103352	6
500	The heterogeneity of cancer endothelium: The relevance of angiogenesis and endothelial progenitor cells in cancer microenvironment. 2021 , 138, 104189	3
499	Upregulation of Enolase (ENO1) crotonylation in colorectal cancer and its promoting effect on cancer cell metastasis. 2021 , 578, 77-83	3
498	Dormancy in cancer bone metastasis. 2022 , 393-410	
497	The Stemness-High Human Colorectal Cancer Cells Promote Angiogenesis by Producing Higher Amounts of Angiogenic Cytokines via Activation of the Egfr/Akt/Nf-B Pathway. 2021 , 22,	1
496	Mechanisms of glioblastoma resistance to antiangiogenic agents and reversal approaches. 2021 , 429-452	0
495	Heparan Sulfate Glycosaminoglycans: (Un)Expected Allies in Cancer Clinical Management. 2021 , 11,	10
494	Hypoxia re-programs 2'-O-Me modifications on ribosomal RNA. 2021 , 24, 102010	8
493	Transcriptional regulation of VEGFA expression in T-regulatory cells from breast cancer patients. 2021 , 70, 1877-1891	3
492	Design of ferrocenylseleno-dopamine derivatives to optimize the Fenton-like reaction efficiency and antitumor efficacy.. 2021 , 11, 25477-25483	1
491	Conventional Nanosized Drug Delivery Systems for Cancer Applications. 2021 , 1295, 3-27	5

490	Snail1 expression in endothelial cells controls growth, angiogenesis and differentiation of breast tumors. 2021 , 11, 7671-7684	3
489	Genetic Polymorphisms of Vascular Endothelial Growth Factor (VEGF) -2549 I/D and +405G/C in the susceptibility to Gastric Cancer. 2021 , 001-006	0
488	Impact on Radiotherapy. 353-376	1
487	Polypharmacological Kinase Inhibitors: New Hopes for Cancer Therapy. 149-165	8
486	Hyperprogression: A novel response pattern under immunotherapy. 2020 , 10, e167	11
485	Bone Stromal Cells As Therapeutic Targets In Osseous Metastasis. 2005 , 369-386	1
484	Angiogenesis: An Overview. 2006 , 1-29	3
483	Effects of Local and Whole Body Hyperthermia on Immunity. 2006 , 247-275	5
482	Brain metastases: epidemiology and pathophysiology. 2007 , 136, 1-21	44
481	Eph Receptor Tyrosine Kinases: Modulators of Angiogenesis. 2008 , 203-219	1
480	Memory T-cell responses and survival in human cancer: remember to stay alive. 2010 , 684, 166-77	8
479	The Angiogenic Switch: Role of Immune Cells. 2011 , 57-75	1
478	Metastasis and angiogenesis. 2004 , 117, 285-304	44
477	The host support niche as a control point for tumor dormancy: implications for tumor development and beyond. 2013 , 734, 19-35	11
476	Insights into the regulation of tumor dormancy by angiogenesis in experimental tumors. 2013 , 734, 37-52	14
475	Targeting Multiple Myeloma Tumor Angiogenesis: Focus on VEGF. 2013 , 283-299	1
474	Angiogenesis in Cancer. 2013 , 335-356	4
473	Oxidative Stress and Lung Cancer. 2014 , 245-257	1

472	Modulating the tumor microenvironment with RNA interference as a cancer treatment strategy. 2015 , 1218, 143-61	8
471	Angiogenesis and Ocular Tumorigenesis. 2006 , 161-171	1
470	VEGF and PDGF Receptors: Biologic Relevance and Clinical Approaches to Inhibition. 2009 , 119-149	1
469	Targeting stromal-cancer cell interactions with siRNAs. 2009 , 487, 243-66	22
468	Methods to assess pericyte-endothelial cell interactions in a coculture model. 2011 , 686, 379-99	14
467	Endothelial Cells (ECs) Metabolism: A Valuable Piece to Disentangle Cancer Biology. 2020 , 1219, 143-159	2
466	Oxygen in the Tumor Microenvironment: Mathematical and Numerical Modeling. 2020 , 1259, 53-76	3
465	Drivers of EMT and Immune Evasion. 2017 , 221-239	1
464	Role of Tumor Microenvironment in Hepatocellular Carcinoma Resistance. 2017 , 45-64	1
463	The Angiogenic Switch in Tumorigenesis. 2008 , 67-88	6
462	Molecular Signaling Pathways in Nasopharyngeal Cancer. 2010 , 27-40	2
461	The Role of Matrix Metalloproteinases in Cellular Invasion and Metastasis. 2011 , 145-191	2
460	Angiogenic Switch - Mixed Spatial Evolutionary Game Approach. 2016 , 420-429	1
459	MMP-Mediated Collagen Remodeling and Vessel Functions. 2013 , 471-489	1
458	Cancer: Clinical Background and Key Challenges. 2011 , 29-93	1
457	Hypoxia and Tumor Dormancy: Can the Two Tango?. 2014 , 13-24	2
456	Poor perfusion of the microvasculature in peritoneal metastases of ovarian cancer. 2020 , 37, 293-304	6
455	Anaplastic Astrocytoma. 2005 , 122-142	1

454	Pathobiology of True Arteriovenous Malformations. 2011 , 4004-4015	2
453	Neoplasia. 2010 , 259-330	25
452	Methanolic extract of <i>Boswellia serrata</i> exhibits anti-cancer activities by targeting microsomal prostaglandin E synthase-1 in human colon cancer cells. 2017 , 131, 1-8	18
451	Endothelial Cords Promote Tumor Initial Growth prior to Vascular Function through a Paracrine Mechanism. 2016 , 6, 19404	7
450	Discovery of Potent VEGFR-2 Inhibitors based on Furopyrimidine and Thienopyrimidine Scaffolds as Cancer Targeting Agents. 2016 , 6, 24460	85
449	CHAPTER 4:Designing Enzyme-responsive Biomaterials. 2020 , 76-125	1
448	Optical and magnetic resonance imaging approaches for investigating the tumour microenvironment: state-of-the-art review and future trends. 2021 , 32, 062001	8
447	Mechanisms of new blood-vessel formation and proliferative heterogeneity of endothelial cells. 2020 , 32, 295-305	36
446	The disruption of trace element homeostasis due to aneuploidy as a unifying theme in the etiology of cancer.	2
445	Tumor stroma fosters neovascularization by recruitment of progenitor cells into the tumor bed. 2006 , 10, 857-65	32
444	Opto-acoustic imaging of relative blood oxygen saturation and total hemoglobin for breast cancer diagnosis. 2019 , 24, 1-16	8
443	Oncogenic ras-induced expression of cytokines: a new target of anti-cancer therapeutics. 2008 , 8, 22-7	73
442	Wnt/ β -catenin-activated Ewing sarcoma cells promote the angiogenic switch. 2020 , 5,	10
441	An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. 2004 , 114, 623-633	452
440	An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. 2004 , 114, 623-33	246
439	Tlx acts as a proangiogenic switch by regulating extracellular assembly of fibronectin matrices in retinal astrocytes. 2006 , 116, 369-77	95
438	Blocking TNF- α in mice reduces colorectal carcinogenesis associated with chronic colitis. 2008 , 118, 560-70	610
437	HIF2 α cooperates with RAS to promote lung tumorigenesis in mice. 2009 , 119, 2160-70	115

436	Adipocyte-derived endotrophin promotes malignant tumor progression. 2012 , 122, 4243-56	196
435	Protein kinase LKB1 promotes RAB7-mediated neuropilin-1 degradation to inhibit angiogenesis. 2014 , 124, 4590-602	30
434	Cathepsins and Other Proteases in Tumor Angiogenesis. 2013 , 297-339	1
433	Can serial monitoring of serum Vascular Endothelial Growth Factor (VEGF), Nitric Oxide (NO), and Angiotensin II (ANGII) levels have predictive role during Bevacizumab treatment?. 2014 , 20, 428-33	4
432	M867, a novel selective inhibitor of caspase-3 enhances cell death and extends tumor growth delay in irradiated lung cancer models. 2008 , 3, e2275	40
431	Suppression of tumor growth and angiogenesis by a specific antagonist of the cell-surface expressed nucleolin. 2008 , 3, e2518	108
430	Suppression of MMP-2 attenuates TNF- α -induced NF- κ B activation and leads to JNK mediated cell death in glioma. 2011 , 6, e19341	22
429	A novel xenograft model in zebrafish for high-resolution investigating dynamics of neovascularization in tumors. 2011 , 6, e21768	81
428	Hwanggeumchal sorghum induces cell cycle arrest, and suppresses tumor growth and metastasis through Jak2/STAT pathways in breast cancer xenografts. 2012 , 7, e40531	53
427	Primed infusion with delayed equilibrium of Gd.DTPA for enhanced imaging of small pulmonary metastases. 2013 , 8, e54903	2
426	Tumor environmental factors glucose deprivation and lactic acidosis induce mitotic chromosomal instability--an implication in aneuploid human tumors. 2013 , 8, e63054	30
425	Hypoxic tumor kinase signaling mediated by STAT5A in development of castration-resistant prostate cancer. 2013 , 8, e63723	13
424	Role of activated Rac1/Cdc42 in mediating endothelial cell proliferation and tumor angiogenesis in breast cancer. 2013 , 8, e66275	36
423	Enhanced cancer metastasis in mice deficient in vasohibin-1 gene. 2013 , 8, e73931	17
422	Metabotropic glutamate receptor-1 as a novel target for the antiangiogenic treatment of breast cancer. 2014 , 9, e88830	41
421	Evolution of proliferation and the angiogenic switch in tumors with high clonal diversity. 2014 , 9, e91992	6
420	Chemokine receptor CXCR7 is a functional receptor for CXCL12 in brain endothelial cells. 2014 , 9, e103938	18
419	Red wine polyphenol compounds favor neovascularisation through estrogen receptor independent mechanism in mice. 2014 , 9, e110080	7

418	A combretastatin-mediated decrease in neutrophil concentration in peripheral blood and the impact on the anti-tumor activity of this drug in two different murine tumor models. 2014 , 9, e110091	5
417	Bioinformatics Analyses of the Role of Vascular Endothelial Growth Factor in Patients with Non-Small Cell Lung Cancer. 2015 , 10, e0139285	10
416	Trefoil Factor-3 (TFF3) Stimulates De Novo Angiogenesis in Mammary Carcinoma both Directly and Indirectly via IL-8/CXCR2. 2015 , 10, e0141947	23
415	RGD-Targeted Ultrasound Contrast Agent for Longitudinal Assessment of Hep-2 Tumor Angiogenesis In Vivo. 2016 , 11, e0149075	17
414	The Development of an Angiogenic Protein "Signature" in Ovarian Cancer Ascites as a Tool for Biologic and Prognostic Profiling. 2016 , 11, e0156403	18
413	MACC-1 Promotes Endothelium-Dependent Angiogenesis in Gastric Cancer by Activating TWIST1/VEGF-A Signal Pathway. 2016 , 11, e0157137	16
412	Oxidized Lipoprotein as a Major Vessel Cell Proliferator in Oxidized Human Serum. 2016 , 11, e0160530	3
411	Evolutionary emergence of angiogenesis in avascular tumors using a spatial public goods game. 2017 , 12, e0175063	5
410	Linn. ethanolic extract inhibits angiogenesis in human lung adenocarcinoma (a549) cells. 2020 , 13, 2028-2032	1
409	The Counter-Regulation of Atherogenesis: a Role for Interleukin-33. 2010 , 53, 125-129	6
408	Biological prognostic markers in chronic lymphocytic leukemia. 2009 , 52, 3-8	9
407	Glioblastoma Genomics: A Very Complicated Story. 3-25	8
406	Inhibition of STAT3 by RNA interference suppresses angiogenesis in colorectal carcinoma. 2011 , 44, 1222-30	18
405	Angiogenesis in the progression of cutaneous squamous cell carcinoma: an immunohistochemical study of endothelial markers. 2011 , 66, 465-8	13
404	Safety and efficacy profile of lenvatinib in cancer therapy: a systematic review and meta-analysis. 2016 , 7, 44545-44557	43
403	Zingerone suppresses angiogenesis via inhibition of matrix metalloproteinases during tumor development. 2016 , 7, 47232-47241	23
402	The truncated somatostatin receptor sst5TMD4 stimulates the angiogenic process and is associated to lymphatic metastasis and disease-free survival in breast cancer patients. 2016 , 7, 60110-60122	13
401	Assessing angiogenic responses induced by primary human prostate stromal cells in a three-dimensional fibrin matrix assay. 2016 , 7, 71298-71308	11

400	Isolation and genome-wide expression and methylation characterization of CD31+ cells from normal and malignant human prostate tissue. 2013 , 4, 1472-83	14
399	Genetic variants in RhoA and ROCK1 genes are associated with the development, progression and prognosis of prostate cancer. 2017 , 8, 19298-19309	9
398	Preoperative serum lipids as prognostic predictors in esophageal squamous cell carcinoma patients with esophagectomy. 2017 , 8, 41605-41619	11
397	Prostate cancer-derived CCN3 induces M2 macrophage infiltration and contributes to angiogenesis in prostate cancer microenvironment. 2014 , 5, 1595-608	61
396	RNAi-mediated inhibition of Lgr5 leads to decreased angiogenesis in gastric cancer. 2017 , 8, 31581-31591	10
395	Stat3-positive tumor cells contribute to vessels neoformation in primary central nervous system lymphoma. 2017 , 8, 31254-31269	10
394	Elevated TATA-binding protein expression drives vascular endothelial growth factor expression in colon cancer. 2017 , 8, 48832-48845	7
393	Apelin: A putative novel predictive biomarker for bevacizumab response in colorectal cancer. 2017 , 8, 42949-42961	31
392	ROS enhance angiogenic properties via regulation of NRF2 in tumor endothelial cells. 2017 , 8, 45484-45495	29
391	A new mosaic pattern in glioma vascularization: exogenous endothelial progenitor cells integrating into the vessels containing tumor-derived endothelial cells. 2014 , 5, 1955-68	22
390	Postoperative course and prognostic value of circulating angiogenic cytokines after pancreatic cancer resection. 2017 , 8, 72315-72323	6
389	Troponin through the looking-glass: emerging roles beyond regulation of striated muscle contraction. 2018 , 9, 1461-1482	40
388	EZH2 promotes angiogenesis through inhibition of miR-1/Endothelin-1 axis in nasopharyngeal carcinoma. 2014 , 5, 11319-32	34
387	AngioMatrix, a signature of the tumor angiogenic switch-specific matrisome, correlates with poor prognosis for glioma and colorectal cancer patients. 2014 , 5, 10529-45	37
386	WISP-1 a novel angiogenic regulator of the CCN family promotes oral squamous cell carcinoma angiogenesis through VEGF-A expression. 2015 , 6, 4239-52	47
385	A new chemical inhibitor of angiogenesis and tumorigenesis that targets the VEGF signaling pathway upstream of Ras. 2015 , 6, 5382-411	9
384	The anti-tumor effect is enhanced by simultaneously targeting VEGF and PROK1 in colorectal cancer. 2015 , 6, 6053-61	15
383	PC-1/PrLZ confers resistance to rapamycin in prostate cancer cells through increased 4E-BP1 stability. 2015 , 6, 20356-69	15

382	A retrospective analysis of cisplatin, pemetrexed, and bevacizumab in previously treated non-small-cell lung cancer. 2015 , 6, 22750-7	5
381	Vascular patterns provide therapeutic targets in aggressive neuroblastic tumors. 2016 , 7, 19935-47	14
380	Angiogenesis in NSCLC: is vessel co-option the trunk that sustains the branches?. 2017 , 8, 39795-39804	26
379	Chromatin dysregulation by mutant p53. 2016 , 7, 29875-6	3
378	Volatile anaesthetics enhance the metastasis related cellular signalling including CXCR2 of ovarian cancer cells. 2016 , 7, 26042-56	73
377	The feasibility of 18F-ALF-NOTA-PRGD2 PET/CT for monitoring early response of Endostar antiangiogenic therapy in human nasopharyngeal carcinoma xenograft model compared with 18F-FDG. 2016 , 7, 27243-54	8
376	Relationship between hypoxia and response to antiangiogenic therapy in metastatic colorectal cancer. 2016 , 7, 46678-46691	30
375	The dual role of complement in cancer and its implication in anti-tumor therapy. 2016 , 4, 265	35
374	Intercellular Crosstalk Via Extracellular Vesicles in Tumor Milieu as Emerging Therapies for Cancer Progression. 2019 , 25, 1980-2006	5
373	Efficacy and Toxicity of Addition of Bevacizumab to Chemotherapy in Patients with Metastatic Colorectal Cancer. 2018 , 21, 718-724	7
372	Changes in the Expression Profile of VEGF-A, VEGF-B, VEGFR-1, VEGFR-2 in Different Grades of Endometrial Cancer. 2019 , 20, 955-963	10
371	Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy. 2010 , 11, 1000-17	231
370	Molecular and Biological Functions of Melatonin in Endometrial Cancer. 2020 , 21, 519-526	5
369	Targeting tumor microenvironment with silibinin: promise and potential for a translational cancer chemopreventive strategy. 2013 , 13, 486-99	49
368	Challenges and Opportunities from Basic Cancer Biology for Nanomedicine for Targeted Drug Delivery. 2019 , 19, 257-276	13
367	Membrane Derived Vesicles as Biomimetic Carriers for Targeted Drug Delivery System. 2020 , 20, 2472-2492	5
366	Integrin β (CD49f), The Microenvironment and Cancer Stem Cells. 2019 , 14, 428-436	13
365	Synergies of Targeting Angiogenesis and Immune Checkpoints in Cancer: From Mechanism to Clinical Applications. 2020 , 20, 768-776	3

364	Exosomes Function in Pro- and Anti-Angiogenesis. 2013 , 2, 54-59	112
363	The Anti-Angiogenic Effect of Atorvastatin in Glioblastoma Spheroids Tumor Cultured in Fibrin Gel: in 3D in Vitro Model. 2018 , 19, 2553-2560	12
362	The multidisciplinary team for gastroenteropancreatic neuroendocrine tumours: the radiologist's challenge. 2019 , 53, 373-387	22
361	The Contribution of Endothelial Marker Proteins in the Determination of Vascular Angiogenic Potential, in Normal Physiological Conditions and in Neoplasia. 2011 , 3, 69-83	2
360	EPR effect and development of new strategy for nanoparticle delivery via remodeling tumor microenvironment based on tumor vasculature targeting. 2018 , 33, 98-104	1
359	Molecular Targets of Tumor Vasculature. 2005 , 396-415	3
358	Radiological apoplexy and its correlation with acute clinical presentation, angiogenesis and tumor microvascular density in pituitary adenomas. 2011 , 50, 281-7	23
357	The Role of Selected Chemokines and Their Receptors in the Development of Gliomas. 2020 , 21,	26
356	Expression of semaphorin 6D in gastric carcinoma and its significance. 2006 , 12, 7388-90	23
355	Combined treatment of vitamin K2 and angiotensin-converting enzyme inhibitor ameliorates hepatic dysplastic nodule in a patient with liver cirrhosis. 2007 , 13, 3259-61	17
354	Inhibition of angiogenesis and HCT-116 xenograft tumor growth in mice by kallistatin. 2007 , 13, 4615-9	20
353	PlexinA1 expression in gastric carcinoma and its relationship with tumor angiogenesis and proliferation. 2007 , 13, 6558-61	13
352	Cancer-associated fibroblasts in digestive tumors. 2014 , 20, 17804-18	42
351	[Correlation of aquaporin 3 expression with the clinicopathologic characteristics of non-small cell lung cancer]. 2012 , 15, 404-8	3
350	Activation of PGK1 under hypoxic conditions promotes glycolysis and increases stem cell-like properties and the epithelial-mesenchymal transition in oral squamous cell carcinoma cells via the AKT signalling pathway. 2020 , 57, 743-755	9
349	High gene expression levels of VEGFA and CXCL8 in the peritumoral brain zone are associated with the recurrence of glioblastoma: A bioinformatics analysis. 2019 , 18, 6171-6179	5
348	Metronomic chemotherapy in non-small cell lung cancer. 2020 , 20, 307	0
347	Antiangiogenic Effect of Rutin and its Regulatory Effect on the Production of VEGF, IL-1 β and TNF- α in Tumor Associated Macrophages. 2007 , 7, 1511-1519	19

346	Venous Loop Reveals an Occult Retinoblastoma Tumor. 2017 , 48, 768-770	4
345	Involvement of CXCL12 Pathway in HPV-related Diseases. 2016 , 3, 417-440	1
344	Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. 2015 , 4, 36-54	389
343	Antiangiogenic mechanisms and factors in breast cancer treatment. 2016 , 15, 1	30
342	Evaluation of collagen derived antiangiogenic factors and matrix metalloproteinases in anterior lens epithelial cells of pediatric eyes with persistent fetal vasculature. 2019 , 67, 1618-1622	5
341	Antiangiogenic activity of sophorolipids extracted from refined bleached deodorized palm olein. 2019 , 51, 45-54	6
340	Anti-Cancer Effects and Mechanisms of Capsaicin in Chili Peppers. 2015 , 06, 3075-3081	18
339	Combined Ang-2 and VEGF Targeting Therapies in Renal Cell Carcinoma. 2013 , 04, 1-6	5
338	Thymoquinone Suppresses Cellular Proliferation, Inhibits VEGF Production and Obstructs Tumor Progression and Invasion in the Rat Model of DMH-Induced Colon Carcinogenesis. 2013 , 04, 7-17	18
337	Endothelial cells in colorectal cancer. 2019 , 11, 946-956	13
336	Tumor progression-dependent angiogenesis in gastric cancer and its potential application. 2019 , 11, 686-704	21
335	Effect of Melatonin on the Expression of VEGF-A and on the Degeneration of Follicle Reserve in Rat Ovary. 2018 , 50, 160-163	3
334	Review of the treatment of metastatic non small cell lung carcinoma: A practical approach. 2011 , 2, 262-71	7
333	BMPs and their clinical potentials. 2011 , 44, 619-34	61
332	Standards of care and novel approaches in the management of glioblastoma multiforme. 2014 , 33, 32-9	91
331	Macrophage migration inhibitory factor: a potential marker for cancer diagnosis and therapy. 2012 , 13, 1737-44	38
330	Synergistic effects of tamoxifen and tranilast on VEGF and MMP-9 regulation in cultured human breast cancer cells. 2013 , 14, 6869-74	19
329	Enhanced antitumor effect of curcumin liposomes with local hyperthermia in the LL/2 model. 2013 , 14, 2307-10	11

328	Prognostic value of PLCE1 expression in upper gastrointestinal cancer: a systematic review and meta-analysis. 2014 , 15, 9661-6	15
327	VEGFR2 Expression in Head and Neck Squamous Cell Carcinoma Cancer Cells Mediates Proliferation and Invasion. 2016 , 17, 2217-21	7
326	Malignant Transformation in Glioma Steered by an Angiogenic Switch: Defining a Role for Bone Marrow-Derived Cells. 2016 , 8, e471	9
325	Antivascular endothelial growth factor antibody for treatment of glioblastoma multiforme. 2013 , 17, 68-74	3
324	Tumor Microenvironment-Associated Pericyte Populations May Impact Therapeutic Response in Thyroid Cancer. 2021 , 1329, 253-269	0
323	Molecular Targets for Gastric Cancer Treatment and Future Perspectives from a Clinical and Translational Point of View. 2021 , 13,	2
322	Crystallization of the Multi-Receptor Tyrosine Kinase Inhibitor Sorafenib for Controlled Long-Term Drug Delivery Following a Single Injection. 2021 , 14, 471-486	
321	Effects of radiation on tumor vasculature. 2021 ,	1
320	Aspiration-mediated hydrogel micropatterning using rail-based open microfluidic devices for high-throughput 3D cell culture. 2021 , 11, 19986	0
319	Prostate-Specific Membrane Antigen-Targeted Turn-on Probe for Imaging Cargo Release in Prostate Cancer Cells. 2021 , 32, 2386-2396	0
318	Comparative analysis of expression of angiogenic factors and CD44 gene in human glioma and neuroblastoma cell lines in vitro. 2004 , 23, 19-24	
317	The Regulatory Roles of Estrogen in Carcinogenesis. 2004 ,	1
316	The hemostatic system in angiogenesis. 2005 , 247-66	
315	Vascular Biology of the Placenta. 2005 , 289-313	
314	The Endothelium. 2006 , 1-15	
313	Tumor stroma fosters neovascularization by recruitment of progenitor cells into the tumor bed. 2006 , 10, 1-9	1
312	Angiogenic Switch. 2007 , 365-388	
311	Endothelial Cell Responses to Physiological and Pathophysiological Environments. 2007 , 349-364	

310 New Treatments and New Strategies. **2008**, 567-585

309 The Cell. **2008**, 3-35

308 Tumor Endothelial Markers. **2008**, 333-342

307 Emerging Molecular Therapies: Drugs Interfering With Signal Transduction Pathways. **2008**, 317-365

306 An Overview of Clinical Trials of Targeted Therapies in Pancreatic Cancer. **2008**, 565-575

305 Pericytes, the Mural Cells of the Microvascular System. **2008**, 45-53

3

304 Perspectives on the Future of Angiogenesis Research. **2008**, 575-583

303 Significance of the Tumour Microenvironment in Radiotherapy. **2009**, 137-156

302 Combined Targeting of EGFR and Angiogenesis in Aerodigestive Carcinomas. **2009**, 297-307

301 Molecular Imaging of Angiogenesis. **2009**, 52, 135

300 Tumor Microvasculature and Microenvironment: Therapeutic Targets for Inhibition of Tumor Angiogenesis and Metastasis. **2009**, 1-47

299 Effects of Tumor Microenvironment on Hyperthermia, Photodynamic and Nanotherapy. **2009**, 181-201

1

298 Stat3 Oncogenic Signaling in Glioblastoma Multiforme. **2009**, 899-918

297 Bone Marrow-Derived Cells in GBM Neovascularization. **2009**, 749-773

1

296 Modulation of Protein Stability: Targeting the VHL Pathway. **2009**, 45-63

295 RAS Oncogenes and Tumor-Vascular Interface. **2010**, 133-165

1

294 Medicinal Applications of Hydrocolloid Beads. **2010**, 117-136

293 Angiogenesis Inhibitors in Lung Cancer. **2010**, 227-252

1

- 292 Three-Photon/Two-Photon Resonance Enhancement of Third Harmonic Generation in Human Oxyhemoglobin and Deoxyhemoglobin. **2010**,
- 291 The Impact of Inflammation Control and Active Cancer Palliation on Metabolic Pathways Determining Tumor Progression and Patient Survival. **2010**, 313-340
- 290 Chapter 7: Mesenchymal Stromal/Stem Cells from Tissue Repair to Destruction of Tumor Cells. **2010**, 141-158
- 289 Translational Implications of Stromal-Epithelial Interactions in Prostate Cancer and the Potential Role of Prostate Cancer Stem/Progenitor Cells. **2010**, 2773-2782
- 288 Tumor Microenvironment. **2010**, 27-69 1
- 287 The ERK1/2 MAP Kinase Signaling Pathway in Tumor Progression and Metastasis. **2010**, 25-40
- 286 Anti-vascular Therapy for Brain Tumors. **2011**, 97-108
- 285 Hypoxia-Inducible Factor 1 (HIF-1) Mediated Adaptive Responses in the Solid Tumor. 271-290
- 284 Challenges and Successes in Developing Effective Anti-angiogenic Agents. **2011**, 347-401
- 283 Inhibitors of Tumor Angiogenesis. **2011**, 331-340
- 282 Role of CXC Chemokines and Receptors in Liver Metastasis - Impact on Liver Resection-Induced Engraftment and Tumor Growth. **2011**, 129-154
- 281 Targeting Tumor Associated Fibroblasts Tumor Associated Fibroblasts and Chemotherapy. **2011**, 403-418
- 280 Patients with Recurrent High-Grade Glioma: Therapy with Combination of Bevacizumab and Irinotecan. **2011**, 289-299
- 279 Exploration of MMP Function in Mouse Models of Angiogenesis. **2011**, 105-115
- 278 Novel therapies in gynaecological cancer. **2011**, 554-565
- 277 Molecular Targeted Therapies in Head and Neck Cancer. **2011**, 293-305 1
- 276 Combination therapy & future directions in RCC. **2011**, 126-142
- 275 Targeting Signal Transducer and Activator of Transcription (STAT) for Anticancer Therapy. **2012**, 299-321

274 Index. 1631-1689

273 Somatic Alterations and Targeted Therapy. **2012**, 51-101

272 Tumor microenvironment and Tumor Endothelial Cells. **2012**, 27, 34-39

271 Tumor Markers. **2012**, 617-667

1

270 Angiopoietins and Other Non-VEGF Antiangiogenic Targets in Advanced Renal Cell Carcinoma. **2012**, 135-160

269 Pathophysiological Barriers Impeding the Delivery of Heat Shock Protein (HSP)-Based Macromolecules and Nanotherapeutics to Solid Tumors. **2012**, 185-199

268 Differential protein expression in EC304 gastric cancer cells induced by alphastatin. **2012**, 13, 1667-74

267 Novel Anti-angiogenic Therapies Using Naturally Occurring and Synthetic Drugs to Combat Progesterin-Dependent Breast Cancer. **2013**, 123-147

266 Molecular Oncology in Gynecologic Cancer. **2013**, 623-633

1

265 Metastasis Initiation. **2013**, 445-469

264 RGD-Based Molecular Probes for Integrin $\alpha_5\beta_1$ Imaging. **2013**, 513-538

263 Introduction. **2013**, 3-10

262 Krüppel-like Factor 5 (KLF5) and Tumor Angiogenesis. **2013**, 341-355

261 Stem Cell-Based Antiangiogenic Therapies for Brain Tumors. 87-101

260 MET Inhibitors. **2013**, 209-234

0

259 Microvesicular Transfer of MicroRNA in Tumor Microenvironment. **2014**, 327-348

258 Various Factors Contributing to Tumor Dormancy: Therapeutic Implications in Breast Cancer. **2014**, 51-57

257 Pentraxin 3 as Biomarker. **2014**, 1-20

256 Normal Cell. **2015**, 1-38

255 Optimization of Photodynamic Therapy Response by Survivin Gene. **2015**, 163-182

1

254 Cellular Plasticity, Cancer Stem Cells and Metastasis. **2015**, 13-66

253 Follistatin, a Novel Biomarker for Malignant Gliomas. **2015**, 06, 121-129

1

252 Pentraxin 3 as Biomarker. **2015**, 267-290

251 Gastrointestinal Blood Flow. 161-182

250 Metabolic Syndrome and the Liver. **2016**, 149-177

249 New Treatments and New Therapies. **2016**, 681-710

248 Significance of Cryobiopsy for Morphological and Immunohistochemical Analyses of Xenografted Human Lung Cancer Tissues and Functional Blood Vessels. **2016**, 263-268

247 DDA suppresses angiogenesis and tumor growth of colorectal cancer in vivo through decreasing VEGFR2 signaling. **2016**, 7, 63124-63137

4

246 Physiologic and Molecular Basis of PET in Cancer Imaging. **2017**, 399-427

0

245 Current Status and Characteristics of Cancer. **2017**, 1-5

244 Anti-tumor effect of recombinant plasminogen kringle 1B in KB cells: Histological observation and immunoprecipitation-based high performance liquid chromatography. **2017**, 41, 45-54

243 Predictive model identifies strategies to enhance TSP1-mediated apoptosis signaling.

242 "Comparative Experimental Studies of Few L-Type and T-Type Ca²⁺ Channel Blockers Against In-Ovo and In-Vitro Models of Angiogenesis". **2017**, 9, 1-9

241 The impact of tumor receptor heterogeneity on the response to anti-angiogenic cancer treatment.

240 Angiogenesis and Anti-angiogenic Therapy in Head and Neck Cancer. **2018**, 439-467

239 Anti-angiogenic effects of VEGF stimulation on endothelium deficient in phosphoinositide recycling.

- 238 Mapping Mammary Tumor Traits in the Rat. **2019**, 2018, 249-267 1
- 237 Approach and Management of Cervical Cancer. **2019**, 491-549
- 236 Preclinical Non-invasive Imaging in Cancer Research and Drug Discovery: An Overview. **2019**, 419-469
- 235 Tumor Blood Vessels as Targets for Cancer Therapy. **2019**, 41-56
- 234 Future Prospective of Nanotechnology in Skin Cancer Therapeutics. **2019**, 87-100
- 233 longitudinal depth-wise visualization of tumorigenesis by needle-shaped side-view confocal endomicroscopy. **2019**, 10, 2719-2729 2
- 232 A VEGF reaction-diffusion mechanism that selects variable densities of endothelial tip cells.
- 231 Fine-grained simulations of the microenvironment of vascularized tumours.
- 230 Tumor-Infiltrantig Lymphocytes Density as Determinant in Early Stage Colorectal Cancer Prognosis: A Single Centre Pilot Study. **2019**, 1-5
- 229 Exopolysaccharide from *Paecilomyces lilacinus* modulates macrophage activities through the TLR4/NF- κ B/MAPK pathway. **2019**, 20, 4943-4952 1
- 228 Colorectal cancer cells differentially impact migration and microRNA expression in endothelial cells. **2019**, 18, 6361-6370 1
- 227 Expression and regulation effects of chemokine receptor 7 in colon cancer cells. **2020**, 20, 226-234 1
- 226 Cancer and Anticancer Activity. **2020**, 51-56
- 225 Advances in the role of exosomal non-coding RNA in the development, diagnosis, and treatment of gastric cancer (Review). **2020**, 13, 101-108 2
- 224 Tumor-Responsive Drug Release Strategies. **2020**, 57-86
- 223 Cancer. 1, 645-660
- 222 'Plate-like-coral' polymer particles with dendritic structure and porous channels: Effective delivery of anti-cancer drugs. **2021**, 138, 50386 2
- 221 MicroRNA-181a is elevated by 10-hydroxycamptothecin and represses lung carcinoma progression by downregulating FOXP1. **2022**, 46, 417-431 1

- 220 Microwaves assisted synthesis of antitumor agents of novel azoles, azines, and azoloazines pendant to phenyl sulfone moiety and molecular docking for VEGFR-2 kinase. **2022**, 1249, 131657 6
- 219 Combined therapy for treating solid tumors with chemotherapy and angiogenic inhibitors. **2020**,
- 218 Applications of Small Animal PET. **2020**, 216, 493-507
- 217 ROS and Oxidative Stress in Cancer: Recent Advances. **2020**, 109-138 2
- 216 Ligand Nanoparticle Conjugation Approach for Targeted Cancer Chemotherapy. **2020**, 377-403
- 215 TGF β Suppresses Type 2 Immunity to Cancer.
- 214 P90 ribosomal S6 kinase confers cancer cell survival by mediating checkpoint kinase 1 degradation in response to glucose stress. **2021**, 1
- 213 Chemokine receptors in tissue cells and angiogenesis. **2006**, 183-203 1
- 212 Influence of Tumor Microenvironment on Thermoresponse. **2006**, 67-91 2
- 211 Cult of Selfishness. **2008**, 45-63
- 210 Co-Targeting Therapeutics for Hormone Refractory Prostate Cancer. **2007**, 463-473
- 209 Molecular Targeting of Colorectal Cancer. **2008**, 133-163
- 208 β -Angiogenin tumorale. **2008**, 9-13
- 207 Stromal cells as new therapeutic targets in rheumatoid arthritis. **2005**, 2, 121-129
- 206 Biological Therapies for Metastatic Breast Cancer: Antiangiogenesis. **2006**, 671-704
- 205 The Use of Orthotopic Models to Validate Antivascular Therapies for Cancer. **2008**, 477-490
- 204 Molekulare Toxikologie. **2006**, 153-259
- 203 Nucleolin is expressed in human fetal brain development and reactivated in human glial brain tumors regulating angiogenesis and vascular metabolism. 0

202	Targeted therapy of advanced non-small cell lung cancer: the role of bevacizumab. 2007 , 1, 185-94	4
201	RNAi and cancer: Implications and applications. 2006 , 2, 136-45	11
200	Five-year survival of metastatic pancreatic carcinoma: a study of courage and hope. 2009 , 3, 208-11	7
199	Multimodality molecular imaging of CD105 (Endoglin) expression. 2011 , 4, 32-42	40
198	Preclinical molecular imaging of tumor angiogenesis. 2010 , 54, 291-308	27
197	Targeting stromal cells in chronic inflammation. 2007 , 7, 20-6	8
196	Understanding tumor-stroma interplays for targeted therapies by armed mesenchymal stromal progenitors: the Mesenkillers. 2011 , 1, 787-805	22
195	Expanding roles of ZEB factors in tumorigenesis and tumor progression. 2011 , 1, 897-912	85
194	Hedgehog pathway and GLI1 isoforms in human cancer. 2012 , 13, 105-13	72
193	Beyond anti-VEGF: dual-targeting antiangiogenic and antiproliferative therapy. 2013 , 5, 393-403	20
192	Molecular MRI of VEGFR-2 reveals intra-tumor and inter-tumor heterogeneity. 2013 , 3, 312-6	8
191	Inhibitory effect of a mixture containing vitamin C, lysine, proline, epigallocatechin gallate, zinc and alpha-1-antitrypsin on lung carcinogenesis induced by benzo(a) pyrene in mice. 2013 , 18, 427-34	2
190	S100 protein family in human cancer. 2014 , 4, 89-115	98
189	Immunohistochemical expression of CD117 and vascular endothelial growth factor in retinoblastoma: possible targets of new therapies. 2014 , 7, 5725-37	13
188	Angiogenesis, multitarget kinase inhibitors and non-small cell lung cancer: a lesson from MONET1 trial. 2013 , 2, E13-6	
187	Differential growth inhibition of cerebral metastases by anti-angiogenic compounds. 2014 , 34, 3293-302	4
186	OKN-007 decreases VEGFR-2 levels in a preclinical GL261 mouse glioma model. 2015 , 5, 363-78	7
185	Progranulin promotes colorectal cancer proliferation and angiogenesis through TNFR2/Akt and ERK signaling pathways. 2015 , 5, 3085-97	34

184	A VEGFR1 antagonistic peptide inhibits tumor growth and metastasis through VEGFR1-PI3K-AKT signaling pathway inhibition. 2015 , 5, 3149-61	21
183	Targeting oncogenic KRAS in non-small cell lung cancer cells by phenformin inhibits growth and angiogenesis. 2015 , 5, 3339-49	17
182	MiR-195 is a key negative regulator of hepatocellular carcinoma metastasis by targeting FGF2 and VEGFA. 2015 , 8, 14110-20	35
181	Understanding tumor anabolism and patient catabolism in cancer-associated cachexia. 2017 , 7, 1107-1135	13
180	[Metronomic Chemotherapy--A New Path to Treat Advanced Non-small Cell Lung Cancer]. 2015 , 18, 232-9	1
179	[The Supernatant Obtained from Cultured Anip973 Cells Enhances the Biological Activities of HUVEC]. 2015 , 18, 668-73	1
178	Impact of Adrenoceptor antagonists on prostate cancer development, progression and prevention. 2019 , 7, 46-60	5
177	TRIM11 promotes tumor angiogenesis via activation of STAT3/VEGFA signaling in lung adenocarcinoma. 2019 , 9, 2019-2027	8
176	The correlation of the expressions of WWOX, LGR5 and vasohibin-1 in epithelial ovarian cancer and their clinical significance. 2019 , 12, 327-336	
175	High EGFL6 expression is associated with clinicopathological characteristics in colorectal cancer. 2018 , 11, 5893-5900	1
174	[In situ visual imaging of oral squamous cell carcinoma in mice by using near-infrared quantum dots conjugated with arginine-glycine-aspartic acid peptide fluorescent probes]. 2014 , 32, 498-503	
173	Characterization of pathways involved in colorectal cancer using real-time RT-PCR gene expression data. 2021 , 14, 123-131	2
172	Ultrasound super-resolution imaging enables multiparameter analyses of tumor angiogenesis during growth. 2021 ,	
171	Mechanism and prevention strategy of a bidirectional relationship between heart failure and cancer (Review). 2021 , 22, 1463	1
170	Targeting Tumor-Stromal Interactions in Pancreatic Cancer: Impact of Collagens and Mechanical Traits.. 2021 , 9, 787485	3
169	Angiogenesis inhibition in lung cancer: emerging novel strategies. 2022 , 34, 107-114	0
168	The Evolution and Future of Targeted Cancer Therapy: From Nanoparticles, Oncolytic Viruses, and Oncolytic Bacteria to the Treatment of Solid Tumors. 2021 , 11,	1
167	Stem Cell-Based Therapies: What Interventional Radiologists Need to Know. 2021 , 38, 523-534	

166	Therapeutic efficacy of proton transport inhibitors alone or in combination with cisplatin in triple negative and hormone sensitive breast cancer models. 2021 , 11, 183	1
165	Targeting hypoxia and hypoxia-inducible factor-1 in the tumor microenvironment for optimal cancer immunotherapy. 2021 ,	2
164	Targeting VEGFR-2 by new quinoxaline derivatives: Design, synthesis, antiproliferative assay, apoptosis induction, and in silico studies. 2021 , e2100359	1
163	Blood and urine concentrations of vascular endothelial growth factor in dogs with tumours. 2021 , 24, 596-600	
162	The notion of fractals in tumour angiogenic sprout initiation model based on cellular automata. 2022 , 155, 111717	1
161	Genetic variant of CXCR1 (rs2234671) associates with clinical outcome in perihilar cholangiocarcinoma.	0
160	The Good, the Bad, and the Ugly: Neutrophils, Angiogenesis, and Cancer.. 2022 , 14,	2
159	Passive targeting. 2022 , 37-47	
158	A brief tour guide to cancer disease. 2022 , 1-20	0
157	Inducing Vascular Grammars for Anomaly Classification in Brain Angiograms. 2022 ,	
156	Yap Expression Is Closely Related to Tumor Angiogenesis and Poor Prognosis in Hepatoblastoma.. 2022 , 1-11	0
155	Antiangiogenic drugs as chemosensitizer in melanoma. 2022 , 93-109	
154	Exosome-derived noncoding RNAs: Function, mechanism, and application in tumor angiogenesis.. 2022 , 27, 983-997	1
153	Genetic Modifications That Expand Oncolytic Virus Potency.. 2022 , 9, 831091	1
152	The Anti-Angiogenic Effect of Atorvastatin Loaded Exosomes on Glioblastoma Tumor Cells: An in Vitro 3D Culture Model.	
151	Melatonin is a potential oncostatic agent to inhibit HepG2 cell proliferation through multiple pathways.. 2022 , 8, e08837	1
150	Synthesis, bioactive properties, and biomedical applications of intrinsically therapeutic nanoparticles for disease treatment. 2022 , 435, 134970	10
149	The Role of Decorin Proteoglycan in Mitophagy.. 2022 , 14,	1

148	Modulating Angiogenesis by Proteomimetics of Vascular Endothelial Growth Factor.. 2021 ,	5
147	Molecular Pathogenesis of Glioblastoma in Adults and Future Perspectives: A Systematic Review.. 2022 , 23,	1
146	A chemical probe inhibitor targeting STAT1 restricts cancer stem cell traits and angiogenesis in colorectal cancer.. 2022 , 29, 20	0
145	A Novel Prognostic Model for Identifying the Risk of Hepatocellular Carcinoma Based on Angiogenesis Factors.. 2022 , 13, 857215	1
144	Preoperative Helical Dynamic Enhanced Multidetector Row Computed Tomography: Can It Be a Prognostic Indicator in Early-Stage Non-small Cell Lung Cancer?. 2022 , 46, 308-314	
143	Development and Evaluation of Targeted Optical Imaging Probes for Image-Guided Surgery in Head and Neck Cancer. 2100196	0
142	Intelligent Nanodelivery System-Generated O Mediates Tumor Vessel Normalization by Activating Endothelial TRPV4-eNOS Signaling.. 2022 , e2200038	0
141	Mutation-Harboring Lung Cancer Cells Produce CLEC11A with Endothelial Trophic and Tumor-Promoting Activities.. 2022 , 14,	0
140	Combination Therapy Case Studies in Anticancer and Anti-Infectious Disease Drug Discovery and Development. 2022 , 341-384	
139	Posttranslational Modifications in Thyroid Cancer: Implications for Pathogenesis, Diagnosis, Classification, and Treatment.. 2022 , 14,	1
138	A comprehensive systematic review and network meta-analysis: the role of anti-angiogenic agents in advanced epithelial ovarian cancer.. 2022 , 12, 3803	3
137	A simple agent-based model to simulate 3D tumor-induced angiogenesis considering the evolution of the hypoxic conditions of the cells. 1	1
136	Reversing chemokine/chemokine receptor mismatch to enhance the antitumor efficacy of CAR-T cells.. 2022 ,	1
135	Endometriosis-Associated Angiogenesis and Anti-angiogenic Therapy for Endometriosis.. 2022 , 3, 856316	0
134	RMAC study: A randomized study for evaluation of metronomic adjuvant chemotherapy in recurrent head and neck cancers post salvage surgical resection in those who are ineligible for re-irradiation.. 2022 , 128, 105816	
133	BLOOD BRAIN BARRIER AS AN INTERFACE FOR ALCOHOL INDUCED NEUROTOXICITY DURING DEVELOPMENT.. 2022 ,	0
132	HMGA2 promotes the migration and invasion of gallbladder cancer cells and HMGA2 knockdown inhibits angiogenesis via targeting VEGFA.. 2022 , 25,	
131	The p38 MAPK Components and Modulators as Biomarkers and Molecular Targets in Cancer.. 2021 , 23,	6

- 130 Impact of Immune Cell Heterogeneity on HER2+ Breast Cancer Prognosis and Response to Therapy.. **2021**, 13, 0
- 129 Strategies for Remodeling the Tumor Microenvironment Using Active Ingredients of Ginseng-A Promising Approach for Cancer Therapy.. **2021**, 12, 797634 2
- 128 The role of vascular endothelial growth factor as a prognostic and clinicopathological marker in osteosarcoma: a systematic review and meta-analysis.. **2021**, 16, 738 2
- 127 Emerging Role of Autophagy in the Development and Progression of Oral Squamous Cell Carcinoma.. **2021**, 13, 0
- 126 Role of MicroRNAs and Long Non-Coding RNAs in Regulating Angiogenesis in Human Breast Cancer- A Molecular Medicine Perspective.. **2021**,
- 125 Pathology and Epidemiology of Oral Squamous Cell Carcinoma. 05-08
- 124 Materials-driven approaches to understand extrinsic drug resistance in cancer.. **2022**,
- 123 Table_1.docx. **2020**,
- 122 Table_2.xlsx. **2020**,
- 121 Table_1.pdf. **2018**,
- 120 Table_1.docx. **2020**,
- 119 Data_Sheet_1.PDF. **2018**,
- 118 Table_1.PDF. **2018**,
- 117 Non-coding RNA regulatory networks in post-transcriptional regulation of VEGFA in cancer.. **2022**, 2
- 116 The pathophysiology of chronic subdural hematoma revisited: emphasis on aging processes as key factor.. **2022**, 1 0
- 115 LINC00022 acts as an oncogene in colorectal cancer progression via sponging miR-375-3p to regulate FOXF1 expression.. **2022**, 22, 453 0
- 114 TILA-TACE - an approach for effective local control of hepatocellular carcinoma. **2018**, 1, 58-63
- 113 Progress in nanotechnology-based targeted cancer treatment. **2022**, 239-250

112	Application of Bioinformatics Techniques to Screen and Characterize the Plant-Based Anti-Cancer Compounds. 2022 , 466-484	0
111	In Vitro Effects of Papaverine on Cell Migration and Vascular Endothelial Growth Factor in Cancer Cell Lines.. 2022 , 23,	1
110	Microfluidics for detection of exosomes and microRNAs in cancer: state of the art. 2022 ,	1
109	The Role of Extracellular Vesicles in Metabolic Reprogramming of the Tumor Microenvironment.. 2022 , 11,	2
108	EFNA1 in gastrointestinal cancer: Expression, regulation and clinical significance. 2022 , 14, 973-988	
107	Thrombospondin-1 Disrupts Estrogen-Induced Endothelial Cell Proliferation and Migration and Its Expression Is Suppressed by Estradiol. 2004 , 2, 150-158	41
106	Challenges and the Evolving Landscape of Assessing Blood-Based PD-L1 Expression as a Biomarker for Anti-PD-(L)1 Immunotherapy. 2022 , 10, 1181	1
105	CircRNA: An emerging star in the progression of glioma. 2022 , 151, 113150	0
104	Zebrafish: A Model Organism to Understand Tumor Angiogenesis Mechanism. 2022 , 17-42	
103	Resistance Mechanisms of the Metastatic Tumor Microenvironment to Anti-Angiogenic Therapy. 12,	0
102	Multi-Phase, Contrast-Enhanced Computed Tomography-Based Radiomic Prognostic Marker of Non-Metastatic Pancreatic Ductal Adenocarcinoma. 2022 , 14, 2476	0
101	The Impact of MicroRNAs in Cell Adhesion and Tumour Angiogenesis. 2022 , 53-71	
100	Impact of tumor microenvironment on adoptive T cell transfer activity. 2022 ,	0
99	Hallmarks of Cancer: Molecular Underpinnings. 2022 , 3-14	0
98	Dimeric G-quadruplex DNA Structure in the Proximal Promoter of VEGFR -2 Reveals A New Drug Target to Inhibit Tumor Angiogenesis.	
97	Novel Drugs with High Efficacy against Tumor Angiogenesis. 2022 , 23, 6934	1
96	Gastric Cancer-Derived Extracellular Vesicles (EVs) Promote Angiogenesis via Angiopoietin-2. 2022 , 14, 2953	0
95	Concentration of hypoxia-inducible factor-1, glucose transporter 1 and vascular endothelial growth factor in tissue samples and serum in patients with primary laryngeal carcinoma. 1-5	0

94	Inducible endothelial leakiness in nanotherapeutic applications. 2022 , 121640	1
93	Hypoxia-induced ELF3 promotes tumor angiogenesis through IGF1/IGF1R.	0
92	FOLFIRI plus BEvacizumab or aFLIbercept after FOLFOX-bevacizumab failure for COlorectal cancer (BEFLICO): an AGEO multicenter study.	0
91	3D-Cultured Vascular-Like Networks Enable Validation of Vascular Disruption Properties of Drugs In Vitro. 10,	0
90	Drivers of EMT and Immune Evasion. 2022 , 183-194	
89	Advances in 3D Vascularized Tumor-on-a-Chip Technology. 2022 , 231-256	0
88	Methyladenosine Modification in RNAs: From Regulatory Roles to Therapeutic Implications in Cancer. 2022 , 14, 3195	0
87	Sanguinarine Regulates Tumor-Associated Macrophages to Prevent Lung Cancer Angiogenesis Through the WNT/ β Catenin Pathway. 12,	0
86	The Role of Imaging Biomarkers to Guide Pharmacological Interventions Targeting Tumor Hypoxia. 13,	1
85	Long-term cultured microvascular networks on chip for tumor vascularization research and drug testing. 2022 , 16, 044101	
84	Therapy of Hematogenous Melanoma Brain Metastases with Endostatin. 2005 , 11, 1259-1267	1
83	Vascularization of Melanoma by Mobilization and Remodeling of Preexisting Latent Vessels to Patency. 2005 , 65, 913-918	6
82	KRN633: A selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase that suppresses tumor angiogenesis and growth. 2004 , 3, 1639-1649	23
81	Carbon Quantum Dots: A Promising Nanocarrier for Bioimaging and Drug Delivery in Cancer. 2022 , 104068	3
80	Novel artemisinin derivative FO8643 with anti-angiogenic activity inhibits growth and migration of cancer cells via VEGFR2 signaling. 2022 , 175158	1
79	Plants as a Source of Anticancer Agents: From Bench to Bedside. 2022 , 27, 4818	2
78	RGS6 suppresses TGF- β -Induced epithelial-mesenchymal transition in non-small cell lung cancers via a novel mechanism dependent on its interaction with SMAD4. 2022 , 13,	1
77	A comprehensive review on different approaches for tumor targeting using nanocarriers and recent developments with special focus on multifunctional approaches.	0

- 76 Breast cancer cell-derived EVs promote HUVECs proliferation and migration by regulating JAK2/STAT3 pathway.
- 75 Targeting the extra domain A of fibronectin for cancer therapy with CAR-T cells. **2022**, 10, e004479 2
- 74 Annona cherimola Mill. Leaf Extracts Affect Melanoma Cells Growth and Progression. **2022**, 11, 2420
- 73 The application of zebrafish patient-derived xenograft tumor models in the development of antitumor agents. 0
- 72 A self-activating nanoized vascular disrupting agent for selective anti-tumor therapy. **2022**, 121736 1
- 71 In situ forming oxygen/ROS-responsive niche-like hydrogel enabling gelation-triggered chemotherapy and inhibition of metastasis. **2023**, 21, 86-96 1
- 70 The biology of cancer. **2023**, 35-45 0
- 69 Prostate Cancer Tumor Stroma: Responsibility in Tumor Biology, Diagnosis and Treatment. **2022**, 14, 4412 2
- 68 The extracellular matrix alteration, implication in modulation of drug resistance mechanism: friends or foes?. **2022**, 41, 0
- 67 MYCN Impact on High-Risk Neuroblastoma: From Diagnosis and Prognosis to Targeted Treatment. **2022**, 14, 4421 0
- 66 Efficacy of rechallenge transcatheter arterial chemoembolization after lenvatinib treatment for advanced hepatocellular carcinoma. 0
- 65 Inhibitor of differentiation 1 in U87MG glioblastoma cells promotes HUVEC sprouting through endothelin-1. **2022**, 24, 0
- 64 Counter regulation of tumor angiogenesis by vascular endothelial growth factor and thrombospondin-1. **2022**, 86, 126-135 0
- 63 Capturing the spatial and temporal dynamics of tumor stroma for on-chip optimization of microenvironmental targeting nanomedicine. 0
- 62 Cranial Spinal Spreading of Canine Brain Gliomas after Hypofractionated Volumetric-Modulated Arc Radiotherapy and Concomitant Temozolomide Chemotherapy: A Four-Case Report. **2022**, 9, 541 0
- 61 The Biological Relevance of Papaverine in Cancer Cells. **2022**, 11, 3385 1
- 60 Identification of Specific Cervical Cancer Subtypes and Prognostic Gene Sets in Tumor and Nontumor Tissues Based on GSVA Analysis. **2022**, 2022, 1-17 0
- 59 Matrix stiffness in regulation of tumor angiogenesis. **2022**, 30, 871-878 0

- 58 3D microengineered vascularized tumor spheroids for drug delivery and efficacy testing. **2022**, 1
- 57 Current and emerging anti-angiogenic therapies in gastrointestinal and hepatobiliary cancers. 12, 0
- 56 An Application of Tumor-Associated Macrophages as Immunotherapy Targets: Sialic Acid-Modified EPI-Loaded Liposomes Inhibit Breast Cancer Metastasis. **2022**, 23, 0
- 55 Current landscape and future directions of bispecific antibodies in cancer immunotherapy. 13, 0
- 54 Tau Protein as Therapeutic Target for Cancer? Focus on Glioblastoma. **2022**, 14, 5386 0
- 53 Assessment of Cardiotoxicity after a Single Dose of Combretastatin A4-Phosphate in Dogs Using Two-Dimensional Speckle-Tracking Echocardiography. **2022**, 12, 3005 0
- 52 Nanomodulation and nanotherapeutics of tumor-microenvironment. **2022**, 8, 100099 0
- 51 FOXK2 transcription factor and its roles in tumorigenesis (Review). **2022**, 24, 0
- 50 A microfluidic model of human vascularized breast cancer metastasis to bone for the study of neutrophil-cancer cell interactions. **2022**, 17, 100460 0
- 49 The malignant phenotype. **2006**, 116, 0
- 48 New target DDR1: A "double-edged sword" in solid tumors. **2023**, 1878, 188829 0
- 47 Adjuvant therapy options in renal cell carcinoma "targeting the metastatic cascade." 0
- 46 From Macro to Micro: Comparison of Imaging Techniques to Detect Vascular Network Formation in Left Ventricle Decellularized Extracellular Matrix Hydrogels. **2022**, 8, 729 1
- 45 Tumor Immune Microenvironment and Immunotherapy in Non-Small Cell Lung Cancer: Update and New Challenges. **2022**, 13, 1615 0
- 44 Nisin delivery by nanosponges increases its anticancer activity against in-vivo melanoma model. **2023**, 79, 104065 0
- 43 Selective Anticancer Effects by Oxytocin in Triple-Negative Breast Cancer Expressing S100A9. **2022**, 1, 1-11 0
- 42 SGLT-2 Inhibitors in Cancer Treatment: Mechanisms of Action and Emerging New Perspectives. **2022**, 14, 5811 1
- 41 Prenatal exposure to alcohol: mechanisms of cerebral vascular damage and lifelong consequences. 2, 0

- 40 Recent advances of nanomaterial-based anti-angiogenic therapy in tumor vascular normalization and immunotherapy. 12, 0
- 39 Notch signaling regulates vasculogenic mimicry and promotes cell morphogenesis and the epithelial-to-mesenchymal transition in pancreatic ductal adenocarcinoma. **2022**, 17, e0279001 0
- 38 Stromal cells in prostate cancer pathobiology: friends or foes? 0
- 37 Expression analysis and regulation of GLI and its correlation with stemness and metabolic alteration in human brain tumor. **2023**, 13, 0
- 36 Role of hypoxia-inducible proteins in ameloblastoma: A review. **2022**, 0
- 35 Design of Nanoparticles in Cancer Therapy Based on Tumor Microenvironment Properties. **2022**, 14, 2708 0
- 34 Modulatory activity of ADNP on the hypoxia-induced angiogenic process in glioblastoma. **2022**, 62, 0
- 33 Targeting macrophages: a novel treatment strategy in solid tumors. **2022**, 20, 1
- 32 Targeting Tumor Microenvironment by Metal Peroxide Nanoparticles in Cancer Therapy. **2022**, 2022, 1-20 1
- 31 Constructing 3D In Vitro Models of Heterocellular Solid Tumors and Stromal Tissues Using Extrusion-Based Bioprinting. 1
- 30 Pembrolizumab for first-line treatment of advanced unresectable or metastatic esophageal or gastroesophageal junction cancer. **2023**, 16, 175628482211482 0
- 29 Infiltrating CD8+ T cells and M2 macrophages are retained in tumor matrix tracks enriched in low tension fibronectin fibers. **2023**, 0
- 28 The Tumor Microenvironment in Tumorigenesis and Therapy Resistance Revisited. **2023**, 15, 376 3
- 27 In vivo detection of bile duct pre-cancer with endoscopic light scattering spectroscopy. **2023**, 14, 0
- 26 Correlation of four-phase CT findings of rectal neuroendocrine neoplasms with different World Health Organization grades. 0
- 25 Design, synthesis, and antitumor evaluation of trimethoxyflavonoid with arylurea structure against hepatocellular carcinoma. 0
- 24 Insights into the role of senescence in tumor dormancy: mechanisms and applications. 0
- 23 The Effect of Single Bout and Prolonged Aerobic Exercise on Tumour Hypoxia in Mice. 0

- 22 A proof-of-concept pipeline to guide evaluation of tumor tissue perfusion by dynamic contrast-agent imaging: Direct simulation and inverse tracer-kinetic procedures. 3, ○
- 21 Neo-vascularization-based therapeutic perspectives in advanced ovarian cancer. **2023**, 1878, 188888 ○
- 20 Metabolic codependencies in the tumor microenvironment and gastric cancer: Difficulties and opportunities. **2023**, 162, 114601 ○
- 19 Tumor vasculature vs tumor cell targeting: Understanding the latest trends in using functional nanoparticles for cancer treatment. **2023**, 11, 100136 ○
- 18 Cancer Angiogenesis and Its Master Regulator Perlecan. **2022**, 399-419 ○
- 17 Could senescence phenotypes strike the balance to promote tumor dormancy?. **2023**, 42, 143-160 ○
- 16 Changes in Expression of Tumor Suppressor Gene RKIP Impact How Cancers Interact with Their Complex Environment. **2023**, 15, 958 ○
- 15 Inhalant cannabidiol impedes tumor growth through decreased tumor stemness and impaired angiogenic switch in NCI-H1437-induced human lung cancer model. **2023**, 36, 1204-1210 ○
- 14 Inhibiting Angiogenesis by Anti-Cancer Saponins: From Phytochemistry to Cellular Signaling Pathways. **2023**, 13, 323 ○
- 13 Exploration of Pyrido[3,4-d]pyrimidines as Antagonists of the Human Chemokine Receptor CXCR2. **2023**, 28, 2099 ○
- 12 Invasion and Metastasis. **2023**, 205-234 ○
- 11 A Kernel-Based Multilayer Perceptron Framework to Identify Pathways Related to Cancer Stages. **2023**, 62-77 ○
- 10 Angiogenesis Inhibitors in the Treatment of Cancer. **2023**, 1-33 ○
- 9 Chaperone-mediated autophagy promotes breast cancer angiogenesis via regulation of aerobic glycolysis. **2023**, 18, e0281577 ○
- 8 Automated immunohistochemical quantification of hypoxia biomarkers shows correlation with dysplastic epithelial changes. ○
- 7 Nucleolin promotes angiogenesis and endothelial metabolism along the onco-fetal axis in the human brain vasculature. ○
- 6 Shaping the brain vasculature in development and disease in the single-cell era. **2023**, 24, 271-298 ○
- 5 The strange Microenvironment of Glioblastoma. **2023**, ○

- 4 Exploiting E3 ubiquitin ligases to reeducate the tumor microenvironment for cancer therapy. **2023**, 12, ○
- 3 Role of Magnesium in Tumor Microenvironment and Underlying Molecular Mechanisms. **2023**, 13, 207-214 ○
- 2 Nanoformulations-Based Metronomic Chemotherapy: Mechanism, Challenges, Recent Advances, and Future Perspectives. **2023**, 15, 1192 ○
- 1 Barriers to immune cell infiltration in tumors. **2023**, 11, e006401 ○